

CURRICULUM VITAE AND BIBLIOGRAPHY

Tanios Bekaii-Saab, MD

PERSONAL INFORMATION

Work Address: Mayo Clinic
5881 East Mayo Boulevard
Phoenix, AZ 85054
Email Address: Bekaii-Saab.Tanios@mayo.edu

PRESENT ACADEMIC RANK AND POSITIONS

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I – Mayo Clinic College of Medicine and Science 04/2024-Present
Chair –Division of Medical Oncology and Hematology - Mayo Clinic, Phoenix, Arizona 09/2023-Present
Professor of Medicine - Mayo Clinic College of Medicine and Science 02/2017-Present
Co-Leader – Advanced Clinical and Translational Sciences Program - Mayo Clinic Comprehensive Cancer Center 02/2024-Present
Disease Group Leader – Gastrointestinal Cancer - Mayo Clinic Comprehensive Cancer Center 05/2017-Present
Consultant - Division of Hematology/Oncology - Department of Internal Medicine, Mayo Clinic, Scottsdale/Phoenix, Arizona 05/2019-Present
Member - Research Operations Management Team -Mayo Clinic in Arizona 01/2022-Present
Associate Medical Director – International Subcommittee, Mayo Clinic, Phoenix, Arizona 08/2023-Present
Member – Executive Steering Committee - Mayo Clinic Comprehensive Cancer Center in Arizona 01/2024- Present
Chair – Medical Oncology Council – Mayo Clinic Enterprise 01/2025-Present

EDUCATION

University of Montpellier, Montpellier, France - Undergraduate Studies, Faculty of Medicine 1986 - 1987
American University of Beirut, Beirut, Lebanon - Undergraduate Studies 1987 - 1989
McGill University, Montreal, Quebec, Canada - BSc, (Neuro) Biology 1990 - 1992
American University of Beirut, Beirut, Lebanon - MD 1992 - 1996
Indiana University Medical Center, Indianapolis, Indiana - Residency, Internal Medicine 1996 - 1999
Tufts-New England Medical Center, Boston, Massachusetts - Fellow, Hematology-Oncology 1999 - 2002
Tufts University School of Medicine, Boston, Massachusetts - Fellow, Clinical Pharmacology and Experimental Therapeutics 2000 - 2002

ADDITIONAL EDUCATION

Graduate Pharmacology II (293K) 2000 - 2001
Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts

Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation Tufts Center for the Study of Drug Development, Boston, Massachusetts	2000 - 2001
Methods in Clinical Cancer Research ASCO/AACR Workshop, Vail, Colorado	2001
Pharmacokinetics for Pharmaceutical Scientists University of California at San Francisco, San Francisco, California	2002
Accelerating Anticancer Agent Development and Validation Workshop ASCO/AACR/NCI/FDA Workshop	2005

CERTIFICATIONS

Board Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine	1999 - 2009
Medical Oncology	2002 - Present

Educational Commission for Foreign Medical Graduates (ECFMG)

ECFMG	1997 - Present
-------	----------------

LICENSURE

Arizona	(Medical)	04/2016- Present
Lebanon	Colloquium Exam (Medical)	01/1996 - Present
Ohio	35-08-1336-B (Medical)	06/2002 - 2017

HONORS AND AWARDS

Dean's Honor List - American University of Beirut	1987 - 1989
Bachelor of Science with Great Distinction - McGill University	1992
Oliver Smith Award for Excellence in Patient Care - Tufts-New England Medical Center	1999
Workshop Award for Methods in Clinical Cancer Research - ASCO/AACR	2001
Workshop Award for Accelerating Anticancer Agent Development and Validation Workshop - ASCO/AACR/NCI/FDA	2005
Clinical Investigator Team Leadership Award - National Cancer Institute	2011 - 2013
Leadership Development Award Program - American Society of Clinical Oncology	2012 - 2013
Top Doctor - Castle Connolly	2010 - 2016
Best Doctors in America - Best Doctors	2013 - 2016

PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS

Assistant Professor of Pharmacology - The Ohio State University College of Pharmacy, Columbus, Ohio	2003 - 2010
Assistant Professor of Internal Medicine - The Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio	2003 - 2010
Medical Director - Gastrointestinal Oncology in the Division of Hematology/Oncology, The Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio	2009 - 2012

Associate Professor of Medicine - The Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio	2011 - 2015
Associate Professor of Pharmacy - The Ohio State University College of Pharmacy, Columbus, Ohio	2011 - 2016
Section Chief - Gastrointestinal Oncology. The Ohio State University-Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio	2012 - 2016
Professor of Medicine With Tenure - The Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio	2015 - 2016
Medical Director - Cancer Clinical Research Office, Phoenix, Arizona	2017- 2021
Senior Associate Consultant - Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale/Phoenix, Arizona	2016- 2019
Director - Cancer Clinical Research Office- Mayo Clinic Cancer Center	2021-2022
Vice Chair – Division of Medical Oncology and Hematology, Mayo Clinic, Phoenix, Arizona	06/2018-08/2023
Associate Director - Industry Relations and Clinical Trial Networks – Mayo Clinic Comprehensive Cancer Center	2022-2024
Leader - Gastrointestinal Cancer Program - Mayo Clinic Comprehensive Cancer Center	05/2016-02/2024
Consortium Chair - Academic and Community Cancer Research United (ACCRU)	03/2018-02/2024

PROFESSIONAL MEMBERSHIPS AND SERVICES

Alliance for Clinical Trials in Oncology (ALLIANCE)	
GI Committee	
Cadre Member	2011 - Present
Hepatobiliary Cancers	
Leader	2016 - Present
Pancreas Cancer Working Group	
Member	2014 - Present
Prevention Committee	
Member	2011 - 2014
Quality of Life Subcommittee	
GI Liaison	2011 - 2014
American Association for Cancer Research (AACR)	
Member	2001 - Present
Scientific Program Committee	
Member	2010
Hepatobiliary Cancer Research Session	
Co-Chair	2009
American College of Physicians	
Member	1996 - 2021
American Society for Clinical Pharmacology and Therapeutics	
Member	2000 - 2016
American Society of Clinical Oncology (ASCO)	
Member	1999 - Present
ASCO LDP Reviewer	2024 - Present

ASCO-SEP Co-Author	2024 - Present
ASCO-SEP Peer Review	2023
Scientific Program Committee	
Gastrointestinal Cancer-Colorectal/Liver Track	
Member	2020-2022
Track Leader	2022-2023
Clinical Cancer Guideline	
Gastrointestinal Cancer – Biliary Tract	2018 - Present
Cancer Education Committee	
Gastrointestinal Cancer-Non-Colorectal Tract	
Member	2013 - 2016
Continuing Medical Education Subcommittee	
Member	2009 - 2011
Gastrointestinal (Colorectal) Cancer	
Co-Chair	2010 and 2021
Pancreas Cancer Education Session	
Chair	2015
Scientific Program Committee	
Gastrointestinal Cancer-Colorectal/Liver Track	
Member	2008 - 2011
Cancer and Leukemia Group B (CALGB)	
GI Committee	
Cadre Member	2007 - 2011
Quality of Life Subcommittee	
GI Liaison	2007 - 2011
Cancer Research UK Centers	
Ad Hoc Reviewer	2013
Cancer Research UK	
Biomarkers and Imaging Discovery and Development Committee	
Ad Hoc Reviewer	2010
Clinical Trials Awards and Advisory Committee	
Late Phase Study	
Ad Hoc Reviewer	2012 - 2013
Collaborative Group of the Americas on Inherited Colorectal Cancer	
Scientific Program Committee	
Planning Committee	
Member	2010
European Society of Medical Oncology	
Scientific Program Committee	
Gastrointestinal Tumours, Lower Digestive	
Member	2024-2025
Lebanese Order of Physicians	
Member	1996 - Present
National Cancer Institute (NCI/NIH)	
NCI Special Emphasis Panel review of Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (RFA-CA-20-043 for U01s)	
Reviewer	2021

NCI Special Emphasis Panel review of SEP-6: Answers to NCI Provocative Questions (RFA-CA-20-004 for R01s and RFA-CA-20-005 for R21s) focusing on how cancer cachexia can be reversed?	
Reviewer	2021
External Committee (RAID Program)	
Reviewer	2006
ASSIGN Trial Therapeutics Committee	
Member	2014 -2016
NCI-Pancreas Cancer Task Force	
Member	2014 - 2021
NCI-Hepatobiliary Cancer Task Force	
Member	2016 - Present
Co-Chair	2020 - Present
Patient Navigation Research Program	
Colorectal Cancer	
Panel Member	2005 - 2012
National Comprehensive Cancer Network (NCCN)	
BRAF and MEK Request for Proposals Development Teams (RFPDTs)	
Member	2011
MEK Scientific Review Committee	
Member	2011
Colon/Rectum/Anal Cancer Panel	
Member	2011 - Present
Esophageal Cancer Panel and Writing Member	
Member	2004 - 2010
Gastric Cancer Panel and Writing Member	
Member	2004 - 2010
Hepatobiliary Panel	
Member	2003 - 2006
Oncology Outcomes Database Disease Specific Executive Committee (DSEC)	
Colorectal Cancer	
Member	2011-2013
NCCN Guidelines Steering Committee	
Member, Mayo Clinic Representative	2019-Present
Ohio Collaborative Group	
Institute for Pharmacy Outcomes of the Rx	
Colon Cancer Panel	
Member	2009
Pancreatic Cancer Research Fund (UK)	
Ad Hoc Reviewer	2014
Southwest Oncology Group	
Member	2014 - Present
GI Cancer Leadership Working Group	
Member	2014 - Present
Pancreas Cancer Subcommittee	
Co-Chair	2014 - 2021
The Italian Association for Cancer Research (AIRC)	
Expert Reviewer	2008 - Present
The Wellcome Trust/DBT India Alliance Grants	

Ad Hoc Reviewer	2014
United States Department of Defense	
Peer Reviewed Cancer Research Program (PRCRP)	
Colorectal Cancer Panel	
Scientific Reviewer	2010
Pancreas Cancer-2 Panel	
Scientific Reviewer	2012 - 2014
Swiss National Foundation	
Ad Hoc Reviewer	2022

DATA SAFETY AND MONITORING BOARD (DSMB/IDMC) SERVICES

Fibrogen	
Chair	2021-Present
Pancreas Cancer Action Network – Precision Promise	
Member	2019-2024
Astrazeneca	
Member	2019-Present
1-Globe	
Chair	2019-Present
Lilly	
Chair	2019-2020
Merck	
Member	2016-Present
Exelexis	
Chair	2013-Present
Polaris	
Member	2010-2015
Sillajen	
Member	2015-2017
ARMO Biosciences	
Chair	2016-2018

SCIENTIFIC ADISORY BOARD MEMBERSHIP*

Sun Biopharma (Panbela Therapeutics)	
Member	2019 - Present
Immuneering	
Member	2019 – Present
Imugene	
Member	2019 - Present
Xilis	
Member	2021 - 2025
Replimune	
Chair	2022 – 2024

* Member of multiple advisory boards including industry partners such as Roche/Genentech, Pfizer, Bayer, Astra Zeneca, EMD Serono, Boehringer Ingelheim, BMS, Amgen, GSK, Merck, Eisai, Seattle Genetics, etc.. since 2005

INDUSTRY TRIALS STEERING COMMITTEE MEMBERSHIP

Lead PI, International

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer (INVICTAN®-3; NCT02776683)	
Boehringer Ingelheim	2015-2019
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P; NCT02993731)	
Sumitomo Dainippon Pharma Oncology, Inc	2016- 2022
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MONTAINEER; NCT03043313)	
Cascadian Therapeutics/Seagen Inc./Pfizer	2017- Present
A Study to Evaluate the Efficacy and Safety of Pemigatinib vs. Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302; NCT03656536)	
Incyte, Corp.	2018- Present
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01; NCT00000419)	
Astra Zeneca	2023-Present

Lead PI, USA

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE; NCT04515394)	
EMD Serono and Merck KGaA	2020- 2023

Steering Committee Member

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel + Gemcitabine Treatment (NAPOLI 3; NCT04083235)	
Ipsen	2019 - Present
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MONTAINEER-02; NCT04499924)	
Seagen Inc.	2020- 2022
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (SGN-019; NCT04579380)	
Seagen Inc./Pfizer	2020-Present
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (SGN-024; NCT04430738)	
Seagen Inc./Pfizer	2020-Present
An open-label, randomized, phase 3 study of tucatinib in combination with trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either cetuximab or bevacizumab as first-line treatment for subjects with HER2+ metastatic colorectal cancer (MONTAINEER 03: NCT05253651)	
Seagen Inc./Pfizer	2022-Present
A phase 2, randomized, open-label study of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab alone in participants with previously	

untreated *BRAF* V600E-mutant, MSIH/DMMR metastatic colorectal cancer (SEAMARK; NCT04607421)

Pfizer

2021-Present

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Not Previously Treated in the Metastatic Setting

Arcus

2024-Present

JOURNAL RESPONSABILITIES

Journal Editorial Responsibilities

Journal of the National Cancer Institute	
Editorial Board Member	2017 - Present
Journal of the National Comprehensive Cancer Network	
Editorial Board Member	2013 - 2017
Chinese Clinical Oncology	
Editorial Board Member	2021 - Present
Clinical Advances in Hematology and Oncology	
Editorial Board Member	2020 - Present
Oncology	
Editorial Board Member, Chair GI Cancer	2020 - Present
OncLive	
Editorial Board Member	2017 - Present
US Oncological Review	
Editorial Board Member	2009 - Present
HemOnc Today	
Editorial Board Member	2011 - 2014
Frontiers in Oncology	
Associate Editor for Gastrointestinal Cancers	2020 - 2021
World Journal of Hepatology	
Editorial Board Member	2009 - 2016

Journal Other Responsibilities

Acta Biochimica et Biophysica Sinica	
Journal Reviewer	2010 - 2012
American Journal of Clinical Oncology	
Journal Reviewer	2010 - 2016
American Journal of Human Genetics	
Journal Reviewer	2010 - 2015
Anticancer Drugs	
Journal Reviewer	2010 - 2014
Asian-Pacific Journal of Clinical Oncology	
Journal Reviewer	2010 - 2012
Biodrugs	
Journal Reviewer	2010 - 2012
BMC Cancer	
Journal Reviewer	2010 - 2014
British Journal of Cancer	

Journal Reviewer	2010 - 2016
Cancer	
Journal Reviewer	2010 - 2016
Cancer Chemotherapy and Pharmacology	
Journal Reviewer	2010 - 2016
Cancer Discovery	
Journal Reviewer	2022 - Present
Cancer Epidemiology, Biomarkers & Prevention	
Journal Reviewer	2012 - 2015
Cancer Investigation	
Journal Reviewer	2010 - 2014
Cancer Research	
Journal Reviewer	2010 - 2013
Chemotherapy	
Journal Reviewer	2012
Cleveland Clinic Journal of Medicine	
Journal Reviewer	2010 - 2013
Clinical Cancer Research	
Journal Reviewer	2010 - Present
Clinical Colorectal Cancer	
Journal Reviewer	2010 - Present
Critical Reviews in Oncology/Hematology	
Journal Reviewer	2010 - 2012
Current Opinion in Investigational Drugs	
Journal Reviewer	2010 - 2012
Diseases of the Esophagus	
Journal Reviewer	2010 - 2012
Drug Profiles	
Journal Reviewer	2010 - 2013
European Journal of Cancer	
Journal Reviewer	2010 - 2014
Expert Opinion on Biological Therapy	
Journal Reviewer	2010 - 2015
Expert Opinion on Therapeutic Targets	
Journal Reviewer	2010 - 2014
Expert Review of Anticancer Therapy	
Journal Reviewer	2010 - 2013
Future Oncology	
Journal Reviewer	2010 - 2016
Gastrointestinal Cancer Research	
Journal Reviewer	2010 - 2012
Human Immunology	
Journal Reviewer	2010 - 2011
International Journal of Cancer	
Journal Reviewer	2010 - 2012
International Journal of Radiation Oncology*Biology*Physics	
Journal Reviewer	2010 - 2013
Investigational New Drugs	

Journal Reviewer	2010 - 2015
JAMA journals	
Journal Reviewer	2010 - Present
Journal of Chemotherapy	
Journal Reviewer	2010
Journal of Clinical Oncology	
Journal Reviewer	2010 - Present
Journal of Gastrointestinal Oncology	
Journal Reviewer	2010 - 2015
Journal of Medical Case Reports	
Journal Reviewer	2010 - 2014
Journal of National Comprehensive Cancer Network	
Journal Reviewer	2010 - Present
Journal of the National Cancer Institute	
Journal Reviewer	2010 - Present
Lancet Oncology	
Journal Reviewer	2014 - Present
Lancet Gastroenterology and Hepatology	
Journal Reviewer	
Mayo Clinic Proceedings	
Journal Reviewer	2010 - Present
Medical Genetics	
Journal Reviewer	2010
Medical Oncology	
Journal Reviewer	2010 - 2014
Molecular Cancer Therapeutics	
Journal Reviewer	2010 - 2014
New England Journal of Medicine	
Journal Reviewer	2025
Oncology	
Journal Reviewer	2010 - 2012
OncoTargets and Therapy	
Journal Reviewer	2010 - 2014
PLoS Genetics	
Journal Reviewer	2010 - 2014
PLoS ONE	
Journal Reviewer	2010 - 2016
The Oncologist	
Journal Reviewer	2010 - 2016
World Journal of Hepatology	
Journal Reviewer	2010 - 2014

EDUCATION AND MENTORSHIP

Teaching

Oncologic Emergencies	2002
Medicine 3 students rotating in internal medicine	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	

Physician Development Preceptorship III	2003-2004
Pharmacology of Chemotherapeutic Agents	2003-2015
Division of Hematology/Oncology Fellow Lecture Series	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	
Pancreas Cancer	2003-2012
Division of Hematology/Oncology Fellow Lecture Series	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	
Physician Development Preceptorship II	2004-2005
Med 2 Physical Exam Preceptorship	2006-2008
Gastro-Esophageal Cancer	2006
Department of Internal Medicine Residents Conference	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	
Med 2 Hospital Based Preceptorship	2007
Med 1 Longitudinal Preceptorship	2009-2011
Metastatic Colorectal Cancer	2009
Division of Hematology/Oncology Fellow Lecture Series	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	
Diagnosis and Management of Patients with Colorectal Cancer	2009
Seminar Series presented by the College of Pharmacy	
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Columbus, Ohio	
Med 1 CAPS Preceptorship	2012-2013
Metastatic Colorectal Cancer	2017-Present
Academic Half Day – Fellows Lecture Series	
Mayo Clinic in Arizona	

Mentorship

Kosuri, Kavitha (Faculty)	01/2004 - 04/2010
Description: Mentored as Fellow then Faculty. Dr. Kosuri was a faculty member with the GI oncology group from 2006-2010.	
Current Status: Staff Physician at the David C Pratt Cancer Center, Saint Louis MO	
Fortune, Brett (Resident)	01/2005 - 01/2008
Description: Role: Primary Mentor and Career Advisor	
Current Status: Associate Professor, Hepatology/Liver Transplantation, Weill Cornell, NY.	
Pant, Subham (Fellow/Faculty)	06/2005-Present
Description: Role: Primary Mentor (Fellow) and Career Advisor (Faculty)	
Current Status: Professor, GI Medical Oncology, MD Anderson Cancer Center, Houston, TX.	
South, Christopher (Fellow)	01/2006 – 01/2008
Description: Role: Primary Mentor and Career Advisor	
Current Status: Staff Physician at the Ohio Gastroenterology and Liver Institute, Cincinnati, OH	
Hill, Marisa (Resident)	01/2006 - 01/2008
Description: Role: Primary Mentor and Career Advisor	
Current Status: Assistant Professor in GI Medical Oncology at Rush University in Chicago, IL.	

Ntukidem, Nsebon (Fellow)	01/2006 - 01/2008
Description: Role: Primary Mentor and Career Advisor	
Current Status: Staff Physician with the Columbus Oncology Associates, Columbus, OH. He is the current Co-PI on the NCI Columbus COP grant.	
Markowitz, Joseph (Resident/Fellow)	01/2007 - 01/2013
Description: Role: Primary Mentor and Career Advisor	
Current Status: Dr. Markowitz is an Assistant Professor of Medicine at the Moffit Cancer Center, Tampa, FL	
Martin, Katherine (Resident/Fellow)	01/2007 - 01/2013
Description: Role: Primary Mentor and Career Advisor	
Current Status: Staff Medical Oncologist Northwest Medical Specialties, WA	
Lam, Elaine (Fellow)	01/2008 - 01/2010
Description: Role: Mentor	
Current Status: Associate Professor and Medical Director of the kidney cancer program at the University of Colorado, Denver, CO.	
Serna, Derek (Fellow)	01/2008 - 01/2011
Description: Role: Primary Mentor and Career Advisor	
Current Status: Staff Medical Oncologist with ProHealth Cancer Center , WI.	
Mortazavi, Amir (Faculty)	01/2008 - 01/2012
Description: Role: Mentor	
Current Status: Dr. Mortazavi is currently an Associate Professor at the Ohio State University, Columbus, OH.	
Blazer, Marlo (Pharmacy Staff)	01/2008 - 01/2016
Description: Role: Primary Mentor	
Current Status: Dr. Blazer was a GI cancer specialty pharmacist, The Ohio State University-James Cancer Hospital and Solove Research Institute. She currently is the Director of Pharmacy at Columbus Oncology & Hematology Associates..	
Lustberg, Maryam (Resident/Fellow/Faculty)	01/2009 - 01/2016
Description: Role: Mentor. Mentored as resident, fellow and then faculty.	
Current Status: Dr. Lustberg was an Associate Professor at the Ohio State University in Columbus, OH. She is currently the director of the Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center.	
Bauer, Todd (Resident)	01/2010 - 01/2016
Description: Role: Primary Mentor and Career Advisor	
Current Status: Associate Director, Drug Development; Principal Investigator, Sarah Cannon Research Institute, TN	
Peck, Joshua (Resident)	01/2011 - Present
Description: Role: Primary Mentor and Career Advisor	
Current Status: Fellow in Gastroenterology at the Ohio State University Medical Center, OH. He is currently a staff Physician at the Ohio Gastroenterology and Liver Institute, Cincinnati, OH	
Kapoor, Kapil (Medical Student)	01/2011-01/2012
Description: Primary Mentor	
Current Status: Ophthalmology Staff, Wagner Macula and Retina Center, VA	
Majumder, Arnab (Medical Student)	01/2011-01/2012
Description: Primary Mentor	
Current Status: Assistant Professor in GI Surgery, Washington University School of Medicine in St Louis , MO.	
Wu, Christina (Faculty)	01/2011 - Present
Description: Role: Primary Mentor and Career Advisor	
Current Status: Dr. Wu was an Assistant Professor in GI Oncology, The Ohio State University-James Cancer Hospital and Solove Research Institute. Then she was an Associate Professor at Emory Winship Cancer Institute. She is currently	

the disease group leader for GI cancers at Mayo Clinic in Arizona and a Professor of Medical Oncology.

Williams, Terrence (Faculty) 01/2012 - 01/2016

Description: Role: Mentor

Current Status: He was at The Ohio State University-James Cancer Hospital and Solove Research Institute. Currently, a Professor and Chair of the Department of Radiation Oncology at the City of Hope Cancer Center in Duarte, CA.

Ciombor, Kristen (Faculty) 01/2013 - Present

Description: Role: Mentor

Current Status: Dr. Ciombor was at The Ohio State University-James Cancer Hospital and Solove Research Institute. She is currently an Associate Professor at Vanderbilt University in TN.

Mikhail, Sameh (Faculty) 01/2013 - 01/2016

Description: Role: Primary Mentor and Career Advisor

Current Status: Dr. Mikhail was an Assistant Professor of GI Oncology, The Ohio State University-James Cancer Hospital and Solove Research Institute. He is currently at the Zangmeister Cancer Center in Columbus, OH.

Noonan, Anne (Faculty) 01/2013 - 01/2016

Description: Role: Primary Mentor and Career Advisor

Current Status: Dr. Noonan is an Associate Professor and Leader of GI Oncology, The Ohio State University-James Cancer Hospital and Solove Research Institute.

Ahn, Daniel (Fellow and Faculty) 01/2013- Present

Description: Primary Mentor and Career Advisor

Current Status: Disease Group Leader, GI cancer. Medical Director, CCRO for MCA. Professor in Medical Oncology, Mayo Clinic, AZ

Haraldsdottir, Sigurdís (Fellow) 01/2014-01/2016

Description: Role: Mentor and Career Advisor

Current Status: Assistant Professor in Medical (GI) Oncology, Stanford University, CA then Assistant Professor at the Dana Farber Cancer Institute in Boston MA. She is currently the Associate Professor at Landspítali University Hospital in Reykjavík Iceland.

Krishna, Kavya (Fellow) 01/2013-01/2016

Description: Role: Primary Mentor and Career Advisor

Current Status: Medical Oncology Staff, Columbus Oncology and Hematology, OH

Chee Chee Stuckey (Faculty) 01/2016-Present

Description: Role: Primary Mentor and Career Advisor

Current Status: Assistant Professor in Surgical Oncology and Leader of HPB SPORE biobanking, Mayo Clinic, AZ

M Bassam Sonbol (Fellow and Faculty) 01/2017-Present

Description: Role: Primary Mentor and Career Advisor

Current Status: Associate Professor in Medical Oncology, Mayo Clinic, AZ

Koichiro Haruki (Visiting Fellow through ASCO/JSCO program) 2017

Description: Primary Mentor

Current Status: Assistant Professor in HPB surgery at The Jikei University School of Medicine in Tokyo, Japan.

Pedro Luiz Serrano Uson Jr (Visiting Faculty) 2019-2021

Description: Primary Mentor

Current Status: Gastrointestinal Medical Oncologist at the Hospital Israelita Albert Einstein in Sao Paulo Brazil

Alyx Porter (Faculty) 01/2019-Present

Description: Mentor and Career Advisor

Current Status: Professor in Neuro-Oncology, Mayo Clinic, AZ. She is also the director of Cultural Humility Course for the Mayo Clinic School of Medicine in AZ.

Gehan Botrus (Fellow)	07/2019-06/2022
Description: Role: Primary Mentor and Career Advisor	
Current Status: Assistant Professor in GI Oncology, Emory University.	
Mojun Zhu (Fellow and Faculty)	01/2020-Present
Description: Role: Primary Mentor and Career Advisor	
Current Status: Assistant Professor in GI Medical Oncology, Mayo Clinic, Rochester, MN.	
Daniel Walden (Resident/Fellow)	01/2020-06/2024
Description: Role: Primary Mentor	
Current Status: Staff Medical Oncologist at Medical College of WI	
Hani Babiker (Faculty)	06/2021-Present
Description: Role: Mentor and Career Advisor	
Current Status: Assistant Professor in GI Medical Oncology, Mayo Clinic Florida.	
Lida Mina (Faculty)	08/2021-Present
Description: Role: Primary Mentor and Career Advisor	
Current Status: Assistant Professor in Breast Medical Oncology and Disease Group Leader for Women's Cancers group, Mayo Clinic AZ.	
Celine Hoyek (Medical Student)	07/2023-Present
Description: Role: Primary Mentor	
Current Status: Accepted into IM residency at Mayo Clinic in AZ	

And many others

INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSABILITIES, COMMITTEE MEMBERSHIPS AND EXTERNAL ACTIVITIES

Mayo Clinic Enterprise

Mayo Clinic Comprehensive Cancer Center Internal Scientific Advisory Committee Member	2016 – 2021
Mayo Clinic Comprehensive Cancer Center ECTX Group Member	2016 – Present
Mayo Clinic Comprehensive Cancer Center Clinical Research Sub-Committee Member	2017 – 2021
Mayo-ASU Med-Tech Accelerator Mentor/Subject Matter Expert	2018 – Present
Mayo Clinic Research Clinical Trial Sub-Committee Member	2019 – 2021
Mayo Clinic Mayo Clinic Cancer Center Transition Planning Team Member	2019
Mayo Clinic Comprehensive Cancer Center Clinical Research Committee Member	2021 – Present
Mayo Clinic Comprehensive Cancer Center HPB Disease Group Executive Team Member	2021 – Present
Mayo Clinic Cancer Center and Mayo Clinic Enterprise Transformation Leadership Team- Develop Leading Clinical Trials Capability Co-Leader	2021 – Present
Mayo Clinic Strategy and Governance Leadership Team Clinical Trials Operations Team Leader, Common Enterprise Research Infrastructure	2021 - Present
Mayo Clinic Cancer Center Leadership Transition Team- Cancer Clinical Trials / Clinical Research Infrastructure	

Co-Leader/Senior Advisor

2022 – Present

Mayo Clinic in Arizona (MCA)

Southwest Cancer Coordinating Committee (SWCCC)

Member

2017 – Present

Clinical Research Sub-Committee

Member

2017 – 2021

Marley Cancer Research Award Program

Member

2017 – Present

ASU Mayo Clinic Seed Grant Program

Member

2017 – Present

Space & Capital Committee

Member

2019 – Present

Research Operations Management Team (ROMT)

Member

2021 – Present

Activities at Other Institutions

American University of Beirut

Program Project Research Applications

Reviewer

2012

Kansas State University

Kansas Bioscience Authority

Eminent Scholar

Ad Hoc Reviewer

2010

Lebanese American University

Academic Consultant

2009 - 2011

The Ohio State University

Appointments, Promotion and Tenure Committee

Member

2013 - 2016

Grateful Patient Pilot Program

Member

2013 - 2016

Search Committee

Member

2011 - 2013

Director of the Division of Gastroenterology, Hepatology, and Nutrition

The Ohio State University College of Medicine

Faculty Advisory Committee

Medical Student Research (MDSR)

Member

2010 - 2016

The Ohio State University Comprehensive Cancer Center

ACS Grant Review Committee

Member

2010 - 2016

Clinical Scientific Review Executive Committee

Member

2004 - 2016

Disease Specific Research Group (DSRG) for Gastrointestinal Oncology

Chair

2011 - 2016

Experimental Therapeutics Program

Member

2003 - 2012

Feasibility Review Committee

Member

2009 - 2011

Gastrointestinal Cancers Disease Specific Committee	
Chair	2004 - 2011
Pelotonia Grant Review Committee	
Member	2011 - 2012
Translational Therapeutics Program	
Member	2013 - 2016
The Ohio State University Hospitals	
Clinical Patient Safety Committee	
Member	2003 - 2005
Gastrointestinal Oncology Multi-Modality Steering Committee	
Founding Member	2003 - 2012
Policy and Surveillance Executive Committee	
Pharmacy and Therapeutics	
Member	2003 - 2012
The Ohio State University-James Cancer Hospital	
Hematology-Oncology Formulary Subcommittee Group	
Chair	2003 - 2016
The Ohio State University-James Cancer Hospital and Solove Research Institute	
Division of Medical Oncology	
Finance Committee	
Member	2012 - 2016
Leadership Committee	
Member	2012 - 2016
The Ohio State University-Wexner Medical Center	
Digestive Diseases Executive Committee	
Member	2013 - 2014
The Ohio State University-Wexner Medical Center and James Cancer Hospital and Solove Research Institute	
Fellows Competency Committee	
Member	2010 - 2016
Fellowship Recruitment Committee	
Member	2005 - 2006
Methotrexate Shortage Oversight Committee	
Member	2012
Paclitaxel Shortage Oversight Committee	
Member	2011 - 2012
University of Cincinnati and The Ohio State University and Case Western Reserve University	
NetWellness	
Advisory Panelist	2006 - 2013
Colon Cancer Articles	

PRESENTATIONS EXTRAMURAL

National or International

Visiting Professorships and Lectureships

Metastatic Esophageal and Gastric Cancer: First Line, Second Line, and Beyond	10/2018
Stephen and Gail Jarislowsky Visiting Professorship in Upper Gastrointestinal Malignancies – McGill University	
Montreal, Quebec, Canada	

Hitting the Target - Precision Medicine and Colorectal Cancer Gail Klein Garlove Lectureship at the Norton Cancer Institute Louisville, KY, USA	11/2021
Transforming the Pancreatic Cancer Treatment Landscape: From Barren Sands to Abundant Waters Keynote Speaker at UTSW Pancreatic Cancer Symposium Dallas, TX , USA	04/2025
Course Director	
Gastrointestinal Cancers: Current Updates on State-of-the-Art Screening, Prevention, and Multi-Disciplinary Treatment Columbus, Ohio	2005-2016
Oncology and Hematology Review and Interpretation of the ASCO, ASH, AACR and Other Major International Meetings Columbus, Ohio	6/2007-2008
Oncology Update: Current and New Horizons Columbus, Ohio	2009
ASCO Review: Review and Interpretation of the ASCO Conference Columbus, Ohio	6/2009-2015
International Pancreatic Cancer Symposium Columbus, Ohio	9/2013
Mayo Clinic Gastrointestinal Cancers San Diego, CA	3/2018-Present
Mayo Clinic Hepatobiliary Cancer Symposium Las Vegas, NV	11/2019-Present
International Society of Gastrointestinal Oncology (ISGIO) Annual Symposium Various locations	10/2020-Present
Invited Oral	
Photodynamic therapy (PDT) can be incorporated into the multimodality treatment of loco-regionally advanced non-small cell lung cancer (NSCLC) with obstructive lesions 10th World Conference on Lung Cancer Vancouver, British Columbia, Canada	08/2003
Emerging therapies and early phase I-II trials in Hepatocellular Carcinoma National Taiwan University Hospital Hepatocellular Carcinoma Cooperative Symposium. NTUH Center Taipei, Taiwan	10/2007
Molecularly Targeted Therapies in Gastrointestinal Cancers: Smart Bombs or Cluster Bombs X Congreso de Hematología y Oncología Punta Cana, Dominican Republic	04/2008
Updates in the Treatment of Gastrointestinal Malignancies X Congreso de Hematología y Oncología Punta Cana, Dominican Republic	04/2008
Initial results from ARIES, a multi-indication bevacizumab observational cohort study (OCS): Characteristics of metastatic colorectal cancer patients receiving BV and chemotherapy (CT) in 2nd line. ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer Barcelona, Spain	06/2008

Phase II Study of AZD 6244 in Advanced Biliary Cancers NCI/CTEP Early Drug Development (EDD) Meeting 2009. Natcher Conference Center, National Institutes of Health Bethesda, Maryland	03/2009
Recent Advances in Hepatocellular Cancer: From Molecular Profiling to Therapeutics Session Co-Chair for the New Organ Specific Concepts Session AACR Annual Meeting 2009 Denver, Colorado	04/2009
Systemic Therapy in Hepatocellular Carcinoma 11th Annual Palm Beach Cancer Symposium: Personalized Medicine in the Era of Targeted Therapy Palm Beach, Florida	04/2009
Biomarkers and Molecular Targets in Therapy for Gastrointestinal Tract Malignancies XI Congress of the Dominican Society of the Hematology and Oncology Punta Cana, Dominican Republic	04/2010
Dilemmas in the Management of Upper Gastrointestinal Cancer XI Congress of the Dominican Society of the Hematology and Oncology Punta Cana, Dominican Republic	04/2010
FDA Approved Treatments and Their Side Effects Pancreatic Cancer Action Network Pittsburgh, Pennsylvania	05/2010
Gastrointestinal (Colorectal) Cancer Oral Abstract Session Session Co-Chair ASCO Annual Meeting Chicago, Illinois	06/2010
Gastrointestinal (Colorectal) Cancer Review Best of ASCO 2010 Boston, Massachusetts	07/2010
Abstract Podium Presentations Session Chair Collaborative Group of the Americas on Inherited Colorectal Cancer Dallas, Texas	08/2010
Gastrointestinal (Colorectal) Cancer Invited Discussant for the Oral Abstract Session for session "Selection of anti- EGFR antibodies in the treatment of MCRC" ASCO Chicago, Illinois	06/2011
Targeted Therapies in Pancreas Cancer National Cheng-Kung University Tainan, Taiwan	10/2011
Advances in the Treatment of Pancreas Cancer National Taiwan University Hospital Taipei, Taiwan	10/2011
Gastrointestinal Review II American Physician Institute MOC Medical Oncology Review Course Orlando, Florida	03/2013
Systemic Treatment for HCC and Biliary Tract Malignancy 4th Annual Gastrointestinal Cancers Symposium. Winship Cancer Institute of	11/2013

Emory University
Atlanta, Georgia

Therapeutic Advances in Pancreatic Cancer: Is Nihilism Justified 11/2013
National Institute of Medical Sciences and Nutrition
Mexico City, Mexico

Adjuvant Radiation Therapy, Debating its Role in Pancreatic Cancer 02/2014
American College of Radiation Oncology Annual Meeting
Orlando, Florida

What is the Optimal Sequence of Systemic Therapy in Metastatic Colorectal Cancer? 03/2014
NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care
Hollywood, Florida

Systemic Therapy for mCRC 05/2014
World Congress on Interventional Oncology
New York, New York

Systemic Therapy for NET 05/2014
World Congress on Interventional Oncology
New York, New York

Ampullary Cancer 06/2014
Education Session
American Society of Clinical Oncology Annual Meeting (ASCO)
Chicago, Illinois

A Multi-institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (MAP) 10/2014
NCI/CTEP Early Drug Development (EDD) Meeting 2014.
Natcher Conference Center, National Institutes of Health
Bethesda, Maryland

The Emerging Role of Immunotherapeutic Approaches in Pancreas Cancer: The Future is Now? 06/2015
American Society of Clinical Oncology Annual Meeting (ASCO)
Chicago, Illinois

Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track? 06/2015
Session Chair Pancreas Cancer Education Session
ASCO Annual Meeting
Chicago, Illinois

Fighting a Smarter War Against Cancer : Innovations in GI Cancer 12/2018
Bringing Precision Medicine into GI Cancer: Innovative Trial Designs
Ruesch Center for the Cure of Gastrointestinal Cancers Symposium
Washington DC

The Emerging Role of Microbiome and Its Influence on Response to Cancer Therapeutics 01/2019
Keynote Speaker
Microbiome in Precision Medicine Era Symposium
Taipei Medical University
Taipei Taiwan

ASCO Review 06/2019
GI Cancer Update
The Ohio State CCC
Columbus, OH

Highlights of ASCO 2019 08/2019

GI Malignancies NCORP, Aurora Cancer Care and WI association of Hem/Onc Milwaukee, WI	
Integrating New Options in Hepatocellular Carcinoma and Colorectal Cancer in the Community Optimizing Outcomes After Prior Therapy: CRC Clinical Cases USON Clinical Update Symposium San Antonio, TX	10/2019
Targeting DNA Repair Defects in Pancreatic Adenocarcinoma (PDAC) Japanese Society of Clinical Oncology (JSCO) Fukuoka, Japan	10/2019
Biomarker-Based Basket Trials: A New Model for Biliary Cancer Drug Development ASCO GI Cancers Symposium San Francisco, CA	01/2020
Multidisciplinary Symposium of HPB and CRC Liver Metastasis Colorectal Cancer with Liver Metastasis: Systemic Therapy for all? Instituto Nacional de Cancerologia Mexico City, Mexico	02/2020
ASCO GI Highlights GI Cancer Updates Springer Healthcare São Paulo LATAM	06/2020
Multidisciplinary Symposium of HPB and CRC Liver Metastasis Neoadjuvant therapy of pancreatic cancer. A new standard of care? Symposio Latinoamericano de Gastroenterologia Oncologica Santiago, Chile	04/2021
Gastrointestinal (Colorectal) Cancer Oral Abstract Session Co-Chair ASCO Annual Meeting Chicago, Illinois	06/2021
Session II: Cancers of the Pancreas and Biliary Molecular Unraveling in Bile Duct Cancer: What to Look For? ESMO World Congress on GI Cancers Barcelona, Spain	06/2021
ASCO Highlights Webinar GI Session Updates Springer Healthcare São Paulo LATAM	07/2021
Metastatic Colorectal Cancer Session Conversion therapy - I chose triplets with Monoclonal Antibodies 6º International Gastrointestinal Tumors Symposium Sao Paulo, Brazil	08/2021
GI Oncology: HPB Session Best Sequence for the Treatment of HCC: IO followed by TKI Middle East and North Africa Summit (MENA) Beirut, Lebanon	09/2021
Middle East Oncology Summit (BOOST) Treatment Beyond 2 nd Line mCRC	10/2021

Gastrointestinal Malignancies Successes and failures in drug development: The future of research in pancreatic cancer looks brighter than the past Mayo Clinic Joint Venture with Huimei to develop Research Training Program Beijing and other Cities, China	12/2021
Opportunities with translational partnerships, independent funding and drug development Building a National Cancer Research Consortium to Translate Discoveries into Treatment Options for Patients with Cancer Mayo Clinic Joint Venture with Huimei to develop Research Training Program Beijing and other cities, China	12/2021
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS ^{G12C} mutation. ASCO GI Cancer Symposium San Francisco, CA	01/2022
Current Molecular Treatment Landscape of Advanced Colorectal Cancer based on COLOMATE Platform and Collaboration with SCRUM-Japan GOZILA Japanese Society of Medical Oncology (JSMO) Symposium Kyoto, Japan	02/2022
The application of "Liquid Biopsies" in the search of molecular targets: The great Equalizer for International Trial Collaboration Japanese Society of Medical Oncology (JSMO) Symposium Kyoto, Japan	02/2022
KRYSTAL-1 : l'adagrasib (MRTX849) en monothérapie ou en association avec le cétuximab chez des patients présentant un cancer colorectal avec une mutation KRAS ^{G12C} Journées Francophones d'Hépto-gastroentérologie et d'Oncologie Digestive Paris, France	03/2022
Session X : Discussant for Selected Colorectal Cancer Abstracts ESMO 24th World Congress on GI Cancers Barcelona, Spain	06/2022
Session XIII : Chair and Presenter for Meet The Experts Optimal Dosing Strategy For Multikinase Inhibitors ESMO 24th World Congress on GI Cancers Barcelona, Spain	06/2022
UPMC Annual Oncology Symposium: Experts and Evidence 2022 Targeted Therapies in BRAF Mutant CRC Pittsburgh, PA	07/2022
UPMC – Pittsburgh Annual Oncology Symposium: Advances in Molecular Targeted Therapy in Advanced Stage MSS Colorectal Cancer Pittsburgh, PA	07/2023
Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER ESMO Congress , Madrid	10/2023
Standard of Care in the Management of Biliary Tract Cancer GI Oncology MENA Region Summit 2024 Beirut, Lebanon	10/2024
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone	06/2025

in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
 ASCO Annual Meeting, Chicago

Invited Regional and Grand Rounds*

**I have given Hundreds of lectures in every corner of North America since 2003.
 Below listed are only select few.*

Current Strategies for the Treatment of Advanced Colorectal Cancer Grand Rounds Charleston Area Medical Center-West Virginia University Charleston, West Virginia	01/2004
Neoadjuvant, Adjuvant and Palliative Chemotherapy in the Treatment of Pancreas Cancer Advances in the Multidisciplinary Management of Pancreatic Disease Symposium at the Ohio State University Columbus, Ohio	09/2004
Current Strategies for the Treatment of Advanced Colorectal Cancer with a Focus on Anti-angiogenic Strategies Case Comprehensive Cancer Center Grand Rounds University Hospitals Ireland Cancer Center Cleveland, Ohio	10/2004
Pancreas Cancer Department of Internal Medicine Grand Rounds The Ohio State University Columbus, Ohio	11/2004
Emerging Trends in the Management of Pancreatic Cancer Grand Rounds University of Oklahoma Health Sciences Center Norman, Oklahoma	09/2005
Adjuvant Therapy in Colorectal Cancer: Who is a candidate? The First Annual GI Cancer Symposium: Colorectal Cancer. University of Cincinnati Cincinnati, Ohio	11/2005
Role of Targeted Therapies in Pancreatic Cancer Grand Rounds Brown Cancer Center-University of Louisville Louisville, Kentucky	01/2006
Molecular Mechanisms of Cachexia in Pancreatic Cancer Pancreas Cancer Research Grand Rounds Karmanos Cancer Institute-Wayne State University Detroit, Michigan	02/2006
Colorectal Cancer and Surveillance Early Detection, Surveillance and Behavioral Issues in Cancer Conference. The Ohio State University Comprehensive Cancer Center and Holzer Medical Center Gallipolis, Ohio	06/2006
Pancreatic Cancer: Early and Advanced Stage Gastrointestinal Cancers Symposium. Karmanos Cancer Institute-Wayne State University Detroit, Michigan	11/2006

Emerging Trends in the Management of Colorectal Cancer Grand Rounds Arkansas Cancer Research Center - University of Arkansas Little Rock, Arkansas	01/2007
Advances in Pancreas Cancer Grand Rounds University of Mississippi Medical Center Jackson, Mississippi	02/2007
Colorectal Cancer Genetics from a Medical Standpoint An Update on Colorectal Cancer Genetic Conference. The Ohio State University, Comprehensive Cancer Center Columbus, Ohio	03/2007
The Role of Targeted Therapies in the Treatment of Colorectal Cancers Hematology & Medical Oncology Grand Rounds University of Cincinnati Cincinnati, Ohio	05/2007
Updates and Controversies in the Treatment of Pancreatic Cancer Grand Rounds Stanford Hospital - University of South Dakota Sioux Falls, South Dakota	06/2007
The impact of GI malignancies in the United States, the growing need for novel therapies and updates on ongoing research at the Ohio State University Grand Rounds Amgen Headquarters Thousand Oaks, California	12/2007
Shifting Paradigms in the Treatment of Advanced Colorectal Cancer Grand Rounds Institute for Drug Development-The University of Texas Health Science Center at San Antonio San Antonio, Texas	02/2008
Treatment Advances in Metastatic Adenocarcinoma of the Pancreas: Is nihilism justified? Grand Rounds Indiana University Indianapolis, Indiana	03/2008
Medical Aspects of Cholangiocarcinoma, Chemotherapy and Experimental Therapeutics 2008 Ohio Liver Professional Transplant Symposium Columbus, Ohio	04/2008
Treatment Advances in Adenocarcinoma of the Pancreas University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin	04/2008
Molecularly Targeted Therapy in Advanced Hepatobiliary Cancers The University of Texas, MD Anderson Cancer Center Houston, Texas	12/2008
Molecularly Targeted Therapy in Advanced Hepatobiliary Cancers Cleveland Clinic Cleveland, Ohio	01/2009
Treatment of Biliary Cancers: Past, Present and Future Grand Rounds Roswell Park Cancer Institute Buffalo, New York	01/2010

Treatment Options for Advanced Biliary Cancers: Past, Present, and Future Emory University Atlanta, Georgia	02/2011
Treatment of Metastatic Colorectal Cancer GI Oncology Fellows Conference Emory University Atlanta, Georgia	02/2011
Targeted Therapies in Biliary Cancer Special Seminar University of Illinois at Chicago Chicago, Illinois	11/2011
Updates in the Treatment of Metastatic Pancreas Cancer Emory University GI Oncology Symposium Atlanta, Georgia	11/2011
Targeted Therapies in Advanced Biliary Cancer Grand Rounds Oregon Health and Science University Portland, Oregon	01/2012
Targeted Therapies in Advanced Biliary Cancer Grand Rounds University of Kentucky – Markey Cancer Center Lexington, Kentucky	02/2012
Novel Approaches to Hepatocellular Carcinoma 13th Annual Palm Beach Cancer Symposium: Evolving Approaches to Personalized Therapy Palm Beach, Florida	03/2012
Strategies for the Management of Hepatocellular Carcinoma: Paths to Progress Gwinnett Medical Center Atlanta, Georgia	03/2012
Molecularly Targeted Therapy in Biliary Cancer (BC): Emerging Data Grand Rounds University of Cincinnati Hematology/Oncology Cincinnati, Ohio	05/2012
Recent Advances in the Treatment of Metastatic Colorectal Cancer 6th Annual Georgia Health Sciences University Cancer Center Symposium Savannah, Georgia	09/2012
Metastatic Colorectal Cancer Case Debates - Practical Solutions to Provide Optimal Management Beaumont Cancer Center Royal Oaks, Michigan	12/2012
ASCO Clinical Review: Gastrointestinal Cancers 5th Annual Midwest Cancer Alliance Membership Meeting. The University of Kansas Cancer Center Kansas City, Kansas	09/2013
Therapeutic Advances in Pancreatic Cancer: Is Nihilism Justified? Grand Rounds University of Cincinnati Hematology & Oncology Cincinnati, Ohio	12/2013
Biliary Cancer: A Case for a Rare Cancer Developing into a Comprehensive Program	05/2015

Jefferson University/Kimmel Cancer Center Philadelphia, Pennsylvania	
Immunotherapy and Gastrointestinal Cancers: The Next Frontier Medical Grand Rounds Mayo Clinic Phoenix, AZ	09/2016
Biliary Tract Cancer: A Genetically Heterogeneous Disease Grand Rounds Northshore University Health System/ Northwestern University Evanston, IL	05/2017
Emerging Targets in Biliary Tract Cancers Grand Rounds Emory University/Winship Cancer Center Atlanta, GA	02/2018
Advances in the Treatment of Pancreas Cancer Oncology Grand Rounds Mayo Clinic Cancer Center Scottsdale, AZ	05/2018
A New Era for Precision Medicine in Gastrointestinal Cancers Grand Rounds Methodist Hospital Houston, TX	02/2019
Advances in the Care of Patients with Pancreas Cancer 2019 GI Oncology Conference Tyler, TX	11/2020
A New Era for Precision (Personalized) Medicine in Gastrointestinal Cancers Grand Rounds Roswell Park Cancer Institute Buffalo, NY	11/2020
Hitting the Target: Precision Medicine and Colorectal Cancer Grand Rounds Jefferson University/Kimmel Cancer Center Philadelphia, Pennsylvania	02/2021
Advanced Hepatocellular Carcinoma: The Emerging Role of Immune Based Therapy Grand Rounds Oakland University William Beaumont School of Medicine Detroit, MI	12/2021

RESEARCH GRANTS and AWARDS

Active Grants

Federal

P30 CA015083-46 Comprehensive Cancer Center Grant Role: Associate Medical Director	06/2019-Present
P30 CA015083 PROGRAM LDSHP-12 Comprehensive Cancer Center – Program Leadership	06/2019-Present

Role: Co-Principal Investigator

UH2 CA238926-01

03/2020-Present

HRD-IA Signatures in Pancreatic Ductal Adenocarcinoma

Role: Co-Investigator

Federal sub award

Program Director / Principal Investigator	Dr. Bekaii-Saab Portion Yr 44 of CCSG for Program Leadership: Starting Year 40 Renewal Mayo Comprehensive Cancer Center - Program Leadership. Funded by National Cancer Institute. (CA015083 PROGRAM LDSHP)	05/2016 - Present
Program Director / Principal Investigator	National Cancer Institute, National Clinical Trials Network U10 Lead Academic Site. Funded by National Cancer Institute. (U10 CA180790)	05/2016 - Present

Industry

Program Director / Principal Investigator	ACCRU-GI-1618 (Kopetz-Array) Combination of MEK inhibitor Binimetinib and CDK4/6 inhibitor Palbociclib in KRAS and NRAS mutant metastatic colorectal cancers. Funded by Array BioPharma, Inc.. (ACCRU-GI-1618 Pfizer Tracking IST-162-20X / 53233297)	10/2018 - 09/2021
Program Director / Principal Investigator	Crossover to Pemigatinib. Funded by Incyte Corporation. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	Treatment Group A: Pemigatinib. Funded by Incyte Corporation. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	Treatment Group B: Gemcitabine / Cisplatin. Funded by Incyte Corporation. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	ECTx: MCLA-128-CL01 (MCA). Funded by Merus N.V.. (MCLA-128-CL01)	11/2019 - 11/2021
Program Director / Principal Investigator	16-004349: MCA ARM B and D - A Phase Ib Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Metastatic Pancreatic Adenocarcinoma: 16-004349: MCA A Phase Ib Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Metastatic Pancreatic Adenocarcinoma. Funded by Boston Biomedical, Inc.	09/2016 - 09/2018
Program Director / Principal Investigator	Saab / 1302.3 / 16-007836 - A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated locally advanced or metastatic colorectal cancer: Saab / 1302.3 / ACCRU Mayo Mbshp / 16-007836 - A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated locally advanced or metastatic colorectal cancer. Funded by Boehringer Ingelheim. (ACCRU 1302.3)	01/2017 - 12/2018
Program Director /	AMEND 3 Cohort 1E Phase 1b - Utilizing FOLFOX, Tucatinib, Trastuzumab, Pembrolizumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021

Principal Investigator		
Program Director / Principal Investigator	AMEND 3 Cohort 1F Phase 1b - Utilizing CAPOX, Tucatinib, Trastuzumab, Pembrolizumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	AMEND 3 Cohort 1G Phase 1b - Utilizing Tucatinib, Trastuzumab, Pembrolizumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	AMEND 3 Cohort 2A Phase 2 - Utilizing CAPOX, Tucatinib, Trastuzumab, Pembrolizumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	AMEND 3 Cohort 2A Phase 2 - Utilizing FOLFOX, Tucatinib, Trastuzumab, Pembrolizumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	AMEND 3 Cohort 2B Phase 2 - Utilizing FOLFOX, Tucatinib, Trastuzumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	AMEND 3 Cohort D Phase 1b - Utilizing FOLFOX, Tucatinib, Trastuzumab. Funded by SeaGen. (SGNTUC-024)	10/2020 - 09/2021
Program Director / Principal Investigator	(ACCRU-Sonbol) ACCRU-GI-1810 Ramucirumab +trifluridine/tipiracil for Pts W/ Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Randomized Non-inferiority Phase 2 Study. Funded by Lilly USA, LLC. (ACCRU-GI-1810 / I4T-US-I024 4501655091)	12/2020 - 12/2023
Program Director / Principal Investigator	(ACCRU-Sonbol) ACCRU-GI-1810 Ramucirumab +trifluridine/tipiracil for Pts W/ Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Randomized Non-inferiority Phase 2 Study. Funded by Taiho Oncology, Inc. . (ACCRU-GI-1810)	12/2020 - 12/2023
Program Director / Principal Investigator	Amend #1 / Saab / SGNTUC-019 / 20-012925. Funded by SeaGen. (SGNTUC-019)	05/2021 - 05/2023
Program Director / Principal Investigator	(ACCRU-Ciombor) M14-064, Ph 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Met CRC Prev treated w/Fluoropyrimidine/Oxaliplatin and Bevacizumab. Funded by AbbVie Inc.. (M14-064)	05/2017 - 04/2020
Program Director / Principal Investigator	Saab / ACCRU-GI-1617 - A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer: ACCRU-GI-1617 (Mayo Membership) (IRB# 17-003777) A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer. Funded by ACCRU (Industry). (ACCRU-GI-1617)	06/2017 - 05/2020
Program Director / Principal Investigator	Saab / CanStem111P / 17-001268 - ARM 1 - A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma: Saab / ACCRU Mayo Mbrship / CanStem111P / 17-001268 - A Phase III Study of BBI-608 plus nab-	06/2017 - 05/2020

	Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma . Funded by ACCRU (Industry)	
Program Director / Principal Investigator	Saab / CanStem111P / 17-001268 - ARM 2 - A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma: Saab / ACCRU Mayo Mbrship / CanStem111P / 17-001268 - A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma . Funded by ACCRU (Industry)	06/2017 - 05/2020
Program Director / Principal Investigator	Arm 1- CanStem303C - A Phase III Study of (BBI-608) in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC): (ACCRU Membership) CanStem303C 17-001119 - A Phase III Study of (BBI-608) in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). Funded by ACCRU (Industry)	07/2017 - 06/2019
Program Director / Principal Investigator	Arm 2-CanStem303C - A Phase III Study of (BBI-608) in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC): (ACCRU Membership) CanStem303C 17-001119 - A Phase III Study of (BBI-608) in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). Funded by ACCRU (Industry)	07/2017 - 06/2019
Program Director / Principal Investigator	Saab / GI14-198 / HCRN / 16-007322 - Phase II Randomized, Double-Blind Study of mFOLFIRINOX plus Ramucirumab: GI14-198 / HCRN / 16-007322 - Phase II Randomized, Double-Blind Study of mFOLFIRINOX plus Ramucirumab. Funded by Eli Lilly And Company. (GI14-198)	07/2017 - 06/2020
Program Director / Principal Investigator	Saab / ARRAY-818-302 / Triplet ARM: MCA ACCRU Mayo Membership 17-002303 Saab / ARRAY-818-302 . Funded by ACCRU (Industry). (226949 ARRAY- 818302)	11/2017 - 10/2019
Program Director / Principal Investigator	eFT508-0006 Combination Therapy/Part 1 Dose-Escalation: eFT508-0006 /17-004492-A Ph 2, Open-Label, Randomized, Non-comparative Study With Preliminary Dose-Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory CRC. Funded by eFFECTOR Therapeutics. (eFT508-0006)	01/2018 - 12/2019
Program Director / Principal Investigator	eFT508-006 Monotherapy: eFT508-0006 /17-004492-A Ph 2, Open-Label, Randomized, Non-comparative Study With Preliminary Dose-Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory CRC. Funded by eFFECTOR Therapeutics. (eFT508-0006)	01/2018 - 12/2019
Program Director / Principal Investigator	Atezo + BL-8040 ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	Atezo + Cobi ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020

Program Director / Principal Investigator	Atezo + Linagliptin ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	Atezo + mFOLFOX6 followed by Atezo + Cobi: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	Atezo + PEGPH20 ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	Control ARM - mFOLFOX6: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	Control ARM - Ramucirumab + Paclitaxel: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	mFOLFOX6 + Atezo + Cobi ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	mFOLFOX6 + Atezo ARM: 17-006773/ Phase Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC CANCER). Funded by Genentech Incorporated. (YO39609)	01/2018 - 01/2020
Program Director / Principal Investigator	ECTx-MCA 15834: ECTx- 15834 (MCA Lead) Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies. Funded by Bayer HealthCare AG	03/2018 - 03/2020
Program Director / Principal Investigator	ACCRU-GI-1618 (Kopetz-Array) Combination of MEK inhibitor Binimetinib and CDK4/6 inhibitor Palbociclib in KRAS and NRAS mutant metastatic colorectal cancers. Funded by Array BioPharma, Inc.. (ACCRU-GI-1618)	10/2018 - 09/2021
Program Director /	PART 2/ARM A - BMS-813160 +/- FOLFIRI: 18-003782 CV202-103 A Phase 1b/2 Study of BMS-813160 in Combination with	11/2018 - 10/2020

Principal Investigator	Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (advanced colorectal and panc) . Funded by Bristol-Myers Squibb Pharmaceutical. (CV202-103)	
Program Director / Principal Investigator	PART 2/ARM B -BMS-813160/Gemcitabine/Nab-paclitaxel/Nivolumab: 18-003782 CV202-103 A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (advanced colorectal and panc) . Funded by Bristol-Myers Squibb Pharmaceutical. (CV202-103)	11/2018 - 10/2020
Program Director / Principal Investigator	Part 2/ARM C/BMS-813160/Nivolumab (Including Cross Over): 18-003782 CV202-103 A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (advanced colorectal and panc) . Funded by Bristol-Myers Squibb Pharmaceutical. (CV202-103)	11/2018 - 10/2020
Program Director / Principal Investigator	Part 2/ARM D/BMS-813160 Monotherapy: 18-003782 CV202-103 A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors (advanced colorectal and panc) . Funded by Bristol-Myers Squibb Pharmaceutical. (CV202-103)	11/2018 - 10/2020
Program Director / Principal Investigator	Arm A: chemotherapy (gemcitabine/nab-paclitaxel [ABRAXANE] or 5-fluorouracil/leucovorin [calcium folinate]/irinotecan liposome [ONIVYDE]*): 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Arm B: Cabiralizumab / Nivolumab: 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Arm C / 2L Cohort: Cabiralizumab / Nivolumab / Gem / Nab-Paclitaxel: 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Arm D: Cabiralizumab / Nivolumab / Oxaliplatin/5-FU/FOLFOX: 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Arm E / 1L Cohort: Gem / Nab-Paclitaxel: 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Arm F: Cabiralizumab / Nivolumab / Gem / Nab-Paclitaxel: 18-003800 / CTA Amend # A03 / Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Admin in Combo with Nivolumab (BMS-936558) with and without Chemo in Patients with Adv Pancreatic Cancer. Funded by Bristol-Myers Squibb Pharmaceutical. (CA025006)	11/2018 - 10/2021
Program Director / Principal Investigator	Phase I/Ib Study Irinotecan Liposome, 5-FU/Rucaparib in Tx of Gastrointestinal Met Malignancies Followed by Phase II Study of First Line Treatment of Selected Pts with Met Adenocarcinoma of the Panc w/Genomic Markers of Homologous Recombination Deficiency:	11/2018 - 11/2022

	ACCRU - Mayo Membership - MCR ACCRU-GI-1603. Funded by ACCRU (Industry). (ACCRUGI-1603)	
Program Director / Principal Investigator	Phase I/Ib Study Irinotecan Liposome, 5-FU/Rucaparib in Tx of Gastrointestinal Met Malignancies Followed by Phase II Study of First Line Treatment of Selected Pts with Met Adenocarcinoma of the Panc w/Genomic Markers of Homologous Recombination Deficiency: ACCRU Mayo Membership ACCRU-GI-1603 18-006386 I/Ib Study (nal-IRI) 5-FU/Rucaparib in Gastrointestinal Malignancies Followed by Ph II Study of First Line Treatment of Selected Pts Met Adeno.... Funded by ACCRU (Industry). (ACCRU-GI-1603)	11/2018 - 11/2022
Program Director / Principal Investigator	(ACCRU-TBD) 2018-07; Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion. Funded by Exact Sciences. (2018-07)	11/2018 - 11/2022
Program Director / Principal Investigator	ECTx INCMGA-0012-102 Dr. Bekaii-Saab Arm A: (ECTx) INCMGA0012-102 (AZ lead Bekaii-Saab) A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors. Funded by Incyte. (INCMGA0012-102)	12/2018 - 12/2020
Program Director / Principal Investigator	ECTx INCMGA-0012-102 Dr. Bekaii-Saab Arm B: (ECTx) INCMGA0012-102 (AZ lead Bekaii-Saab) A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors. Funded by Incyte. (INCMGA0012-102)	12/2018 - 12/2020
Program Director / Principal Investigator	Combination Treatment through End of Study (Cohorts 1 and 2): ARYS-001 - An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC) . Funded by Arrys Therapeutics, Inc.. (ARYS-001)	01/2019 - 01/2021
Program Director / Principal Investigator	Single Agent Run-in Period (Cohort 1): ARYS-001 - An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC) . Funded by Arrys Therapeutics, Inc.. (ARYS-001)	01/2019 - 01/2021
Program Director / Principal Investigator	Crossover to Pemigatinib: IRB 18-003888 / MCA / INCB 54828-302 / Phs 3, OL, Rando, Active-Control, Multicenter Study to Evaluate Efficacy and Safety of Pemigatinib Vs Gem Plus Cis Chemo in First-Line Tx of Participants W/Unresectable or Metastatic Cholangiocarcinoma W/FGFR2 . Funded by Incyte. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	Treatment Group A: Pemigatinib: IRB 18-003888 / MCA / INCB 54828-302 / Phs 3, OL, Rando, Active-Control, Multicenter Study to Evaluate Efficacy and Safety of Pemigatinib Vs Gem Plus Cis Chemo in First-Line Tx of Participants W/Unresectable or Metastatic Cholangiocarcinoma W/FGFR2 . Funded by Incyte. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	Treatment Group A: Pemigatinib: MCR / Mahipal / INCB54828-302. Funded by Incyte. (INCB 54828-302)	05/2019 - 04/2022
Program Director / Principal Investigator	Treatment Group B: Gemcitabine / Cisplatin: IRB 18-003888 / MCA / INCB 54828-302 / Phs 3, OL, Rando, Active-Control, Multicenter Study to Evaluate Efficacy and Safety of Pemigatinib Vs Gem Plus Cis Chemo in First-Line Tx of Participants W/Unresectable or Metastatic Cholangiocarcinoma W/FGFR2 . Funded by Incyte. (INCB 54828-302)	05/2019 - 04/2022
Co-Investigator	MCA / Saab - Small Bowel Budget: MCA - ACCRU (Mayo Membership) 17-002684 RU021502I, A multicenter phase II study of pembrolizumab (MK-3475) in patients with advanced small bowel adenocarcinomas. Funded by ACCRU (Industry)	05/2017 - 05/2020

Program Director / Principal Investigator	Amend #4 Diva + Cetux. Funded by Genentech Inc. (WO42758)	10/2021 - 09/2023
Program Director / Principal Investigator	Amend #4 Diva + Cetux + FOLFIRI. Funded by Genentech Inc. (WO42758)	10/2021 - 09/2023
Program Director / Principal Investigator	Amend #4 Diva + Cetux + FOLFOX. Funded by Genentech Inc. (WO42758)	10/2021 - 09/2023
Program Director / Principal Investigator	Amend #4 Inavo + Bev Treatment Arm. Funded by Genentech Inc. (WO42758)	10/2021 - 09/2023
Program Director / Principal Investigator	Amend #4 Inavo + Cetux Treatment Arm. Funded by Genentech Inc. (WO42758)	10/2021 - 09/2023
Program Director / Principal Investigator	ACCRU BASE (Acke - ACCRU-GI-1920) Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients with High-risk Hepatocellular Carcinoma. Funded by AstraZeneca Pharmaceuticals LP	11/2021 - 11/2024
Program Director / Principal Investigator	ACCRU BASE (Acke - ACCRU-GI-1920) Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients with High-risk Hepatocellular Carcinoma. Funded by Bayer HealthCare AG. (IIR-US-00139)	11/2021 - 11/2024
Program Director / Principal Investigator	Amend #1- (ACCRU-Ma) ACCRU-GI-2008; A Phase II Randomized Study of Atezolizumab + Multi-Kinase Inhibitor vs Multi-Kinase Inhibitor in Unresectable, Advanced Hepatocellular Carcinoma Prev Rcvd Atezolizumab +Bevacizumab. Funded by Genentech Inc. (ACCRU-GI-2008)	12/2021 - 12/2025
Program Director / Principal Investigator	(Acke - ACCRU-GI-2017) A Phase II study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab. Funded by Bristol Myers Squibb. (CA209-6F7)	01/2022 - 01/2025
Program Director / Principal Investigator	Am #1 Actuate 1801 (MCA lead) - Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors - PART 3 ARM B. Funded by Actuate Therapeutics. (ACT 1801)	01/2022 - 01/2024
Program Director / Principal Investigator	A1(ACCRU-Goetz) D8532C00001 SERENA-4: A Random Dble-Blind, Ps III Study of AZD9833 + Palbociclib vs Anastrozole + Palbociclib for the Txt of Pts w/ Estrogen Receptor-Pos, HER2-Neg Adv Breast Cancer Who Have Not Rcvd Any Systemic Tx for Advanced Disease. Funded by AstraZeneca Pharmaceuticals LP. (D8532C00001)	02/2022 - 02/2025
Program Director / Principal Investigator	ECTx RP-6306-02_MCA_Module 1a_RP-6306+Gemcitabine. Funded by Repare Therapeutics. (RP-6306-02 1018)	06/2022 - 05/2024
Program Director / Principal Investigator	ECTx RP-6306-02_MCA_Module 1b_RP-6306+Gemcitabine. Funded by Repare Therapeutics. (RP-6306-02 1018)	06/2022 - 05/2024

Program Director / Principal Investigator	Am2 ECTx (Combo Substudies) (MCA) A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. Funded by Mirati Therapeutics, Inc.. (849-001)	06/2022 - 06/2024
Program Director / Principal Investigator	Am2 ECTx (Main Study) (MCA) A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. Funded by Mirati Therapeutics, Inc.. (849-001)	06/2022 - 06/2024
Program Director / Principal Investigator	Am2 ECTx (Phase 2 Cetux Combo Cohort G) (MCA) A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation. Funded by Mirati Therapeutics, Inc.. (849-001)	06/2022 - 06/2024
Program Director / Principal Investigator	FOLFOX6. Funded by SeaGen. (SGNTUC-029)	08/2022 - 08/2025
Program Director / Principal Investigator	mFOLFOX6 w/ Bevacizumab. Funded by SeaGen. (SGNTUC-029)	08/2022 - 08/2025
Program Director / Principal Investigator	mFOLFOX6 w/ Cetuximab. Funded by SeaGen. (SGNTUC-029)	08/2022 - 08/2025
Program Director / Principal Investigator	Tucatinib Experimental Arm (Tucatinib + trastuzumab + FOLFOX6). Funded by SeaGen. (SGNTUC-029)	08/2022 - 08/2025
Program Director / Principal Investigator	AM #1: CUE-102. Funded by Cue Biopharma. (CUE-102-01)	10/2022 - 10/2024
Program Director / Principal Investigator	AM 2 & 3 - 1719-001_MCA_Saab_Substudy 1 (PA V5.0) (ARZ). Funded by Mirati Therapeutics, Inc.. (1719-001)	11/2022 - 11/2024
Program Director / Principal Investigator	AM 2 & 3 - 1719-001_MCA_Saab_Substudy 2 (PA V5.0) (ARZ). Funded by Mirati Therapeutics, Inc.. (1719-001)	11/2022 - 11/2024
Program Director / Principal Investigator	AM 2 & 3 - 1719-001_MCA_Saab_Substudy 3 (PA V5.0) (ARZ). Funded by Mirati Therapeutics, Inc.. (1719-001)	11/2022 - 11/2024
Program Director / Principal Investigator	Experimental/Exploratory/CLM Arm. Funded by BioNTech SE . (BNT122-01)	03/2023 - 03/2026
Program Director / Principal Investigator	Observational Group. Funded by BioNTech SE . (BNT122-01)	03/2023 - 03/2026

Program Director / Principal Investigator	Phase 2 Cohort 3B Observation (SOC). Funded by Elicio Therapeutics, Inc. (ELI-002-201)	07/2023 - 07/2025
Program Director / Principal Investigator	Phase 2 Cohorts 2, 3A, & 3C - ELI-002 7P Immunotherapy. Funded by Elicio Therapeutics, Inc. (ELI-002-201)	07/2023 - 07/2025
Program Director / Principal Investigator	Am #1 Phase IA & IB. Funded by Mirati Therapeutics, Inc.. (1133-001 277977 site 311)	07/2023 - 07/2026
Program Director / Principal Investigator	PART A / AFTER INTRAPATIENT DOSE ESCALATION. Funded by Boehringer Ingelheim. (1512-0001)	03/2024 - 03/2028
Program Director / Principal Investigator	PART A / BEFORE INTRAPATIENT DOSE ESCALATION. Funded by Boehringer Ingelheim. (1512-0001)	03/2024 - 03/2028
Program Director / Principal Investigator	Part B / Dose Confirmation. Funded by Boehringer Ingelheim. (1512-0001)	03/2024 - 03/2028
Program Director / Principal Investigator	PART C - Dose Expansion. Funded by Boehringer Ingelheim. (1512-0001)	03/2024 - 03/2028
Program Director / Principal Investigator	MCA(Lead) - Escalation. Funded by Arcus Biosciences, Inc.. (ARC-25)	06/2024 - 06/2026
Program Director / Principal Investigator	MCA(Lead) - Expansion Cohort 2 (Q2W). Funded by Arcus Biosciences, Inc.. (ARC-25)	06/2024 - 06/2026
Program Director / Principal Investigator	Am:2 Rilve/placebo + Capecitabine. Funded by AstraZeneca Pharmaceuticals LP. (D7025C00001)	07/2024 - 06/2027
Program Director / Principal Investigator	Am:2 Rilve/placebo + Gem/cis. Funded by AstraZeneca Pharmaceuticals LP. (D7025C00001)	07/2024 - 06/2027
Program Director / Principal Investigator	Vilastobart (XTX101) in Combination w/Atezolizomab. Funded by Xilio Development, Inc.	10/2024 - 10/2025
Program Director / Principal Investigator	Quemliclustat (AB680) / Placebo / Nab-paclitaxel (NP) and gemcitabine (Gem) (NP-Gem). Funded by Arcus Biosciences, Inc.. (PRISM-1)	02/2025 - 01/2027

Co-Investigator	(ACCRU-Ahn) ACCRU-ICRN-1702, A Phase II Study of Olaparib in Patients with Advanced Biliary Tract Cancer with Aberrant DNA Repair Gene Mutations. Funded by AstraZeneca Pharmaceuticals LP. (ESR-17-13059/D0817C00069)	09/2017 - 09/2020
Co-Program Director / Principal Investigator	Am #2 Phase 3 Arms A, B & C. Funded by Pfizer Inc.. (C4221015 1340)	01/2021 - 01/2022
Co-Program Director / Principal Investigator	Am #2 Phase 3 Arms D & E. Funded by Pfizer Inc.. (C4221015 1340)	01/2021 - 01/2022
Co-Program Director / Principal Investigator	Am #2 Safety Lead-in. Funded by Pfizer Inc.. (C4221015 1340)	01/2021 - 01/2022

Completed Grants

Federal

Principal Investigator	A Phase II study of GW572016 in Hepatobiliary tumors. Funded by Translational Genomics Research funds from CTEP/NCI	01/2005 - 01/2008
Principal Investigator	Phase II Study of the efficacy and tolerability of AZD6244 in patients with advanced Biliary Carcinomas. Funded by Translational Genomics Research funds from CTEP/NCI	01/2006 - 01/2010
Principal Investigator	Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors. Funded by National Cancer Institute . (1R21CA135608-01A2)	01/2009 - 01/2013
Principal Investigator	Clinical Investigator Team Leadership Award. Funded by National Cancer Institute . (Supplement to 3P30CA016058-35W1)	01/2011 - 01/2013
Principal Investigator	Randomized phase II trial of single agent MEK inhibitor Trametinib (GSK1120212) vs. 5-FU or capecitabine in refractory advanced biliary cancer (SWOG 1310). Funded by NCCN / SWOG. (NCT02042443)	01/2014 - 01/2017
Program Director / Principal Investigator	Project 4: Pancreatic SPORE grant w/ Dr. Gloria Peterson at MCR: Mayo Clinic SPORE in Pancreatic Cancer. Funded by National Institutes of Health. (P50CA102701)	09/2017 - 08/2019
Co-Investigator	Biomodulation of capecitabine by docetaxel in non-small cell lung cancer. Funded by National Cancer Institute. (R21 CA 108157)	01/2004 - 01/2006
Co-Investigator	Innate Immunity: Elucidation and Modulation for Cancer Therapy. Funded by National Cancer Institute . (2P01CA095426-06)	01/2007 - 01/2012
Co-Investigator	Innate Immunity: Elucidation and Modulation for Cancer Therapy. Funded by National Cancer Institute . (2P01CA095426-06)	01/2007 - 01/2012
Co-Investigator	CALGB-The Ohio State University. Funded by National Institute of Health/National Cancer Institute. (5 U10 CA077658-06)	01/2007 - 12/2015
Co-Program Director / Principal Investigator	Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors. Funded by National Cancer Institute. (1R21CA135608-01A2)	01/2009 - 01/2013

Co-Investigator	Fatigue, depression, and inflammation in cancer survivors: A prospective study. Funded by National Institute of Health. (1R01CA131029-01)	01/2010 - 12/2014
Co-Investigator	Targeting Somatic Homologous Recombination in Solid Tumors. Funded by National Institute of Health. (1R01CA152101-01)	01/2010 - 12/2015
Principal Investigator	A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel plus Reovirus Serotype-3 Dearing Strain (Reolysin®) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients with Recurrent or Metastatic Pancreatic Cancer. Funded by National Cancer Institute. (N01-CM-62207)	01/2011 - 01/2014
Co-Investigator	Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer. Funded by National Institute of Health. (R21 CA149939)	01/2012 - 01/2014
Co-Investigator	Early Therapeutics Development with a Phase II Emphasis. Funded by National Cancer Institute. (N01-CM-62207)	01/2012 - 01/2016
Co-Program Director / Principal Investigator	Randomized phase II trial of single agent MEK inhibitor Trametinib (GSK1120212) vs. 5-FU or capecitabine in refractory advanced biliary cancer (SWOG 1310). Funded by National Cancer Institute. (NCT02042443)	01/2014 - 01/2016
Co-Program Director / Principal Investigator	Randomized phase II trial of single agent MEK inhibitor Trametinib (GSK1120212) vs. 5-FU or capecitabine in refractory advanced biliary cancer (SWOG 1310). Funded by NCCN / SWOG	01/2014 - 01/2016

Industry

Principal Investigator	A Phase I dose escalation and biological study of capecitabine and mitomycin C in gastrointestinal malignancies. Funded by Roche Pharmaceuticals	01/2004 - 01/2007
Principal Investigator	A phase II study of Capecitabine and Docetaxel in previously untreated advanced non -small cancer patients. Funded by Roche Pharmaceuticals	01/2004 - 01/2007
Principal Investigator	A phase II study of Capecitabine and Docetaxel in previously untreated advanced non -small cancer patients. Funded by Sanofi-Aventis	01/2004 - 01/2007
Principal Investigator	A phase I dose escalation study of capecitabine, carboplatin, and weekly paclitaxel and a phase II trial of the combination in patients with adenocarcinoma of unknown primary site. Funded by Roche Pharmaceuticals	01/2004 - 01/2011
Principal Investigator	A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreas Cancer. Funded by National Comprehensive Cancer Network . (60005181)	01/2005 - 01/2008
Principal Investigator	A phase II trial of preoperative Irinotecan, Cisplatin and radiation in esophageal cancer. Funded by University of Chicago	01/2006 - 01/2010
Principal Investigator	A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5-Fluorouracil and Bevacizumab in Patients with Advanced Pancreas Cancer. Funded by Genentech	01/2006 - 01/2011
Principal Investigator	A multi-institutional phase II study of Neoadjuvant Gemcitabine and Oxaliplatin and radiation therapy in patients with pancreatic cancer. Funded by University of Michigan	01/2007 - 01/2011
Principal Investigator	Phase II trial of bevacizumab, docetaxel, and oxaliplatin in gastric and gastroesophageal junction cancer. Funded by Barbara Ann Karmanos Cancer Institute	01/2008 - 01/2011

Principal Investigator	Mechanistic Radiographic and Biologic Phase II Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastro-esophageal Cancers. Funded by Pfizer	01/2008 - 01/2014
Principal Investigator	Phase I dose-escalation study of oral ARRY-438162 in patients with advanced solid tumors followed by an expansion cohort in patients with advanced or metastatic biliary cancer. Funded by Array BioPharma, Inc.	01/2009 - 01/2013
Principal Investigator	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma who have failed first-line platinum-based therapy . Funded by National Comprehensive Cancer Network . (60005181)	01/2010 - 01/2013
Collaborator	A phase I trial of MEK inhibitor GSK1120212 in combination with neoadjuvant 5-Fluorouracil chemoradiation in the treatment of KRAS, BRAF, and NRAS-mutant rectal cancer. Funded by National Comprehensive Cancer Network . (60005181)	01/2012 - 01/2016
Program Director / Principal Investigator	Saab / RU021302I / 17-002043 - A Double-blind, Placebo-controlled Ph II Trial of Irinotecan, Cetuximab, & Bevacizumab Compared with Irinotecan, Cetuximab, & Placebo in KRAS-Wildtype, Irinotecan-refractory Metastatic Colorectal Cancer: ACCRU Mayo Membership / RU021302I / 17-002043 - A Double-blind, Placebo-controlled Ph II Trial of Irinotecan, Cetuximab, & Bevacizumab Compared with Irinotecan, Cetuximab, & Placebo in KRAS-Wildtype, Irinotecan-refractory Metastatic Colorectal Cancer . Funded by ACCRU (Industry). (RU021302I)	04/2017 - 04/2019
Program Director / Principal Investigator	ECTx GBR 1302-101 (17-005327 MCA) A Phase 1, first-in-man, multicenter, open-label, dose-escalation study of single-agent GBR 1302 in subjects with HER2 positive cancers. Funded by Glenmark Pharmaceuticals, SA	10/2017 - 10/2019
Program Director / Principal Investigator	Atezo + Cobi ARM: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	Atezo + mFOLFOX6 followed by Atezo + Cobi: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	Atezo + PEGPH20 ARM: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	Control ARM - mFOLFOX6: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020

Program Director / Principal Investigator	Control ARM - Ramucirumab + Paclitaxel: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	ECTx-MCA INCB 24360-206 A-3: ECTx INCB 24360-206 MCA (lead) . Funded by Incyte. (INCB 24360-206)	01/2018 - 01/2020
Program Director / Principal Investigator	ECTx-MCA INCB 24360-206 A-4: ECTx INCB 24360-206 MCA (lead) . Funded by Incyte. (INCB 24360-206)	01/2018 - 01/2020
Program Director / Principal Investigator	ECTx-MCA INCB 24360-206 A-5: ECTx INCB 24360-206 MCA (lead) . Funded by Incyte. (INCB 24360-206)	01/2018 - 01/2020
Program Director / Principal Investigator	mFOLFOX6 + Atezo + Cobi ARM: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	mFOLFOX6 + Atezo ARM: 17-006773/ PHASE Ib/II, OL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PTS W LOCALLY ADV UNRESECTABLE OR METASTATIC GASTRIC OR GEJ CANCER (MORPHEUS-GASTRIC . Funded by Genentech Incorporated. (Y039609)	01/2018 - 01/2020
Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TG C,D,E,G, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))	03/2018 - 03/2020
Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TG C,D,E,G-Bx, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))	03/2018 - 03/2020
Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TG F, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety,	03/2018 - 03/2020

Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))

Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TG F-Bx, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))	03/2018 - 03/2020
Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TGA/B, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))	03/2018 - 03/2020
Program Director / Principal Investigator	ECTx INCB24360-207 (17-001784) TGA/B-Bx, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723): ECTx INCB24360-207 (17-001784) MCA, A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723). Funded by Incyte. (INCB24360-207 (ECHO))	03/2018 - 03/2020

Other

Principal Investigator	AZD6244 in Biliary Cancers. Funded by Experimental Therapeutics Program Award. (ETP91)	01/2008 - 01/2009
Principal Investigator	A Phase 2 Study of AZD6244 in Biliary Cancers. Funded by OSU/Nationwide Children's Hospital Collaboration Award Program. (Org 25256/fund 500852/program 15072)	01/2009 - 01/2010
Principal Investigator	Pre-clinical studies to evaluate the efficacy and immunomodulatory effects of MEK inhibition with ARRY162 for biliary cancer. Funded by Experimental Therapeutics Program Award – ETP121	01/2012 - 01/2013
Principal Investigator	Development of Targeted Therapies for Pancreatic Cancer. Funded by The Ohio State University CCC	01/2013 - 01/2015
Collaborator	Ohio Patient Navigator Program. Funded by American Cancer Society. (SIRSG-05-253-01)	01/2005 - 01/2008

*Dr. Bekaii-Saab had been a Co-investigator on > 100 studies over the last 2 decades.

DISCOVERIES/PATENTS/INVENTIONS

Title	Publication Number	Publication Date	Licensed to	Clinical Trial
Human PD1 Peptide Vaccines and Uses Thereof*	WO/2018/183488	04.10.2018	Imugene	NCT04432207

Methods and Compositions for the
Treatment of Cancer Cachexia

WO/2019/055687

21.03.2019

Recursion

NCT05130866

Patent*	Patent Number	Country	Date Filed	Date Issued
Methods for Suppressing Cancer-related Cachexia Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng	20150150832	US	11/2014	06/2015
Human PD1 Peptide Vaccines and Uses Thereof Pravin T.P. Kaumaya, Tanios S. Bekaii-Saab M.D.	11684660	USA	09/2019	06/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	7346302	JP	09/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	3600398	DE	10/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	3600398	EP	10/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	3600398	ES	10/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	3600398	FR	10/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	3600398	IT	10/2019	09/2023
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	10-2653567	KR	10/2019	03/2024
Human PD1 Peptide Vaccines and Uses Thereof Tanios S. Bekaii-Saab M.D., Pravin T.P. Kaumaya	ZL201880022159.X	CN	09/2019	08/2024

CONTRIBUTIONS TO REGULATORY APPROVALS and NCCN Guidelines inclusion

Contributions that led to the regulatory approval of several agents including the following:

- Tucatinib (Tukysa ®) and trastuzumab in patients with *HER2* amplified colorectal cancer (2024)
- Infigratinib (Truseltiq ®) and pemigatinib (Pegizyme ®) in patients with FGFR2 gene fusion in bile duct cancers (2021 and 2020 respectively)
- Liposomal irinotecan (Onyvite ®) for patients with pancreatic cancer (2015 (2L) and 2024 (1L)).
- Adagrasib (Krazati ®) and Cetuximab (Erbix ®) for patients with mCRC and a KRAS G12C mutation (2024)

Contributions that led to inclusion in NCCN guidelines of several agents including the following

- Adagrasib (Krazati ®) for patients with pancreatic cancer and cholangiocarcinoma with a KRAS G12C mutation (2024)
- Tucatinib (Tukysa ®) and trastuzumab in patients with *HER2* amplified cholangiocarcinoma (2024)
- Regorafenib with a dose optimized strategy (ReDOS) in refractory mCRC (2019)

OTHER

Languages: English, French and Arabic (written, read, and spoken fluently).
Spanish and German (Read)

Activities: Racquetball, hiking and travelling

BIBLIOGRAPHY

Peer-reviewed and Original Articles (Out of 422 publications) Google Scholar: *H-Index* = 83; *i10-Index* = 343
Citations = 28869 ; Scopus *H-Index* = 70; *Citations* = 18075

<https://www.ncbi.nlm.nih.gov/myncbi/tanios.bekaii-saab.1/bibliography/public/>

1. Court MH, Hao Q, Krishnaswamy S, **Bekaii-Saab T**, Al-Rohaimi A, von Moltke LL, Greenblatt DJ. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. *J Pharmacol Exp Ther*. 2004 Aug;310(2):656-65. doi: 10.1124/jpet.104.067660. Epub 2004 Mar25. PMID:15044558
2. **Bekaii-Saab TS**, Perloff MD, Weemhoff JL, Greenblatt DJ, von Moltke LL. Interactions of tamoxifen, N-desmethyldoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. *Biopharm Drug Dispos*. 2004 Oct;25(7):283-9. doi: 10.1002/bdd.411. PMID: 15386482.
3. **Bekaii-Saab TS**, Villalona-Calero MA. Preclinical experience with docetaxel in gastrointestinal cancers. *Semin Oncol*. 2005 Apr;32(2 Suppl 4): S3-9. doi: 10.1053/j.seminoncol.2005.04.002. PMID: 16015550.
4. **Bekaii-Saab TS**, Mortazavi A, Hicks LG, Zalupski M, Pelley RJ, Chan KK, Kraut EH. A phase II study of chloroquinoline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCR). *Invest New Drugs*. 2006 Jul;24(4):343-6. doi: 10.1007/s10637-005-4827-3. PMID: 16446986.
5. Li J, Zhu J, Melvin WS, **Bekaii-Saab TS**, Chen CS, Muscarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. *J Gastrointest Surg*. 2006 Feb;10(2):207-14. doi: 10.1016/j.gassur.2005.07.025. PMID: 16455452.
6. Kosuri K, Muscarella P, **Bekaii-Saab TS**. Updates and controversies in the treatment of pancreatic cancer. *Clin Adv Hematol Oncol*. 2006 Jan;4(1):47-54. PMID: 16562370.
7. Ajani J, **Bekaii-Saab T**, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. *J Natl Compr Canc Netw*. 2006 Apr;4(4):328-47. doi: 10.6004/jncn.2006.0029. PMID: 16569387.
8. Ajani J, **Bekaii-Saab T**, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. *J Natl Compr Canc Netw*. 2006 Apr;4(4):350-66. doi: 10.6004/jncn.2006.0030. PMID: 16569388.
9. Benson AB 3rd, **Bekaii-Saab T**, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA Jr, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ; National Comprehensive Cancer Network. Hepatobiliary cancers. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2006 Sep;4(8):728-50. doi: 10.6004/jncn.2006.0064. PMID: 16948952.
10. Bloomston M, **Bekaii-Saab TS**, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P 2nd. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. *Pancreas*. 2006 Oct;33(3): 246-9. doi:10.1097/01.mpa.0000236726.34296.df. PMID: 17003645.
11. Ross P Jr, Grecula J, **Bekaii-Saab T**, Villalona-Calero M, Otterson G, Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. *Lasers Surg Med*. 2006 Dec;38(10):881-9. doi: 10.1002/lsm.20444. PMID: 17115382.
12. **Bekaii-Saab T**, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. *BMC Cancer*. 2006 Dec 6;6:278. doi: 10.1186/1471-2407-6-278. PMID: 17150109; PMCID: PMC1712353.
13. Kapoor KG, **Bekaii-Saab T**. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. *Intern Med J*. 2008 Apr;38(4):281-3. doi: 10.1111/j.1445-5994.2008.01646.x. PMID: 18380703.
14. **Bekaii-Saab TS**, Liu J, Chan KK, Balcerzak SP, Ivy PS, Grever MR, Kraut EH. A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors. *Clin Cancer Res*. 2008 Jun 1;14(11):3434-40. doi: 10.1158/1078-0432.CCR-07-4903. PMID: 18519774
15. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, **Bekaii-Saab T**, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Noncytotoxic suramin as a chemosensitizer in patients

with advanced non-small-cell lung cancer: a phase II study. *Ann Oncol*. 2008 Nov;19(11):1903-9. doi: 10.1093/annonc/mdn412. Epub 2008 Jul 15. PMID: 18632723; PMCID: PMC2733080.

16. Ajani JA, Barthel JS, **Bekaii-Saab T**, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G; NCCN Esophageal Cancer Panel. Esophageal cancer. *J Natl Compr Canc Netw*. 2008 Oct;6(9):818-49. PMID: 18926093.
17. Haghighat P, **Bekaii-Saab T**. An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. *J Natl Compr Canc Netw*. 2008 Oct;6(9):895-900. doi: 10.6004/jnccn.2008.0068. PMID: 18926099.
18. So BJ, **Bekaii-Saab T**, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. *J Hematol Oncol*. 2008 Oct 17;1:18. doi: 10.1186/1756-8722-1-18. PMID: 18928548; PMCID: PMC2575202.
19. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, **Bekaii-Saab TS**. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. *Oncology*. 2009;76(5):333-7. doi: 10.1159/000209962. Epub 2009 Mar 23. PMID: 19307739.
20. Friedman L, Lin L, Ball S, **Bekaii-Saab T**, Fuchs J, Li PK, Li C, Lin J. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. *Anticancer Drugs*. 2009 Jul;20(6):444-9. doi: 10.1097/CAD.0b013e32832af04. PMID: 19384191; PMCID: PMC2855307.
21. Ntukidem N, Arce-Lara C, Otterson GA, Kraut E, Cataland S, **Bekaii-Saab T**. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. *Cancer Chemother Pharmacol*. 2010 Jan;65(2):319-24. doi: 10.1007/s00280-009-1036-3. PMID: 19506871.
22. **Bekaii-Saab T**. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. *Clin Colorectal Cancer*. 2009 Jul;8(3):135-40. doi: 10.3816/CCC.2009.n.022. PMID: 19632927.
23. **Bekaii-Saab T**, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. *Cancer Chemother Pharmacol*. 2010 Apr;65(5):863-9. doi: 10.1007/s00280-009-1091-9. Epub 2009 Aug 6. PMID: 19657639; PMCID: PMC4261191.
24. **Bekaii-Saab T**. Expanding the arsenal for metastatic colorectal cancer: a discussion of current clinical trials. *Clin Adv Hematol Oncol*. 2009 Jul;7(7):430-2. PMID: 19701148.
25. **Bekaii-Saab T**, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. *Clin Cancer Res*. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8. PMID: 19737952; PMCID: PMC2774354.
26. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, **Bekaii-Saab TS**, Carson WE 3rd. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. *J Clin Oncol*. 2009 Nov 1;27(31):5270-7. doi: 10.1200/JCO.2009.22.3883. Epub 2009 Sep 14. PMID: 19752336; PMCID: PMC2773479.
27. Ramaswamy B, **Bekaii-Saab T**, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2010 May;66(1):151-8. doi: 10.1007/s00280-009-1145-z. Epub 2009 Sep 23. PMID: 19774377; PMCID: PMC3540804.
28. El-Rayes BF, Zalupski M, **Bekaii-Saab T**, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almehanna K, Smith D, Philip PA. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. *Ann Oncol*. 2010 Oct;21(10):1999-2004. doi: 10.1093/annonc/mdq065. Epub 2010 Mar 23. PMID: 20332133; PMCID: PMC2980934.

29. Ramaswamy B, Mrozek E, Kuebler JP, **Bekaii-Saab T**, Kraut EH. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. *Invest New Drugs*. 2011 Apr;29(2):347-51. doi: 10.1007/s10637-009-9338-1. Epub 2009 Oct 21. PMID: 19844661; PMCID: PMC3486428.
30. **Bekaii-Saab TS**, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu- expressing malignancies. *Mol Cancer Ther*. 2009 Nov;8(11):2983-91. doi: 10.1158/1535-7163.MCT-09-0820. Epub 2009 Nov 3. PMID: 19887543; PMCID: PMC2996611.
31. Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, **Bekaii-Saab T**, Murgu AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. *Cancer Chemother Pharmacol*. 2010 Nov;66(6):1019-29. doi: 10.1007/s00280-010-1252-x. Epub 2010 Jan 28. PMID: 20107799; PMCID: PMC2919610.
32. Lustberg MB, **Bekaii-Saab T**, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. *J Thorac Oncol*. 2010 May;5(5):713-8. doi: 10.1097/JTO.0b013e3181d7776d. PMID: 20354452; PMCID: PMC3641556.
33. Ajani JA, Barthel JS, **Bekaii-Saab T**, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G; NCCN Gastric Cancer Panel. Gastric cancer. *J Natl Compr Canc Netw*. 2010 Apr;8(4):378-409. doi: 10.6004/jnccn.2010.0030. PMID: 20410333.
34. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, **Bekaii-Saab TS**. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. *Oncology*. 2010;78(3-4):210-2. doi: 10.1159/000313701. Epub 2010 Apr 26. PMID: 20424492.
35. Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, **Bekaii-Saab T**. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. *Cancer Chemother Pharmacol*. 2011 Mar;67(3):511-7. doi: 10.1007/s00280-010-1348-3. Epub 2010 May 12. PMID: 20461379.
36. Serna DS, **Bekaii-Saab T**, Kraut EH. A phase I study of topotecan and gemcitabine in advanced solid tumors. *Invest New Drugs*. 2011 Dec;29(6):1390-4. doi: 10.1007/s10637-010-9480-9. Epub 2010 Jun 25. PMID: 20574789.
37. Ramaswamy B, Phelps MA, Baiocchi R, **Bekaii-Saab T**, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. *Invest New Drugs*. 2012 Apr;30(2):629-38. doi: 10.1007/s10637-010-9563-7. Epub 2010 Oct 12. PMID: 20938713; PMCID: PMC3486515.
38. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, **Bekaii-Saab T**, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM; Cancer and Leukemia Group B. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). *Oncologist*. 2010;15(12):1310-9. doi: 10.1634/theoncologist.2010-0152. Epub 2010 Dec 10. PMID: 21148613; PMCID: PMC3227926.
39. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, **Bekaii-Saab TS**, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebt SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. *J Clin Oncol*. 2011 Jun 10;29(17):2350-6. doi: 10.1200/JCO.2010.33.9432. Epub 2011 Apr 25. PMID: 21519015; PMCID: PMC3107750.
40. **Bekaii-Saab T**, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Lierseemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. *J Clin Oncol*. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25. PMID: 21519026; PMCID: PMC3107751.
41. Rose JS, **Bekaii-Saab TS**. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. *Onco Targets Ther*. 2011 Mar 24;4:21-6. doi: 10.2147/OTT.S10188. PMID: 21552412; PMCID: PMC3084304.

42. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, **Bekaii- Saab T**, Carson WE 3rd, Lesinski GB. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. *Cancer Immunol Immunother*. 2011 Sep;60(9):1269-79. doi: 10.1007/s00262-011-1029-z. Epub 2011 May 21. PMID: 21604071; PMCID: PMC3521517.
43. Kaffenberger BH, **Bekaii-Saab T**. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds. *Clin Appl Thromb Hemost*. 2012 Jan- Feb;18(1):104-6. doi: 10.1177/1076029611416641. Epub 2011 Aug 25. PMID: 21873360.
44. Benson AB 3rd, Arnoletti JP, **Bekaii-Saab T**, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW Jr, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C; National Comprehensive Cancer Network. Colon cancer. *J Natl Compr Canc Netw*. 2011 Nov;9(11):1238-90. doi: 10.6004/jnccn.2011.0104. PMID: 22056656.
45. Lin L, Fuchs J, Li C, Olson V, **Bekaii-Saab T**, Lin J. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells. *Biochem Biophys Res Commun*. 2011 Dec 16;416(3-4):246-51. doi: 10.1016/j.bbrc.2011.10.112. Epub 2011 Oct 31. PMID: 22074823.
46. Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, **Bekaii-Saab T**. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. *Clin Colorectal Cancer*. 2012 Sep;11(3):195-9. doi: 10.1016/j.clcc.2011.12.002. Epub 2012 Jan 24. PMID: 22277350; PMCID: PMC3839284.
47. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, **Bekaii-Saab T**. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. *Oncology*. 2012;82(3):175-9. doi: 10.1159/000336488. Epub 2012 Mar 15. PMID: 22433475.
48. Benson AB 3rd, Arnoletti JP, **Bekaii-Saab T**, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA; National Comprehensive Cancer Network. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2012 Apr;10(4):449-54. doi: 10.6004/jnccn.2012.0046. PMID: 22491045.
49. Prado CM, **Bekaii-Saab T**, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. *Br J Cancer*. 2012 May 8;106(10):1583-6. doi: 10.1038/bjc.2012.144. Epub 2012 Apr 17. PMID: 22510747; PMCID: PMC3349178.
50. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, **Bekaii-Saab T**, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. *Cancer*. 2012 Nov 15;118(22):5497-506. doi: 10.1002/cncr.27592. Epub 2012 May 8. PMID: 22569804; PMCID: PMC4215160.
51. Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, **Bekaii-Saab T**. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. *Cancer*. 2012 Dec 15;118(24):6243-52. doi: 10.1002/cncr.27666. Epub 2012 Jun 6. PMID: 22674181; PMCID: PMC3839285.
52. Martin LK, Wei L, Trolli E, **Bekaii-Saab T**. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. *Med Oncol*. 2012 Dec;29(5):3101-7. doi: 10.1007/s12032-012-0278-9. Epub 2012 Jun 24. PMID: 22729400; PMCID: PMC3839283.
53. Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii- Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. *Ann Oncol*. 2012 Nov;23(11):2812-2820. doi: 10.1093/annonc/mds134. Epub 2012 Jul 5. PMID: 22767582; PMCID: PMC3841413.
54. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, **Bekaii-Saab T**. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine- containing chemotherapy: a pooled analysis of 6 prospective trials.

Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11. PMID: 22786786; PMCID: PMC4261189.

55. Wu C, **Bekaii-Saab T**. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. *Chemother Res Pract*. 2012;2012:359041. doi: 10.1155/2012/359041. Epub 2012 Jun 26. PMID: 22792460; PMCID: PMC3389642.
56. Blazer M, Phillips G, Reardon J, Efries D, Smith Y, Weatherby L, Juergens K, Rose J, Griffith N, **Bekaii-Saab T**. Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. *Oncology*. 2012;83(3):135-40. doi: 10.1159/000339145. Epub 2012 Jul 18. PMID: 22814309.
57. Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, **Bekaii-Saab T**. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. *Int J Radiat Oncol Biol Phys*. 2012 Nov 15;84(4):e475-81. doi: 10.1016/j.ijrobp.2012.06.003. Epub 2012 Jul 17. PMID: 22818416; PMCID: PMC3477302.
58. Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, **Bekaii-Saab T**. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. *Invest New Drugs*. 2013 Jun;31(3):685-95. doi: 10.1007/s10637-012-9863-1. Epub 2012 Jul 31. PMID: 22847785; PMCID: PMC3646991.
59. Dixon M, Seevaratnam R, Wirtzfeld D, McLeod R, Helyer L, Law C, Swallow C, Paszat L, Bocicariu A, Cardoso R, Mahar A, **Bekaii-Saab T**, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N. A RAND/UCLA appropriateness study of the management of familial gastric cancer. *Ann Surg Oncol*. 2013 Feb;20(2):533-41. doi: 10.1245/s10434-012-2584-z. Epub 2012 Sep 1. PMID: 22941158.
60. Martin LK, Otterson GA, **Bekaii-Saab T**. Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. *Photomed Laser Surg*. 2012 Nov;30(11):668-71. doi: 10.1089/pho.2012.3293. Epub 2012 Sep 24. PMID: 23003123.
61. Bendell JC, **Bekaii-Saab TS**, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. *Oncologist*. 2012;17(12):1486-95. doi: 10.1634/theoncologist.2012-0190. Epub 2012 Sep 26. PMID: 23015662; PMCID: PMC3528380.
62. Martin LK, **Bekaii-Saab T**. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? *Thrombosis*. 2012;2012:758385. doi: 10.1155/2012/758385. Epub 2012 Sep 11. PMID: 23024860; PMCID: PMC3447377.
63. Paskett ED, Katz ML, Post DM, Pennell ML, Young GS, Seiber EE, Harrop JP, DeGraffinreid CR, Tatum CM, Dean JA, Murray DM; Ohio Patient Navigation Research Program. The Ohio Patient Navigation Research Program: does the American Cancer Society patient navigation model improve time to resolution in patients with abnormal screening tests? *Cancer Epidemiol Biomarkers Prev*. 2012 Oct;21(10):1620-8. doi: 10.1158/1055-9965.EPI-12-0523. PMID: 23045536; PMCID: PMC3785236.
64. Bertino EM, **Bekaii-Saab T**, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer*. 2013 Jan;79(1):27-32. doi: 10.1016/j.lungcan.2012.09.013. Epub 2012 Oct 16. PMID: 23079156; PMCID: PMC3549571.
65. Benson AB 3rd, **Bekaii-Saab T**, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. *J Natl Compr Canc Netw*. 2012 Dec 1;10(12):1528-64. doi: 10.6004/jnccn.2012.0158. PMID: 23221790.
66. Benson AB 3rd, **Bekaii-Saab T**, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2013 Feb 1;11(2):141-52; quiz 152. doi: 10.6004/jnccn.2013.0022. PMID: 23411381.

67. Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, **Bekaii-Saab TS**. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. *Pancreas*. 2013 Jul;42(5):813-8. doi: 10.1097/MPA.0b013e318279b87f. PMID: 23429495; PMCID: PMC3664263.
68. Coburn N, Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardoso R, Mahar A, Lourenco LG, Dixon M, **Bekaii-Saab T**, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, McLeod R. Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. *Ann Surg*. 2014 Jan;259(1):102-8. doi: 10.1097/SLA.0b013e318288dd2b. PMID: 23478525.
69. Martin LK, **Bekaii-Saab T**. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. *J Natl Compr Canc Netw*. 2013 Mar 1;11(3):298-307; quiz 307. doi: 10.6004/jnccn.2013.0041. PMID: 23486456.
70. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, **Bekaii-Saab T**, Bloomston M, Lesinski GB. Pancreatic cancer- associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. *Cancer Res*. 2013 May 15;73(10):3007-18. doi: 10.1158/0008-5472.CAN-12-4601. Epub 2013 Mar 20. PMID: 23514705; PMCID: PMC3785672.
71. Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, **Bekaii-Saab T**, Lokiec FM, Rezaï K, Buchbinder A. Phase I dose- escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30. PMID: 23543270; PMCID: PMC3839288.
72. Robinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, **Bekaii-Saab T**, Chen HX, Fuchs CS, Ng K. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. *Invest New Drugs*. 2014 Feb;32(1):113-22. doi: 10.1007/s10637-013-9956-5. Epub 2013 Apr 9. PMID: 23568716; PMCID: PMC3775976.
73. Dixon M, Cardoso R, Tinmouth J, Helyer L, Law C, Swallow C, Paszat L, McLeod R, Seevaratnam R, Mahar A, Coburn NG; Gastric Cancer Processes of Care Expert Panel. What studies are appropriate and necessary for staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. *Gastric Cancer*. 2014 Apr;17(2):377-82. doi: 10.1007/s10120-013-0262-x. Epub 2013 Apr 30. PMID: 23633230.
74. Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A, Lourenco LG, Yohanathan L, Bocicariu A, **Bekaii-Saab T**, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn N; International multidisciplinary expert panel. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. *J Am Coll Surg*. 2013 Aug;217(2):347-57.e1. doi: 10.1016/j.jamcollsurg.2013.01.067. Epub 2013 May 8. PMID: 23664139.
75. Benson AB 3rd, **Bekaii-Saab T**, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA; National Comprehensive Cancer Network. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2013 May 1;11(5):519-28. doi: 10.6004/jnccn.2013.0069. PMID: 23667203.
76. Foy KC, Wygle RM, Miller MJ, Overholser JP, **Bekaii-Saab T**, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. *J Immunol*. 2013 Jul 1;191(1):217-27. doi: 10.4049/jimmunol.1300231. Epub 2013 May 22. PMID: 23698748; PMCID: PMC4324564.
77. **Bekaii-Saab T**, Goldberg RM. FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future? *Oncologist*. 2013;18(5):487-9. doi: 10.1634/theoncologist.2013-0157. PMID: 23704222; PMCID: PMC3662837.
78. Kim EJ, Ben-Josef E, Herman JM, **Bekaii-Saab T**, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. *Cancer*. 2013 Aug 1;119(15):2692-700. doi: 10.1002/cncr.28117. Epub 2013 May 29. PMID: 23720019; PMCID: PMC4174603.

79. Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE 3rd, **Bekaii-Saab T**, Martin EW Jr, Schmidt CR, Kiecolt-Glaser JK. Pain, depression, and fatigue: loneliness as a longitudinal risk factor. *Health Psychol*. 2014 Sep;33(9):948-57. doi: 10.1037/a0034012. Epub 2013 Aug 19. PMID: 23957903; PMCID: PMC3992976.
80. Haraldsdottir S, **Bekaii-Saab T**. Integrating anti-EGFR therapies in metastatic colorectal cancer. *J Gastrointest Oncol*. 2013 Sep;4(3):285-98. doi: 10.3978/j.issn.2078-6891.2013.028. PMID: 23997940; PMCID: PMC3712294.
81. Martin LK, Luu DC, Li X, Muscarella P, Ellison EC, Bloomston M, **Bekaii-Saab T**. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. *Ann Surg Oncol*. 2014 Mar;21(3):862-867. doi: 10.1245/s10434-013-3266-1. Epub 2013 Sep 18. PMID: 24046122; PMCID: PMC4041711.
82. Dixon M, Mahar A, Paszat L, McLeod R, Law C, Swallow C, Helyer L, Seevaratnam R, Cardoso R, **Bekaii-Saab T**, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N. What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. *Surgery*. 2013 Nov;154(5):1100-9. doi: 10.1016/j.surg.2013.05.021. Epub 2013 Sep 26. PMID: 24075275.
83. Garrett CR, **Bekaii-Saab TS**, Ryan T, Fisher GA, Clive S, Kavan P, Shacham- Shmueli E, Buchbinder A, Goldberg RM. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. *Cancer*. 2013 Dec 15;119(24):4223-30. doi: 10.1002/cncr.28358. Epub 2013 Sep 16. PMID: 24105075.
84. Ciombor KK, **Bekaii-Saab T**. Emerging treatments in recurrent and metastatic colorectal cancer. *J Natl Compr Canc Netw*. 2013 Sep;11 Suppl 4(Suppl 4):S18-27. doi: 10.6004/jnccn.2013.0217. PMID: 24158967; PMCID: PMC6645683.
85. Martin LK, **Bekaii-Saab T**, Serna D, Monk P, Clinton SK, Grever MR, Kraut EH. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. *Onkologie*. 2013;36(11):657-60. doi: 10.1159/000355665. Epub 2013 Oct 14. PMID: 24192770.
86. Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, Seevaratnam R, Cardoso R, McLeod R, Dixon M, Yohanathan L, Lourenco LG, Bocicariu A, **Bekaii-Saab T**, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn NG. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. *JAMA Surg*. 2014 Jan;149(1):18-25. doi: 10.1001/jamasurg.2013.3959. PMID: 24225775.
87. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, **Bekaii-Saab T**, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. *Genet Med*. 2014 Jul;16(7):553-7. doi: 10.1038/gim.2013.193. Epub 2014 Jan 16. PMID: 24434690; PMCID: PMC4289599.
88. Haraldsdottir S, **Bekaii-Saab T**. Integrating anti-EGFR therapies in metastatic colorectal cancer. *J Gastrointest Oncol*. 2013 Sep;4(3):285-98. doi: 10.3978/j.issn.2078-6891.2013.028. PMID: 23997940; PMCID: PMC3712294.
89. Martin LK, Luu DC, Li X, Muscarella P, Ellison EC, Bloomston M, **Bekaii-Saab T**. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. *Ann Surg Oncol*. 2014 Mar;21(3):862-867. doi: 10.1245/s10434-013-3266-1. Epub 2013 Sep 18. PMID: 24046122; PMCID: PMC4041711.
90. Narang AK, Herman JM. The promise of modern radiotherapy in resected pancreatic adenocarcinoma: a response to **Bekaii-Saab** et al. *Ann Surg Oncol*. 2014 Apr;21(4):1064-6. doi: 10.1245/s10434-013-3344-4. Epub 2014 Feb 13. PMID: 24522986.
91. **Bekaii-Saab T**, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. *Crit Rev Oncol Hematol*. 2014 Jul;91(1):9-34. doi: 10.1016/j.critrevonc.2014.01.001. Epub 2014 Jan 15. PMID: 24534706.
92. Reyngold M, Niland J, ter Veer A, Milne D, **Bekaii-Saab T**, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W Jr, Weiser M, Wilkinson N, Goodman KA. Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. *J Natl Compr Canc Netw*. 2014 Feb;12(2):235-43. doi: 10.6004/jnccn.2014.0024. PMID: 24586085.

93. **Bekaii-Saab T.** Moving forward with expanding to an "all-RAS mutational analysis" in metastatic colorectal cancer: beyond KRAS mutations. *J Natl Compr Canc Netw.* 2014 Feb;12(2):299-300. doi: 10.6004/jnccn.2014.0027. PMID: 24586088.
94. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, **Bekaii-Saab T**, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine- containing doublets plus bevacizumab. *Pancreas.* 2014 Apr;43(3):343-9. doi: 10.1097/MPA.000000000000095. PMID: 24622062; PMCID: PMC3955845.
95. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, **Bekaii-Saab T.** Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. *Cancer.* 2014 Jun 15;120(12):1780-6. doi: 10.1002/cncr.28648. Epub 2014 Mar 13. Erratum in: *Cancer.* 2015 Apr 1;121(7):1154. PMID: 24633933; PMCID: PMC4265390.
96. Hurwitz HI, **Bekaii-Saab TS**, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A; ARIES Study Investigators. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. *Clin Oncol (R Coll Radiol).* 2014 Jun;26(6):323-32. doi: 10.1016/j.clon.2014.03.001. Epub 2014 Mar 28. PMID: 24686090.
97. Grothey A, Flick ED, Cohn AL, **Bekaii-Saab TS**, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. *Pharmacoepidemiol Drug Saf.* 2014 Jul;23(7):726-34. doi: 10.1002/pds.3633. Epub 2014 May 16. PMID: 24830357.
98. Ahn DH, **Bekaii-Saab T.** Ampullary cancer: an overview. *Am Soc Clin Oncol Educ Book.* 2014:112-5. doi: 10.14694/EdBook_AM.2014.34.112. PMID: 24857067; PMCID: PMC4966534.
99. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, **Bekaii-Saab T**, Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. *Carcinogenesis.* 2014 Oct;35(10):2203-13. doi: 10.1093/carcin/bgu124. Epub 2014 May 30. Retraction in: *Carcinogenesis.* 2019 Apr 29;40(2):e16. PMID: 24879635; PMCID: PMC4178465.
100. Benson AB 3rd, Venook AP, **Bekaii-Saab T**, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky- Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA; National Comprehensive Cancer Network. Colon cancer, version 3.2014. *J Natl Compr Canc Netw.* 2014 Jul;12(7):1028-59. doi: 10.6004/jnccn.2014.0099. PMID: 24994923.
101. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, **Bekaii-Saab T.** Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. *Am J Clin Oncol.* 2016 Dec;39(6):614-618. doi: 10.1097/COC.000000000000108. PMID: 25068471; PMCID: PMC4305484.
102. Tejani MA, ter Veer A, Milne D, Ottesen R, **Bekaii-Saab T**, Benson AB 3rd, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. *J Natl Compr Canc Netw.* 2014 Aug;12(8):1123-30. doi: 10.6004/jnccn.2014.0109. PMID: 25099444.
103. Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, **Bekaii-Saab TS**, Ben-Josef E, Dawson LA, Ringash J, Wei AC. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. *Int J Radiat Oncol Biol Phys.* 2014 Oct 1;90(2):270-7. doi: 10.1016/j.ijrobp.2014.05.053. Epub 2014 Aug 4. PMID: 25104069; PMCID: PMC4751588.
104. Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, **Bekaii-Saab T**, Bloomston M. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. *J Gastrointest Surg.* 2014 Dec;18(12):2186-91. doi: 10.1007/s11605-014-2670-6. Epub 2014 Oct 10. PMID: 25300799; PMCID: PMC4809042.
105. Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, **Bekaii-Saab T**, Carson WE 3rd. Patients with pancreatic adenocarcinoma exhibit elevated levels

- of myeloid-derived suppressor cells upon progression of disease. *Cancer Immunol Immunother*. 2015 Feb;64(2):149-59. doi: 10.1007/s00262-014-1618-8. Epub 2014 Oct 11. PMID: 25305035; PMCID: PMC4504424.
106. Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, **Bekaii-Saab TS**, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. *Invest New Drugs*. 2015 Feb;33(1):241-6. doi: 10.1007/s10637-014-0169-3. Epub 2014 Oct 16. PMID: 25318437.
 107. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, **Bekaii-Saab T**. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. *Ann Surg Oncol*. 2015 Apr;22(4):1153-9. doi: 10.1245/s10434-014-4225-1. Epub 2014 Oct 31. PMID: 25358667; PMCID: PMC4373613.
 108. Ciombor KK, **Bekaii-Saab T**. Selumetinib for the treatment of cancer. *Expert Opin Investig Drugs*. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. PMID: 25385055.
 109. Noonan AM, **Bekaii-Saab T**. Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo. *Expert Rev Pharmacoecon Outcomes Res*. 2015 Feb;15(1):133-43. doi: 10.1586/14737167.2015.972376. Epub 2014 Dec 3. PMID: 25467918.
 110. Yeo H, Niland J, Milne D, ter Veer A, **Bekaii-Saab T**, Farma JM, Lai L, Skibber JM, Small W Jr, Wilkinson N, Schrag D, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. *J Natl Cancer Inst*. 2014 Dec 19;107(1):362. doi: 10.1093/jnci/dju362. PMID: 25527640; PMCID: PMC4296195.
 111. **Bekaii-Saab T**, Goldberg R. Therapeutic advances in pancreatic cancer: miles to go before we sleep. *J Natl Cancer Inst*. 2015 Jan 31;107(2):dju439. doi: 10.1093/jnci/dju439. PMID: 25638250.
 112. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, **Bekaii-Saab T**. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. *Am J Clin Oncol*. 2017 Dec;40(6):531-534. doi: 10.1097/COC.000000000000185. PMID: 25723741; PMCID: PMC4549218.
 113. Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W, Marx H, **Bekaii-Saab T**, Lesinski GB, Swanson B, Sanchez D, Manzanera AG, Aguilar-Cordova E, Bloomston M. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. *Cancer Immunol Immunother*. 2015 Jun;64(6):727-36. doi: 10.1007/s00262-015-1679-3. Epub 2015 Mar 21. PMID: 25795132.
 114. Ahn DH, Ko AH, Meropol NJ, **Bekaii-Saab TS**. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. *Am Soc Clin Oncol Educ Book*. 2015:e222-7. doi: 10.14694/EdBook_AM.2015.35.e222. PMID: 25993177; PMCID: PMC4964785.
 115. Petullo B, Wei L, Yereb M, Neal A, Rose J, **Bekaii-Saab T**, Wu C. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum- based therapy. *J Gastrointest Oncol*. 2015 Jun;6(3):336-40. doi: 10.3978/j.issn.2078-6891.2015.011. PMID: 26029462; PMCID: PMC4397239.
 116. Shaib W, Krishna K, Kim S, Goodman M, Rock J, Chen Z, Brucher E, Staley CI, Maithel SK, Abdel-Misih S, El-Rayes BF, **Bekaii-Saab T**. Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. *Cancer Res Treat*. 2016 Apr;48(2):596-604. doi: 10.4143/crt.2015.029. Epub 2015 Jun 5. PMID: 26044156; PMCID: PMC4843718.
 117. Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, **Bekaii-Saab T**, Chakravarti A, Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. *Sci Rep*. 2015 Jun 12;5:10867. doi: 10.1038/srep10867. PMID: 26065715; PMCID: PMC4464260.
 118. Shaib WL, Martin LK, Choi M, Chen Z, Krishna K, Kim S, Brucher E, Staley C 3rd, Maithel SK, Philip P, Abdel-Misih S, **Bekaii-Saab TS**, El-Rayes BF. Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. *Oncologist*. 2015 Aug;20(8):907-14. doi: 10.1634/theoncologist.2014-0294. Epub 2015 Jun 12. PMID: 26070916; PMCID: PMC4524750.
 119. Yeo H, Niland J, Milne D, ter Veer A, **Bekaii-Saab T**, Farma JM, Lai L, Skibber JM, Small W Jr, Wilkinson N, Schrag D, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at National Comprehensive

- Cancer Network centers. *J Natl Cancer Inst.* 2014 Dec 19;107(1):362. doi: 10.1093/jnci/dju362. PMID: 25527640; PMCID: PMC4296195.
120. Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, **Bekaii-Saab T**. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? *Oncotarget.* 2015 Sep 8;6(26):22206-13. doi: 10.18632/oncotarget.4247. PMID: 26082439; PMCID: PMC4673157.
 121. Benson AB 3rd, Venook AP, **Bekaii-Saab T**, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. *J Natl Compr Canc Netw.* 2015 Jun;13(6):719-28; quiz 728. doi: 10.6004/jnccn.2015.0087. PMID: 26085388.
 122. Wu C, Mikhail S, Wei L, Timmers C, Tahiri S, Neal A, Walker J, El-Dika S, Blazer M, Rock J, Clark DJ, Yang X, Chen JL, Liu J, Knopp MV, **Bekaii-Saab T**. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. *Br J Cancer.* 2015 Jul 14;113(2):220-5. doi: 10.1038/bjc.2015.197. Epub 2015 Jul 7. PMID: 26151457; PMCID: PMC4506385.
 123. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona- Calero MA, **Bekaii-Saab T**. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. *Sci Rep.* 2015 Jul 10;5:12122. doi: 10.1038/srep12122. PMID: 26161813; PMCID: PMC4894406.
 124. Ko AH, **Bekaii-Saab T**, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. *Clin Cancer Res.* 2016 Jan 1;22(1):61-8. doi: 10.1158/1078-0432.CCR-15-0979. Epub 2015 Aug 6. PMID: 26251290; PMCID: PMC4703532.
 125. Shaib WL, Goodman M, Chen Z, Kim S, Brucher E, **Bekaii-Saab T**, El-Rayes BF. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. *Am J Clin Oncol.* 2017 Dec;40(6):569-573. doi: 10.1097/COC.0000000000000210. PMID: 26270447.
 126. Wang K, Johnson A, Ali SM, Klempner SJ, **Bekaii-Saab T**, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. *Oncologist.* 2015 Oct;20(10):1132-9. doi: 10.1634/theoncologist.2015-0156. Epub 2015 Sep 2. PMID: 26336083; PMCID: PMC4591943.
 127. Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, **Bekaii-Saab T**, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). *Vaccines (Basel).* 2015 Jul 6;3(3):519-43. doi: 10.3390/vaccines3030519. PMID: 26350593; PMCID: PMC4586465.
 128. Mikhail S, **Bekaii-Saab T**. Maintenance therapy for colorectal cancer: which regimen and which patients? *Drugs.* 2015 Nov;75(16):1833-42. doi: 10.1007/s40265-015-0467-x. PMID: 26377935
 129. Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, **Bekaii-Saab T**. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. *Cancer Chemother Pharmacol.* 2015 Nov;76(5):1005-12. doi: 10.1007/s00280-015-2877-6. Epub 2015 Sep 28. PMID: 26416564.
 130. Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, **Bekaii-Saab T**, Chen CS. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. *J Natl Cancer Inst.* 2015 Oct 12;107(12):djv274. doi: 10.1093/jnci/djv274. PMID: 26464423; PMCID: PMC6280990.
 131. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, **Bekaii-Saab T**, McNamara MG, Valle JW. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. *Ann Oncol.* 2016 Jan;27(1):134-40. doi: 10.1093/annonc/mdv483. Epub 2015 Oct 19. PMID: 26483051.
 132. Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, **Bekaii-Saab T**, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single- Institution Experience. *Am J Clin Oncol.* 2018 Feb;41(2):140-146. doi: 10.1097/COC.0000000000000248. PMID: 26535992; PMCID: PMC4860166.

133. Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, **Bekaii-Saab T**, Bloomston M, Lesinski GB. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. *Oncotarget*. 2015 Dec 29;6(42):44509-22. doi: 10.18632/oncotarget.6332. PMID: 26575024; PMCID: PMC4792572.
134. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartzmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: *Lancet*. 2016 Feb 6;387(10018):536. PMID: 26615328.
135. Chu PC, Yang MC, Kulp SK, Salunke SB, Himmel LE, Fang CS, Jadhav AM, Shan YS, Lee CT, Lai MD, Shirley LA, **Bekaii-Saab T**, Chen CS. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. *Oncogene*. 2016 Jul 28;35(30):3897-908. doi: 10.1038/onc.2015.458. Epub 2015 Nov 30. PMID: 26616862.
136. Ahn DH, Williams TM, Goldstein DA, El-Rayes B, **Bekaii-Saab T**. Adjuvant therapy for pancreas cancer in an era of value based cancer care. *Cancer Treat Rev*. 2016 Jan;42:10-7. doi: 10.1016/j.ctrv.2015.11.004. Epub 2015 Nov 24. PMID: 26620819; PMCID: PMC4976619.
137. Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, **Bekaii-Saab T**. Whole- exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. *Oncotarget*. 2016 Feb 2;7(5):5306-12. doi: 10.18632/oncotarget.6632. PMID: 26683364; PMCID: PMC4868687.
138. Lundberg J, Reardon J, Blazer M, Phillips G, **Bekaii-Saab T**. Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. *Med Oncol*. 2016 Jan;33(1):4. doi: 10.1007/s12032-015-0720-x. Epub 2015 Dec 22. PMID: 26696390.
139. Vargo CA, Blazer M, Reardon J, Gulati M, **Bekaii-Saab T**. Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. *Clin Colorectal Cancer*. 2016 Jun;15(2):e61-3. doi: 10.1016/j.clcc.2015.10.004. Epub 2015 Nov 10. PMID: 26701613.
140. Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, **Bekaii-Saab T**, Chakravarti A, Wuthrick E, Williams TM. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. *Am J Clin Oncol*. 2017 Dec;40(6):561-568. doi: 10.1097/COC.0000000000000214. PMID: 26703815; PMCID: PMC5940000.
141. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, **Bekaii-Saab T**, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. *Clin Cancer Res*. 2016 May 15;22(10):2565-74. doi: 10.1158/1078-0432.CCR-15-1732. Epub 2015 Dec 30. PMID: 26719427; PMCID: PMC4867263.
142. Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, **Bekaii-Saab T**, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. *J Natl Cancer Inst*. 2016 Feb 4;108(7):djv437. doi: 10.1093/jnci/djv437. PMID: 26848151; PMCID: PMC4948564.
143. Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, **Bekaii-Saab T**. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. *Genet Med*. 2016 Sep;18(9):863-8. doi: 10.1038/gim.2015.184. Epub 2016 Feb 11. PMID: 26866578; PMCID: PMC5489337.
144. Mikhail S, Faltas B, Salem ME, **Bekaii-Saab T**. Application of next- generation sequencing in gastrointestinal and liver tumors. *Cancer Lett*. 2016 May 1;374(2):187-91. doi: 10.1016/j.canlet.2016.02.029. Epub 2016 Feb 23. PMID: 26916979.
145. Brathwaite S, Rock J, Yearsley MM, **Bekaii-Saab T**, Wei L, Frankel WL, Hays J, Wu C, Abdel-Misih S. Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. *Ann Surg Oncol*. 2016 Jul;23(7):2281-6. doi: 10.1245/s10434-016-5179-2. Epub 2016 Mar 10. PMID: 26965701; PMCID: PMC4891253.
146. Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, **Bekaii-Saab T**. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. *Med Oncol*. 2016 Apr;33(4):37. doi: 10.1007/s12032-016-0753-9. Epub 2016 Mar 19. PMID: 26995224; PMCID: PMC4976592.

147. Sunakawa Y, **Bekaii-Saab T**, Stintzing S. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. *Cancer Treat Rev*. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. PMID: 27002945.
148. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, **Bekaii-Saab TS**. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. *Mol Ther*. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4. PMID: 27039845; PMCID: PMC4923331.
149. Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, **Bekaii-Saab T**, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. *Med Oncol*. 2016 May;33(5):48. doi: 10.1007/s12032-016-0762-8. Epub 2016 Apr 11. PMID: 27067436.
150. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, **Bekaii-Saab T**, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. *JAMA Surg*. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17. PMID: 27275632; PMCID: PMC5210022.
151. Brathwaite S, Yearsley MM, **Bekaii-Saab T**, Wei L, Schmidt CR, Dillhoff ME, Frankel WL, Hays JL, Wu C, Abdel-Misih S. Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. *Front Oncol*. 2016 Jun 13;6:148. doi: 10.3389/fonc.2016.00148. PMID: 27379210; PMCID: PMC4904130.
152. Ahn DH, Ciombor KK, Mikhail S, **Bekaii-Saab T**. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. *World J Gastroenterol*. 2016 Jul 7;22(25):5668-77. doi: 10.3748/wjg.v22.i25.5668. PMID: 27433082; PMCID: PMC4932204.
153. McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, Tridandapani S, Bloomston M, Ellison EC, Williams TM, **Bekaii-Saab T**, Carson WE 3rd. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. *Clin Cancer Res*. 2017 Jan 15;23(2):489-502. doi: 10.1158/1078-0432.CCR-16-0004. Epub 2016 Jul 19. PMID: 27435400; PMCID: PMC5241232.
154. Mita MM, Nemunaitis J, Grilley-Olson J, El-Rayes B, **Bekaii-Saab T**, Harvey RD, Marshall J, Zhang X, Strout V. Phase 1 Study of CEP-37250/KHK2804, a Tumor- specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. *Target Oncol*. 2016 Dec;11(6):807-814. doi: 10.1007/s11523-016-0449-2. PMID: 27457707.
155. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, **Bekaii-Saab T**. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. *Cancer*. 2016 Dec 1;122(23):3657-3666. doi: 10.1002/cncr.30247. Epub 2016 Aug 6. Erratum in: *Cancer*. 2017 Jun 15;123(12):2376. PMID: 27495988; PMCID: PMC522890.
156. Javle M, **Bekaii-Saab T**, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. *Cancer*. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13. PMID: 27622582.
157. Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, **Bekaii-Saab T**, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE 3rd. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. *Onco Targets Ther*. 2016 Sep 29;9:5931-5941. doi: 10.2147/OTT.S106288. PMID: 27729802; PMCID: PMC5047719.
158. Turner JL, Reardon J, **Bekaii-Saab T**, Cataland SR, Arango MJ. Gemcitabine- Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. *Clin Colorectal Cancer*. 2016 Sep 20:S1533-0028(16)30178-5. doi: 10.1016/j.clcc.2016.09.004. Epub ahead of print. PMID: 27743743.
159. **Bekaii-Saab T**, El-Rayes B. Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. *J Gastrointest Oncol*. 2016 Oct;7(5):673-674. doi: 10.21037/jgo.2016.09.09. PMID: 27747081; PMCID: PMC5056257.

160. Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, **Bekaii-Saab T**, Lesinski GB. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. *Gut*. 2018 Feb;67(2):320-332. doi: 10.1136/gutjnl-2016-311585. Epub 2016 Oct 21. PMID: 27797936; PMCID: PMC5406266.
161. Chen JL, David J, Cook-Spaeth D, Casey S, Cohen D, Selvendiran K, **Bekaii-Saab T**, Hays JL. Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. *Mol Cancer Res*. 2017 Jan;15(1):26-34. doi: 10.1158/1541-7786.MCR-16-0200-T. Epub 2016 Nov 2. PMID: 27807188; PMCID: PMC5909689.
162. Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, **Bekaii-Saab T**, Guttridge DC, Lesinski GB. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. *Mol Cancer Ther*. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3. PMID: 27811010; PMCID: PMC5292063.
163. Mikhail S, Wei L, Salem ME, **Bekaii-Saab T**. Outcomes of definitive chemoradiation in patients with esophageal cancer. *Dis Esophagus*. 2017 Feb 1;30(2):1-7. doi: 10.1111/dote.12506. PMID: 27868290.
164. **Bekaii-Saab T**, Goel S, Dickerson A, Von Roenn J, Thompson MA, Tsao AS. Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. *J Oncol Pract*. 2017 Jan;13(1):e62-e67. doi: 10.1200/JOP.2016.014571. Epub 2016 Nov 22. PMID: 27875070.
165. Henderson SE, Ding LY, Mo X, **Bekaii-Saab T**, Kulp SK, Chen CS, Huang PH. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. *Neoplasia*. 2016 Dec;18(12):765-774. doi: 10.1016/j.neo.2016.10.003. Epub 2016 Nov 25. PMID: 27889645; PMCID: PMC5126135.
166. Chu PC, Kulp SK, **Bekaii-Saab T**, Chen CS. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. *Small GTPases*. 2018 Nov 2;9(6):452-456. doi: 10.1080/21541248.2016.1251383. Epub 2016 Dec 9. PMID: 27936345; PMCID: PMC6204986.
167. Abdel-Misih SR, Wei L, Benson AB 3rd, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, Schrag D, **Bekaii-Saab T**. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. *J Natl Compr Canc Netw*. 2016 Dec;14(12):1528-1534. doi: 10.6004/jnccn.2016.0164. PMID: 27956537; PMCID: PMC5292039.
168. **Bekaii-Saab T**, El-Rayes B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. *Cancer*. 2017 Apr 15;123(8):1303-1312. doi: 10.1002/cncr.30538. Epub 2017 Jan 24. PMID: 28117883; PMCID: PMC5412889.
169. Bendell JC, Javle M, **Bekaii-Saab TS**, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. *Br J Cancer*. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2. PMID: 28152546; PMCID: PMC5344293.
170. Bupathi M, Ahn DH, **Bekaii-Saab T**. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. *Gastrointest Cancer*. 2016;6:21-30. doi: 10.2147/GICTT.S97740. Epub 2016 Jun 30. PMID: 28190957; PMCID: PMC5300250.
171. Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, **Bekaii-Saab T**. A modified regimen of biweekly gemcitabine and nab- paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. *Ther Adv Med Oncol*. 2017 Feb;9(2):75-82. doi: 10.1177/1758834016676011. Epub 2016 Nov 2. PMID: 28203300; PMCID: PMC5298402.
172. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, **Bekaii-Saab T**, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18. PMID: 28223062; PMCID: PMC5809128.
173. Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, **Bekaii-Saab T**, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz- Monserrate Z. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma

- by Regulating Inflammation in the Tumor Microenvironment. *Cancer Res.* 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1. PMID: 28249896; PMCID: PMC5441230.
174. Yang J, Farren MR, Ahn D, **Bekaii-Saab T**, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer. *Expert Opin Ther Targets.* 2017 May;21(5):485-498. doi: 10.1080/14728222.2017.1306055. Epub 2017 Mar 17. PMID: 28282502; PMCID: PMC6751570.
 175. McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, **Bekaii-Saab T**, Valle JW. Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. *BMC Cancer.* 2017 Apr 12;17(1):262. doi: 10.1186/s12885-017-3266-9. PMID: 28403829; PMCID: PMC5389161.
 176. Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, **Bekaii-Saab T**, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K. Comprehensive population- wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. *Nat Commun.* 2017 May 3;8:14755. doi: 10.1038/ncomms14755. PMID: 28466842; PMCID: PMC5418568.
 177. Ahn DH, **Bekaii-Saab T**. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. *J Gastrointest Oncol.* 2017 Apr;8(2):293-301. doi: 10.21037/jgo.2016.10.01. PMID: 28480068; PMCID: PMC5401855.
 178. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, **Bekaii-Saab T**, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. *Oncologist.* 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9. PMID: 28487467; PMCID: PMC5507643.
 179. Bupathi M, Ahn DH, **Bekaii-Saab T**. Therapeutic options for intrahepatic cholangiocarcinoma. *Hepatobiliary Surg Nutr.* 2017 Apr;6(2):91-100. doi: 10.21037/hbsn.2016.12.12. PMID: 28503556; PMCID: PMC5411274.
 180. Ahn DH, **Bekaii-Saab T**. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. *Biomedicines.* 2017 Mar 4;5(1):10. doi: 10.3390/biomedicines5010010. PMID: 28536353; PMCID: PMC5423495.
 181. Ahn DH, **Bekaii-Saab T**. Response to Drs Von Hoff and Renschler. *Ther Adv Med Oncol.* 2017 Jun;9(6):445-446. doi: 10.1177/1758834017709238. Epub 2017 May 30. PMID: 28607583; PMCID: PMC5455884.
 182. Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, **Bekaii-Saab T**. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. *Cancer.* 2017 Dec 1;123(23):4680-4686. doi: 10.1002/cncr.30927. Epub 2017 Aug 17. PMID: 28817187.
 183. Pershad Y, Govindan S, Hara AK, Borad MJ, **Bekaii-Saab T**, Wallace A, Albadawi H, Oklu R. Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. *Diagnostics (Basel).* 2017 Sep 2;7(3):50. doi: 10.3390/diagnostics7030050. PMID: 28869500; PMCID: PMC5617950.
 184. Nemer L, Krishna SG, Shah ZK, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Guttridge DC, Hinton A, Manilchuk A, Pawlik TM, Schmidt CR, Talbert EE, **Bekaii-Saab T**, Hart PA. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. *Pancreas.* 2017 Oct;46(9):1152-1157. doi: 10.1097/MPA.0000000000000898. PMID: 28902785; PMCID: PMC5679236.
 185. Strickler JH, Wu C, **Bekaii-Saab T**. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. *Cancer Treat Rev.* 2017 Nov;60:109-119. doi: 10.1016/j.ctrv.2017.08.006. Epub 2017 Aug 31. PMID: 28946014.
 186. Ciombor KK, **Bekaii-Saab T**. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. *Oncologist.* 2018 Jan;23(1):25-34. doi: 10.1634/theoncologist.2017-0203. Epub 2017 Oct 11. PMID: 29021377; PMCID: PMC5759820.
 187. Ahn DH, Reardon J, Ahn CW, Bupathi M, Mikhail S, Wu CS, **Bekaii-Saab T**. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. *Int J Cancer.* 2018 Apr 15;142(8):1671-1675. doi: 10.1002/ijc.31144. Epub 2017 Nov 17. PMID: 29114851.
 188. Javle M, Lowery M, Shroff RT, Weiss KH, Springfield C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK,

- Bekaii- Saab T.** Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. *J Clin Oncol.* 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. PMID: 29182496; PMCID: PMC6075847.
189. Sonbol MB, **Bekaii-Saab T.** A clinical trial protocol paper discussing the BRIGHTER study. *Future Oncol.* 2018 Apr;14(10):901-906. doi: 10.2217/fo-2017-0406. Epub 2018 Jan 3. PMID: 29297698
 190. Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, **Bekaii-Saab T**, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. *Oncologist.* 2018 Jan;23(1):137. doi: 10.1634/theoncologist.2017-0081erratum. Erratum for: *Oncologist.* 2017 Sep;22(9):1107-1116. PMID: 29317549; PMCID: PMC5759829.
 191. DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, **Bekaii-Saab TS**, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. *Future Oncol.* 2018 Mar;14(6):553-566. doi: 10.2217/fo-2017-0451. Epub 2018 Feb 20. PMID: 29460642.
 192. Mody K, **Bekaii-Saab T.** Clinical Trials and Progress in Metastatic Colon Cancer. *Surg Oncol Clin N Am.* 2018 Apr;27(2):349-365. doi: 10.1016/j.soc.2017.11.008. PMID: 29496094.
 193. Reyngold M, Niland J, Ter Veer A, **Bekaii-Saab T**, Lai L, Meyer JE, Nurkin SJ, Schrag D, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. *Adv Radiat Oncol.* 2017 Oct 12;3(1):34-41. doi: 10.1016/j.adro.2017.10.001. PMID: 29556578; PMCID: PMC5856979.
 194. Chu PC, Lin PC, Wu HY, Lin KT, Wu C, **Bekaii-Saab T**, Lin YJ, Lee CT, Lee JC, Chen CS. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. *Oncogene.* 2018 Jun;37(25):3440-3455. doi: 10.1038/s41388-018-0222-3. Epub 2018 Mar 21. PMID: 29559746.
 195. Ahn DH, **Bekaii-Saab TS.** Genetic Diversity and Treatment Implications in Gastric and Gastroesophageal Cancers: One Size Does Not Fit All. *J Oncol Pract.* 2018 Apr;14(4):227-228. doi: 10.1200/JOP.18.00158. PMID: 29641949.
 196. **Bekaii-Saab T.** Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. *Clin Adv Hematol Oncol.* 2018 Mar;16 Suppl 7(3):16-18. PMID: 29742086.
 197. Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii- Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. *Invest New Drugs.* 2018 Dec;36(6):1037-1043. doi: 10.1007/s10637-018-0600-2. Epub 2018 May 22. PMID: 29785570.
 198. Ahn DH, Ramanathan RK, **Bekaii-Saab T.** Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. *Cancers (Basel).* 2018 Jun 11;10(6):193. doi: 10.3390/cancers10060193. PMID: 29891787; PMCID: PMC6025083.
 199. Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, **Bekaii-Saab TS**, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. *Cancer.* 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15. PMID: 29905927.
 200. Mody K, Baldeo C, **Bekaii-Saab T.** Antiangiogenic Therapy in Colorectal Cancer. *Cancer J.* 2018 Jul/Aug;24(4):165-170. doi: 10.1097/PPO.0000000000000328. PMID: 30119079.
 201. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, **Bekaii-Saab TS**, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. *Immunotherapy.* 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024. PMID: 30185133.
 202. Pant S, Hubbard J, Martinelli E, **Bekaii-Saab T.** Clinical update on K-Ras targeted therapy in gastrointestinal cancers. *Crit Rev Oncol Hematol.* 2018 Oct;130:78-91. doi: 10.1016/j.critrevonc.2018.07.011. Epub 2018 Aug 2. PMID: 30196915.
 203. Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, **Bekaii-Saab T**, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. *Clin Cancer Res.* 2019 Apr 15;25(8):2403-2413. doi: 10.1158/1078-0432.CCR-18-1341. Epub 2018 Nov 13. PMID: 30425090; PMCID: PMC6892342.

204. **Bekaii-Saab T**, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore- Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. *Clin Colorectal Cancer*. 2019 Mar;18(1):e117-e129. doi: 10.1016/j.clcc.2018.11.002. Epub 2018 Nov 16. PMID: 30598357.
205. Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, **Bekaii-Saab T**. A SEER- based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. *J Gastrointest Oncol*. 2018 Dec;9(6):1063-1073. doi: 10.21037/jgo.2018.07.09. PMID: 30603125; PMCID: PMC6286951
206. Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, **Bekaii-Saab T**. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. *Future Oncol*. 2019 Apr;15(12):1295-1302. doi: 10.2217/fon-2018-0903. Epub 2019 Feb 15. PMID: 30768369.
207. **Bekaii-Saab T**, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2019 Jun 15;25(12):3495-3507. doi: 10.1158/1078-0432.CCR-18-3997. Epub 2019 Feb 25. PMID: 30804020; PMCID: PMC7159438.
208. **Bekaii-Saab T**, Yu K, Lima CMSR, Wolin EM. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma. *Clin Adv Hematol Oncol*. 2018 Sep;16 Suppl 17(9):1-16. PMID: 30807558.
209. **Bekaii-Saab T**. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma. *Clin Adv Hematol Oncol*. 2018 Sep;16 Suppl 17(9):5-7. PMID: 30807560.
210. **Bekaii-Saab T**. New guideline-sanctioned and emerging interventions for pancreatic cancer. *Clin Adv Hematol Oncol*. 2018 Sep;16 Suppl 17(9):7-9. PMID: 30807561.
211. **Bekaii-Saab T**. How I treat metastatic colorectal cancer. *Clin Adv Hematol Oncol*. 2018 Sep;16 Suppl 18(9):2-6. PMID: 30807565.
212. Wang CB, Shahjehan F, Merchea A, Li Z, **Bekaii-Saab TS**, Grothey A, Colibaseanu DT, Kasi PM. Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. *Front Oncol*. 2019 Feb 19; 9:76. doi: 10.3389/fonc.2019.00076. PMID: 30838175; PMCID: PMC6389639.
213. Shroff RT, Kennedy EB, Bachini M, **Bekaii-Saab T**, Crane C, Edeline J, El- Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *J Clin Oncol*. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11. PMID: 30856044.
214. Sonbol MB, Ahn DH, **Bekaii-Saab T**. Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. *Biomedicines*. 2019 Mar 10;7(1):17. doi: 10.3390/biomedicines7010017. PMID: 30857342; PMCID: PMC6466109.
215. Ahn DH, **Bekaii-Saab T**. Watch and Wait in Rectal Cancer: Who's In and Who's Out? *J Oncol Pract*. 2019 Mar;15(3):133-134. doi: 10.1200/JOP.19.00071. PMID: 30861365.
216. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, **Bekaii-Saab TS**, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. *JAMA Oncol*. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270. PMID: 30998813; PMCID: PMC6567834.
217. Yang M, Hopp AC, **Bekaii-Saab TS**, Collins JM. Sister Mary Joseph Nodule in Advanced Pancreatic Adenocarcinoma Identified on ¹⁸F-FDG PET/MRI. *J Nucl Med Technol*. 2019 Dec;47(4):341-342. doi: 10.2967/jnm.119.225961. Epub 2019 Apr 24. PMID: 31019031.
218. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, K Kulp S, **Bekaii-Saab T**, Chen CS. Retraction: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. *Carcinogenesis*. 2019 Apr 29;40(2):e16. doi: 10.1093/carcin/bgz056. PMID: 31034565; PMCID: PMC6778455.
219. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, **Bekaii-Saab T**, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ,

- Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. *J Natl Cancer Inst*. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073. PMID: 31086963; PMCID: PMC6695305.
220. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, **Bekaii-Saab T**. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. *Oncologist*. 2019 Sep;24(9):1174-1179. doi: 10.1634/theoncologist.2019-0189. Epub 2019 Jun 4. PMID: 31164455; PMCID: PMC6738316.
 221. **Bekaii-Saab TS**, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. *Lancet Oncol*. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28. PMID: 31262657.
 222. Ahn DH, **Bekaii-Saab T**. AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time? *Chin Clin Oncol*. 2019 Oct;8(S1):S19. doi: 10.21037/cco.2019.04.04. Epub 2019 May 6. PMID: 31280573.
 223. Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, **Bekaii-Saab T**, Siveke JT. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. *Cancers (Basel)*. 2019 Jul 28;11(8):1068. doi: 10.3390/cancers11081068. PMID: 31357748; PMCID: PMC6721419.
 224. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, **Bekaii-Saab TS**, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. *JAMA Oncol*. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792. Erratum in: *JAMA Oncol*. 2019 Oct 10; PMID: 31486832; PMCID: PMC6735405.
 225. Chen M, Cao J, Bai Y, Tong C, Lin J, Jindal V, Barchi LC, Nadalin S, Yang SX, Pesce A, Panaro F, Ariche A, Kai K, Memeo R, **Bekaii-Saab T**, Cai X; Written on behalf of the AME Gallbladder Cancer Collaborative Group. Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. *Clin Transl Gastroenterol*. 2019 Oct;10(10):e00098. doi: 10.14309/ctg.0000000000000098. PMID: 31663905; PMCID: PMC6884352
 226. Grothey A, Marshall JL, **Bekaii-Saab T**. Sequencing beyond the second-line setting in metastatic colorectal cancer. *Clin Adv Hematol Oncol*. 2019 Mar;17 Suppl 7(3):1-19. PMID: 31730588.
 227. **Bekaii-Saab T**. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer. *Clin Adv Hematol Oncol*. 2019 Mar;17 Suppl 7(3):5-13. PMID: 31730590.
 228. Grothey A, Marshall JL, **Bekaii-Saab T**. Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations. *Clin Adv Hematol Oncol*. 2019 Mar;17 Suppl 7(3):16-18. PMID: 31730592.
 229. McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, **Bekaii-Saab T**, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. *Pancreatol*. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21. PMID: 31787526; PMCID: PMC7195700.
 230. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, **Bekaii-Saab TS**, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. *Oncologist*. 2020 May;25(5):380-e763. doi: 10.1634/theoncologist.2019-0874. Epub 2019 Dec 11. PMID: 31826977; PMCID: PMC7216452.
 231. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, **Bekaii-Saab T**. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. *JAMA Oncol*. 2020 Mar 1;6(3):e194489. doi: 10.1001/jamaoncol.2019.4489. Epub 2020 Mar 12. PMID: 31855256; PMCID: PMC6990730.

232. Grothey A, **Bekaii-Saab TS**, Yoshino T, Prager GW. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer. *Clin Adv Hematol Oncol*. 2020 Jan;18 Suppl 2(1):1-24. PMID: 33843903.
233. **Bekaii-Saab TS**. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy. *Clin Adv Hematol Oncol*. 2020 Jan;18 Suppl 2(1):2-7. PMID: 33843904.
234. Grothey A, Prager GW, Yoshino T, **Bekaii-Saab TS**. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussion. *Clin Adv Hematol Oncol*. 2020 Jan;18 Suppl 2(1):21-23. PMID: 33843908.
235. Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, **Bekaii-Saab T**, Phelps MA, Chen CS, Coss CC. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. *EMBO Mol Med*. 2020 Feb 7;12(2):e9910. doi: 10.15252/emmm.201809910. Epub 2020 Jan 13. PMID: 31930715; PMCID: PMC7005646.
236. Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, **Bekaii-Saab T**, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. *Pancreas*. 2020 Feb;49(2):193-200. doi: 10.1097/MPA.0000000000001479. PMID: 32011529; PMCID: PMC7028474.
237. Ahn DH, **Bekaii-Saab T**. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. *Chin Clin Oncol*. 2020 Feb;9(1):6. doi: 10.21037/cco.2020.02.02. Epub 2020 Feb 20. PMID: 32075397.
238. Li Y, Zhang HB, Chen X, Yang X, Ye Y, **Bekaii-Saab T**, Zheng Y, Zhang Y. A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. *Oncologist*. 2020 Mar;25(3):203-207. doi: 10.1634/theoncologist.2019-0405. Epub 2019 Oct 22. PMID: 32162810; PMCID: PMC7066703.
239. Kim RD, McDonough S, El-Khoueiry AB, **Bekaii-Saab TS**, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster H. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. *Eur J Cancer*. 2020 May; 130:219-227. doi: 10.1016/j.ejca.2020.01.026. Epub 2020 Mar 29. PMID: 32234665; PMCID: PMC7539324.
240. Almquist DR, Ahn DH, **Bekaii-Saab TS**. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. *BioDrugs*. 2020 Jun;34(3):349-362. doi: 10.1007/s40259-020-00420-3. PMID: 32246441
241. Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, **Bekaii-Saab T**, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. *Clin Cancer Res*. 2020 Jul 1;26(13):3117-3125. doi: 10.1158/1078-0432.CCR-19-4193. Epub 2020 Apr 6. PMID: 32253228; PMCID: PMC7334091.
242. Morris VK, **Bekaii-Saab T**. Improvements in Clinical Outcomes for *BRAFV600E*-Mutant Metastatic Colorectal Cancer. *Clin Cancer Res*. 2020 Sep 1;26(17):4435-4441. doi: 10.1158/1078-0432.CCR 19-3809. Epub 2020 Apr 6. PMID: 32253230.
243. Sonbol MB, Murad MH, **Bekaii-Saab T**. The Role of Maintenance Therapy in Metastatic Colorectal Cancer-Reply. *JAMA Oncol*. 2020 Jun 1;6(6):937-938. doi: 10.1001/jamaoncol.2020.0583. PMID: 32297910.
244. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, **Bekaii-Saab TS**, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. *Am J Clin Oncol*. 2020 Aug;43(8):586-590. doi: 10.1097/COC.0000000000000708. PMID: 32349022; PMCID: PMC7395872.
245. O'Reilly EM, Barone D, Mahalingam D, **Bekaii-Saab T**, Shao SH, Wolf J, Rosano M, Krause S, Richards DA, Yu KH, Roach JM, Flaherty KT, Ryan DP. Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. *Eur J Cancer*. 2020 Jun; 132:112-121. doi: 10.1016/j.ejca.2020.03.005. Epub 2020 Apr 28. PMID: 32361265; PMCID: PMC8133644.
246. McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, André T, Cunningham D, Moehler M, Jensen LH, Koeberle D, **Bekaii-Saab T**, Bridgewater J, Valle JW. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. *J Hepatol*. 2020 Nov;73(5):1109-1117. doi: 10.1016/j.jhep.2020.05.014. Epub 2020 May 21. PMID: 32446715.

247. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, **Bekaii-Saab T**, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrif A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28. Erratum in: *Lancet*. 2020 Sep 12;396(10253):758. PMID: 32473681; PMCID: PMC7255743.
248. Zhu M, Bassam Sonbol M, Halfdanarson T, Hobday T, Ahn D, Ma WW, **Bekaii-Saab T**. Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. *Oncologist*. 2020 Aug;25(8):e1246-e1248. doi: 10.1634/theoncologist.2020-0029. Epub 2020 Jul 1. PMID: 32510802; PMCID: PMC7418337.
249. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, **Bekaii-Saab TS**, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. *Oncologist*. 2020 Nov;25(11):e1681-e1690. doi: 10.1634/theoncologist.2020-0086. Epub 2020 Aug 4. PMID: 32663355; PMCID: PMC7648330.
250. **Bekaii-Saab TS**, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with *FGFR2* rearrangements. *Future Oncol*. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17. PMID: 32677452.
251. Ware MB, Zaidi MY, Yang J, Turgeon MK, Krasinskas A, Mace TA, Keenan K, Farren MR, Ruggieri AN, Li Y, Zhang C, Chen Z, Young GS, Elnaggar O, Che Z, Maithel SK, **Bekaii-Saab T**, El-Rayes B, Lesinski GB. Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. *Br J Cancer*. 2020 Oct;123(9):1377-1386. doi: 10.1038/s41416-020-1018-0. Epub 2020 Aug 4. PMID: 32747748; PMCID: PMC7591861.
252. Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, Johnson GB, Allred JB, Yin J, Lim VS, **Bekaii-Saab T**, Ma WW, Erlichman C, Adjei AA, Fernandez-Zapico ME. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. *Pancreatol*. 2020 Sep;20(6):1115-1122. doi: 10.1016/j.pan.2020.06.015. Epub 2020 Jul 14. PMID: 32778368.
253. Hochster HS. Next-Generation Sequencing Testing in GI Cancer: A Patient's "Right"? Or Wrong? *Oncology* (Williston Park). 2020 Aug 12;34(8):295. doi: 10.46883/ONC.2020.3408.0295. PMID: 32785921.
254. **Bekaii-Saab, T**. Ushering in the Era of Precision Medicine. *Oncology* (Williston Park). 2020 Aug 12;34(8):314-316. doi: 10.46883/ONC.2020.3408.0314. PMID: 32785927.
255. Usón Junior PLS, Ahn D, Sonbol MB, **Bekaii-Saab T**, Borad MJ. Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. *Hepatobiliary Surg Nutr*. 2020 Aug;9(4):501-504. doi: 10.21037/hbsn.2019.11.20. PMID: 32832503; PMCID: PMC7423557.
256. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, **Bekaii-Saab T**. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. *JAMA Oncol*. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10. PMID: 33090186; PMCID: PMC7582230.
257. Kaumaya PTP, Guo L, Overholser J, Penichet ML, **Bekaii-Saab T**. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. *Oncoimmunology*. 2020 Oct 1;9(1):1818437. doi: 10.1080/2162402X.2020.1818437. PMID: 33117602; PMCID: PMC7553530.
258. Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, **Bekaii-Saab TS**, Sekulic A, Stewart AK. Comparison of Universal Genetic Testing vs Guideline-

Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. *JAMA Oncol.* 2021 Feb 1;7(2):230-237. doi: 10.1001/jamaoncol.2020.6252. Erratum in: *JAMA Oncol.* 2021 Feb 1;7(2):312. PMID: 33126242; PMCID: PMC7600058.

259. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org; COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell.* 2020 Dec 14;38(6):761-766. doi: 10.1016/j.ccell.2020.10.022. Epub 2020 Oct 29. PMID: 33176160; PMCID: PMC7598547.
260. Loupakakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, **Bekaii-Saab T**. Practical considerations in the use of regorafenib in metastatic colorectal cancer. *Ther Adv Med Oncol.* 2020 Oct 31;12:1758835920956862. doi: 10.1177/1758835920956862. PMID: 33193826; PMCID: PMC7607787.
261. **Bekaii-Saab, T**. International Society of Gastrointestinal Oncology Conference Abstracts. *Oncology* (Williston Park). 2020 Nov 12;34(11):468-476. doi: 10.46883/ONC.2020.3411.0468. PMID: 33206986.
262. Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, **Bekaii-Saab T**, Siveke JT. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. *Pancreatology.* 2021 Jan;21(1):192-199. doi: 10.1016/j.pan.2020.10.029. Epub 2020 Oct 10. PMID: 33214082.
263. Botrus G, Raman P, Oliver T, **Bekaii-Saab T**. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. *Expert Opin Investig Drugs.* 2021 Apr;30(4):309-316. doi: 10.1080/13543784.2021.1864320. Epub 2021 Jan 4. PMID: 33307867.
264. Sipra QUAR, Islam M, Riaz IB, Zhaohui J, Babiker HM, **Bekaii-Saab TS**, Sonbol MB. Contemporary Management of Pancreatic Cancer from an Internist Perspective. *Am J Med.* 2021 May;134(5):576-586. doi: 10.1016/j.amjmed.2020.11.009. Epub 2020 Dec 11. PMID: 33316248.
265. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, **Bekaii-Saab T**, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. *Sci Rep.* 2020 Dec 16;10(1):22087. doi: 10.1038/s41598-020-77939-6. PMID: 33328484; PMCID: PMC7745036.
266. Smith CJ, **Bekaii-Saab TS**, Cook KD, Eiring RA, Halfdanarson TR, Hanna M, Jin Z, Jochum JA, Ma WW, Mitchell JL, Pitot HC, Jatoi A. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan - based chemotherapy in patients with pancreas cancer. *Pancreatology.* 2021 Mar;21(2):379-383. doi: 10.1016/j.pan.2020.10.042. Epub 2020 Oct 18. PMID: 33468394.
267. Uson Junior PLS, Liu AJ, Sonbol MB, Borad MJ, **Bekaii-Saab TS**. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. *Chin Clin Oncol.* 2021 Feb;10(1):11. doi: 10.21037/cco-20-231. PMID: 33541088.
268. Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, **Bekaii-Saab TS**, Halfdanarson TR, Sonbol MB. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. *Clin Colorectal Cancer.* 2021 Jun;20(2):e139-e149. doi: 10.1016/j.clcc.2020.12.001. Epub 2020 Dec 17. PMID: 33551318.
269. Botrus G, Kosirerek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, **Bekaii-Saab TS**. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. *Oncologist.* 2021 Jul;26(7):569-578. doi: 10.1002/onco.13717. Epub 2021 Mar 5. PMID: 33555095; PMCID: PMC8265372.
270. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, **Bekaii-Saab T**. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. *Oncologist.* 2021 Jul;26(7):610-618. doi: 10.1002/onco.13730. Epub 2021 Mar 6. PMID: 33604969; PMCID: PMC8265366
271. Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, **Bekaii-Saab T**, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. *Oncologist.* 2021 Aug;26(8):668-675. doi: 10.1002/onco.13741. Epub 2021 Mar 22. PMID: 33631043; PMCID: PMC8342606.

272. Lawal B, Lin LC, Lee JC, Chen JH, **Bekaii-Saab TS**, Wu ATH, Ho CL. Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. *Cancers* (Basel). 2021 Feb 25;13(5):954. doi: 10.3390/cancers13050954. PMID: 33668805; PMCID: PMC7956610.
273. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, **Bekaii-Saab T**, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrif A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper- Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, ShahSA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann Oncol*. 2021 Jun;32(6):787-800. doi: 10.1016/j.annonc.2021.02.024. Epub 2021 Mar 19. PMID:33746047; PMCID: PMC7972830.
274. Muscarella P, **Bekaii-Saab T**, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. *J Pancreat Cancer*. 2021 Mar 23;7(1):8-19. doi: 10.1089/pancan.2020.0021. PMID: 33786412; PMCID: PMC7997807.
275. Sonbol MB, Riaz IB, **Bekaii-Saab T**. Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data- Reply. *JAMA Oncol*. 2021 Jun 1;7(6):941. doi: 10.1001/jamaoncol.2021.0534. PMID: 33830179
276. **Bekaii-Saab TS**. Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the *BRAFV600E* mutation. *Clin Adv Hematol Oncol*. 2020 Nov;18 Suppl 19(11):1-8. PMID: 33843879.
277. **Bekaii-Saab TS**. Proactive transitioning to third-line treatment in metastatic colorectal cancer. *Clin Adv Hematol Oncol*. 2021 Jan;19 Suppl 3(1):5-7. PMID: 33843900.
278. Marshall JL, Loupakis F, **Bekaii-Saab TS**. Transitioning from second-line to third-line therapy in metastatic colorectal cancer. *Clin Adv Hematol Oncol*. 2021 Jan;19 Suppl 3(1):1-20. PMID: 33843898.
279. Marshall JL, **Bekaii-Saab TS**, Loupakis F. Q&A: colorectal cancer in younger patients. *Clin Adv Hematol Oncol*. 2021 Jan;19 Suppl 3(1):15-17. PMID: 33843902.
280. Uson PLS Jr, Riegert-Johnson D, Boardman L, Kisiel J, Mountjoy L, Patel N, Lizaola-Mayo B, Borad MJ, Ahn D, Sonbol MB, Jones J, Leighton JA, Gurudu S, Singh H, Klint M, Kunze KL, Golafshar MA, Esplin ED, Nussbaum RL, Stewart AK, **Bekaii-Saab TS**, Jewel Samadder N. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. *Clin Gastroenterol Hepatol*. 2021 Apr 20:S1542-3565(21)00447-X. doi: 10.1016/j.cgh.2021.04.013. Epub ahead of print. PMID: 33857637.
281. Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, **Bekaii-Saab T**, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. *Clin Cancer Res*. 2021 Jul 1;27(13):3641-3648. doi: 10.1158/1078-0432.CCR-21-0159. Epub 2021 Apr 21. PMID: 33883178.
282. **Bekaii-Saab TS**, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. *Ann Oncol*. 2021 Sep;32(9):1111-1126. doi: 10.1016/j.annonc.2021.04.012. Epub 2021 Apr 28. PMID: 33932504.
283. Wainberg ZA, **Bekaii-Saab T**, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. First- line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. *Eur J Cancer*. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4. PMID: 33957442.

284. Uson Junior PLS, Nagalo BM, Ahn DH, **Bekaii-Saab T**, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? *Semin Liver Dis.* 2021 May;41(2):136-141. doi: 10.1055/s-0040-1722646. Epub 2021 May 6. PMID: 33957697.
285. Goodman KA, Ou FS, Hall NC, **Bekaii-Saab T**, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. *J Clin Oncol.* 2021 Sep 1;39(25):2803-2815. doi: 10.1200/JCO.20.03611. Epub 2021 Jun 2. PMID: 34077237; PMCID: PMC8407649.
286. Afifi AM, Elmeharth AO, Ruhban IA, Saad AM, Gad MM, Al-Husseini MJ, **Bekaii-Saab T**, Sonbol MB. Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis. *Oncologist.* 2021 Sep;26(9):733-739. doi: 10.1002/onco.13854. Epub 2021 Jun 30. PMID: 34101294; PMCID: PMC8417843.
287. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL; COVID-19 and Cancer Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol.* 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799. Epub ahead of print. Erratum in: *JAMA Oncol.* 2021 Aug 1;7(8):1249. PMID: 34137799; PMCID: PMC8377563.
288. Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, **Bekaii-Saab T**, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. *Cancer Immunol Immunother.* 2021 Nov;70(11):3337-3348. doi: 10.1007/s00262-021-02986-5. Epub 2021 Jun 23. PMID: 34160684; PMCID: PMC8511095.
289. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, **Bekaii-Saab TS**, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. *Lancet Gastroenterol Hepatol.* 2021 Oct;6(10):803-815. doi: 10.1016/S2468-1253(21)00196-5. Epub 2021 Aug 3. PMID: 34358484.
290. Ueberroth BE, Liu AJ, Graham RP, **Bekaii-Saab TS**, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. *Pancreas.* 2021 Aug 1;50(7):952-956. doi: 10.1097/MPA.0000000000001858. PMID: 34369897.
291. Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, **Bekaii-Saab TS**, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. *Hepatology.* 2022 Jan;75(1):43-58. doi: 10.1002/hep.32102. Epub 2021 Dec 12. PMID: 34407567.
292. Li JJ, Zhu M, Kashyap PC, Chia N, Tran NH, McWilliams RR, **Bekaii-Saab TS**, Ma WW. The role of microbiome in pancreatic cancer. *Cancer Metastasis Rev.* 2021 Sep;40(3):777-789. doi: 10.1007/s10555-021-09982-2. Epub 2021 Aug 28. PMID: 34455517; PMCID: PMC8402962.
293. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, **Bekaii-Saab T**, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. *Invest New Drugs.* 2021 Aug 31. doi: 10.1007/s10637-021-01170-x. Epub ahead of print. PMID: 34463891.
294. Murugesan K, Sharaf R, Montesin M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, **Bekaii-Saab TS**, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. *JCO Precis Oncol.* 2021 Aug 19;5:PO.20.00397. doi:10.1200/PO.20.00397. PMID: 34476330; PMCID: PMC8384404.

295. Ciombor K, Jones J, Strickler J, **Bekaii-Saab T**, Wu C. The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. *Oncology* (Williston Park). 2021 Sep 15;35(9):553-559. doi:10.46883/ONC.2021.3509.0553. PMID: 34524770.
296. Walden D, Sonbol MB, Buckner Petty S, Yoon HH, Borad M, **Bekaii-Saab TS**, Ahn DH. Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. *Front Oncol*. 2021 Sep 10;11:641044. doi: 10.3389/fonc.2021.641044. PMID: 34568002; PMCID: PMC8461178.
297. Uson PLS Jr, Samadder NJ, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Kunze K, Golafshar M, Klint M, Esplin ED, Nussbaum RL, Stewart AK, **Bekaii-Saab T**. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. *Clin Transl Gastroenterol*. 2021 Oct 8;12(10):e00414. doi: 10.14309/ctg.0000000000000414. PMID: 34620795; PMCID: PMC8500569.
298. Jones J, Ciombor K, Wu C, **Bekaii-Saab T**, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. *Oncology* (Williston Park). 2021 Oct 21;35(10):654-660. doi: 10.46883/ONC.2021.3510.0654. PMID: 34677922.
299. Brendel K, **Bekaii-Saab T**, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. *CPT Pharmacometrics Syst Pharmacol*. 2021 Dec;10(12):1550-1563. doi: 10.1002/psp4.12725. Epub 2021 Nov 20. PMID: 34750990; PMCID: PMC8674005.
300. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, **Bekaii-Saab T**, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. *Dig Dis Sci*. 2022 Aug;67(8):3797-3805. doi: 10.1007/s10620-021-07303-9. Epub 2021 Nov 13. PMID: 34773565.
301. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, **Bekaii-Saab TS**, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. *JCO Precis Oncol*. 2021 Jul 28;5:PO.21.00064. doi: 10.1200/PO.21.00064. PMID: 34778691; PMCID: PMC8575436.
302. Tran NH, **Bekaii-Saab T**. Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. *JAMA Netw Open*. 2021 Nov 1;4(11):e2134458. doi: 10.1001/jamanetworkopen.2021.34458. PMID: 34779853.
303. Uson Junior PL, Kunze KL, Golafshar MA, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Barrus K, Mountjoy L, Esplin ED, Nussbaum RL, Stewart AK, **Bekaii-Saab T**, Samadder NJ. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. *Cancer Prev Res (Phila)*. 2021 Nov 15. doi: 10.1158/1940-6207.CAPR-21-0189. Epub ahead of print. PMID: 34782326.
304. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C; COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. *JAMA Netw Open*. 2022 Jan 4;5(1):e2142046. doi: 10.1001/jamanetworkopen.2021.42046. PMID: 34982158.
305. Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, **Bekaii-Saab T**, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. *JCO Precis Oncol*. 2022 Jan;6:e2100156. doi: 10.1200/PO.21.00156. PMID: 35005992.
306. Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, **Bekaii-Saab TS**. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients with Worse Overall Survival. *Front Oncol*. 2022 Jan 10;11:794009. doi: 10.3389/fonc.2021.794009. PMID: 35083150; PMCID: PMC8784799.

307. Uson PLS Jr, Kunze KL, Golafshar MA, Botrus G, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Kahn A, Klint M, Esplin ED, Nussbaum RL, Stewart AK, **Bekaii-Saab T**, Samadder NJ. Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study. *Dig Dis Sci*. 2022 Feb 5. doi: 10.1007/s10620-022-07387-x. Epub ahead of print. PMID: 35122589.
308. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, **Bekaii-Saab T**. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA Netw Open*. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040. PMID: 35179586.
309. Strickler JH, Yoshino T, Graham RP, Siena S, **Bekaii-Saab T**. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. *JAMA Oncol*. 2022 Mar 3. doi: 10.1001/jamaoncol.2021.8196. Epub ahead of print. PMID: 35238866.
310. Laughlin BS, Petersen MM, Yu NY, Anderson JD, Rule WG, Borad MJ, Aqel BA, Sonbol MB, Mathur AK, Moss AA, **Bekaii-Saab TS**, Ahn DH, DeWees TA, Sio TT, Ashman JB. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. *J Gastrointest Oncol*. 2022 Feb;13(1):288-297. doi: 10.21037/jgo-21-615. PMID: 35284111; PMCID: PMC8899753.
311. Ahn DH, **Bekaii-Saab T**. Editorial comment on: "Systemic treatment of hepatocellular carcinoma: an EASL position paper". *Hepatobiliary Surg Nutr*. 2022 Feb;11(1):112-114. doi: 10.21037/hbsn-21-469. PMID: 35284514; PMCID: PMC8847863.
312. Ahn DH, Walden D, **Bekaii-Saab T**. Tucatinib: An investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. *Expert Opin Investig Drugs*. 2022 Mar 15. doi: 10.1080/13543784.2022.2053107. Epub ahead of print. PMID: 35289234.
313. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, **Bekaii-Saab TS**, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. *Adv Biol (Weinh)*. 2022 Mar 27:e2101319. doi: 10.1002/adbi.202101319. Epub ahead of print. PMID: 35343107.
314. Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP; COVID-19 and Cancer Consortium (CCC19). Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. *JAMA Netw Open*. 2022 Mar 1;5(3):e224304. doi: 10.1001/jamanetworkopen.2022.4304. PMID: 35344045.
315. Zhu M, **Bekaii-Saab TS**. Acquired Immunotherapy Resistance in Gastrointestinal Cancers. *JAMA Netw Open*. 2022 Mar 1;5(3): e224646. doi: 10.1001/jamanetworkopen.2022.4646. PMID: 35348714.
316. Lipsyc-Sharf M, Ou FS, Yurgelun MB, Robinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, **Bekaii-Saab T**, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. *Oncologist*. 2022 Apr 5;27(4):292-298. doi: 10.1093/oncolo/oyab025. PMID: 35380713; PMCID: PMC8982431.
317. Zhu M, **Bekaii-Saab T**. Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors". *Oncologist*. 2022 Apr 11: oyac 068. doi: 10.1093/oncolo/oyac068. Epub ahead of print. PMID: 35403684.
318. Akce M, El-Rayes BF, **Bekaii-Saab TS**. Frontline therapy for advanced hepatocellular carcinoma: an update. *Therap Adv Gastroenterol*. 2022 Apr 11;15:17562848221086126. doi: 10.1177/17562848221086126. PMID: 35432597; PMCID: PMC9006370.
319. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Hermann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, **Bekaii-Saab TS**, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Pembrolizumab

in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. *Clin Cancer Res*. 2022 Jul 15;28(14):3021-3031. doi: 10.1158/1078-0432.CCR-22-0413. PMID: 35552651.

- 320 Ciombor KK, Strickler JH, **Bekaii-Saab TS**, Yaeger R. *BRAF*-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. *J Clin Oncol*. 2022 Jun 1: JCO2102541. doi: 10.1200/JCO.21.02541. Epub ahead of print. PMID: 35649231.
- 321 Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, **Bekaii-Saab TS**, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. *JCO Precis Oncol*. 2022 Jun; 6: e2100274. doi: 10.1200/PO.21.00274. PMID: 35666960.
- 322 Ueberroth BE, Jones JC, **Bekaii-Saab TS**. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. *Pancreatol*. 2022 Jun 12: S1424-3903(22)00204-6. doi: 10.1016/j.pan.2022.06.009. Epub ahead of print. PMID: 35725696.
- 323 Ueberroth BE, Jones JC, **Bekaii-Saab T**. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies. *Clin Adv Hematol Oncol*. 2022 Jul;20(7):444-455. PMID: 35802877.
- 324 Ahn DH, **Bekaii-Saab T**. The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. *JAMA Oncol*. 2022 Jul 14. doi: 10.1001/jamaoncol.2022.2309. Epub ahead of print. PMID: 35834246.
- 325 Walden D, Eslinger C, **Bekaii-Saab T**. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. *Therap Adv Gastroenterol*. 2022 Aug 6;15:17562848221115317. doi: 10.1177/17562848221115317. PMID: 35967919; PMCID: PMC9364186.
- 326 Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, **Bekaii-Saab TS**. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. *Oncologist*. 2022 Aug 16:oyac150. doi: 10.1093/oncolo/oyac150. Epub ahead of print. PMID: 35972334.
- 327 Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams RR, Mahipal A, **Bekaii-Saab TS**, Cleary SP, Kendrick ML, Truty MJ. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. *Ann Surg Oncol*. 2022 Aug 16. doi: 10.1245/s10434-022-12328-z. Epub ahead of print. PMID: 35972667.
- 328 Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, **Bekaii-Saab TS**, Tran NH, Mahipal A. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. *Target Oncol*. 2022 Sep 2. doi: 10.1007/s11523-022-00914-w. Epub ahead of print. PMID: 36056231.
- 329 Cho SK, **Bekaii-Saab T**, Kavati A, Babajanyan S, Hocum B, Barzi A. Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US. *Clin Colorectal Cancer*. 2022 Sep 17:S1533-0028(22)00099-8. doi: 10.1016/j.clcc.2022.09.003. Epub ahead of print. PMID: 36216759.
- 330 Sonbol MB, Siddiqi R, Uson PLS, Pathak S, Firwana B, Botrus G, Almader-Douglas D, Ahn DH, Borad MJ, Starr J, Jones J, Stucky CC, Smoot R, Riaz IB, **Bekaii-Saab T**. The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. *Oncologist*. 2022 Oct 14:oyac212. doi: 10.1093/oncolo/oyac212. Epub ahead of print. PMID: 36239399.
- 331 Hogenson TL, Xie H, Phillips WJ, Toruner MD, Li JJ, Horn IP, Kennedy DJ, Almada LL, Marks DL, Carr RM, Toruner M, Sigafoos AN, Koenig-Kappes AN, Olson RL, Tolosa EJ, Zhang C, Li H, Doles JD, Bleeker J, Barrett MT, Boyum JH, Kipp BR, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Petersen GM, Dasari S, Oberg AL, Truty MJ, Graham RP, Levy MJ, Zhu M, Billadeau DD, Adjei AA, Dusetti N, Iovanna JL, **Bekaii-Saab TS**, Ma WW, Fernandez-Zapico ME. Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers. *JCI Insight*. 2022 Oct 18:e158060. doi: 10.1172/jci.insight.158060. Epub ahead of print. PMID: 36256477.
- 332 Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, **Bekaii-Saab T**, Ko AH, Santoro A, Park JO, Noel MS, Frassinetti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B,

- Biankin AV, Reni M; APACT Investigators. Adjuvant *nab*-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. *J Clin Oncol*. 2022 Dec 15; JCO2201134. doi: 10.1200/JCO.22.01134. Epub ahead of print. PMID: 36521097.
- 333 Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams RR, Mahipal A, **Bekaii-Saab TS**, Cleary SP, Kendrick ML, Truty MJ. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. *Ann Surg Oncol*. 2023 Jan;30(1):395-403. doi: 10.1245/s10434-022-12328-z. Epub 2022 Aug 16. PMID: 35972667.
- 334 Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, **Bekaii-Saab TS**, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated *KRAS* G12C. *N Engl J Med*. 2022 Dec 21. doi: 10.1056/NEJMoa2212419. Epub ahead of print. PMID: 36546659.
- 335 **Bekaii-Saab T**, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, Fang W, Anderson EC, Noel MS, Reni M, Choi HJ, Goldberg JS, Oh SC, Li CP, Tabernero J, Li J, Foos E, Oh C, Van Cutsem E. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. *EClinicalMedicine*. 2023 Mar 16;58:101897. doi: 10.1016/j.eclinm.2023.101897. PMID: 36969338; PMCID: PMC10036520.
- 336 *Serrano Uson Junior PL, **Bekaii-Saab T**. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier? *Immunotherapy*. 2023 May;15(7):531-540. doi: 10.2217/imt-2022-0201. Epub 2023 Apr 25. PMID: 37096922.
- 337 Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. *N Engl J Med*. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. PMID: 37133585.
- 338 Shaib WL, Manali R, Liu Y, El-Rayes B, Loehrer P, O'Neil B, Cohen S, Khair T, Robin E, Huyck T, **Bekaii-Saab T**. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). *Eur J Cancer*. 2023 Mar 11; S0959-8049(23)00128-4. doi: 10.1016/j.ejca.2023.02.030. Epub ahead of print. PMID: 37268519.
- 339 **Bekaii-Saab TS**, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a *KRAS*^{G12C} Mutation. *J Clin Oncol*. 2023 Apr 26;101200JCO2300434. doi: 10.1200/JCO.23.00434. Epub ahead of print. PMID: 37099736.
- 340 Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, **Bekaii-Saab TS**; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. PMID: 37142372.
- 341 Ducreux M, Abou-Alfa GK, **Bekaii-Saab T**, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. *ESMO Open*. 2023 Jun;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. Epub 2023 May 31. PMID: 37263081; PMCID: PMC10245111.
- 342 Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, Esplin ED, Nussbaum RL, Heald B, Klint M, Barrus K, Uson PL Jr, Nguyen CC, Colon-Otero G, **Bekaii-Saab TS**, Dronca R, Kunze KL, Samadder NJ. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program. *Cureus*. 2023 Apr 11;15(4):e37428. doi: 10.7759/cureus.37428. PMID: 37181954; PMCID: PMC10173369.
- 343 Strickler JH, Hsu LI, Wright P, Stecher M, Siadak MF, Palanca-Wessels MC, Yu J, Zhang N, Espenschied CR, Lang K, **Bekaii-Saab TS**. Real-World Treatment Patterns in Patients With HER2-

Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. *J Natl Compr Canc Netw*. 2023 Aug;21(8):805-812.e1. doi: 10.6004/jnccn.2023.7022. PMID: 37549907.

- 344 *Eslinger C, Walden D, Barry T, Shah S, Samadder NJ, **Bekaii-Saab TS**. Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome. *J Natl Compr Canc Netw*. 2023 Sep;21(9):894-899. doi: 10.6004/jnccn.2023.7029. PMID: 37673116.
- 345 Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, **Bekaii-Saab T**, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghoul F, O'Reilly EM. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. *Lancet*. 2023 Sep 11: S0140-6736(23)01366-1. doi: 10.1016/S0140-6736(23)01366-1. Epub ahead of print. PMID: 37708904.
- 346 Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Katz MHG, Bauer TW, Nowak JA, Wolpin BM, Abrams TA, Patel A, Clancy TE, Wang J, Mancias JD, Reilley MJ, Stucky CH, **Bekaii-Saab TS**, Elias R, Merchant N, Slingluff CL, Rahma OE, Dougan SK. PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-κB signaling in patients with pancreatic cancer. *Clin Cancer Res*. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-1444. Epub ahead of print. PMID: 37733830.
- 347 Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, **Bekaii-Saab T**. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. *J Clin Oncol*. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. PMID: 37751561; PMCID: PMC10730072.
- 348 Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, **Bekaii-Saab TS**, Elias R, Merchant N, Dias Costa A, Lenehan P, Cardot-Ruffino V, Rodig S, Pfaff K, Dougan SK, Nowak JA, Varadhachary GR, Slingluff CL, Rahma O. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. *J Immunother Cancer*. 2023 Dec 1;11(12):e007586. doi: 10.1136/jitc-2023-007586. PMID: 38040420; PMCID: PMC10693876.
- 349 Zheng-Lin B, **Bekaii-Saab TS**. Treatment options for HER2-expressing colorectal cancer: updates and recent approvals. *Ther Adv Med Oncol*. 2024 Jan 18;16:17588359231225037. doi: 10.1177/17588359231225037. PMID: 38249334; PMCID: PMC10798128.
- 350 Uson Junior PLS, **Bekaii-Saab T**. Act Local, Think Global: IR and Its Role in Immuno-Oncology in Hepatocellular Carcinoma. *J Vasc Interv Radiol*. 2024 Feb;35(2):173-177. doi: 10.1016/j.jvir.2023.10.008. PMID: 38272637.
- 351 Ko AH, Coveler AL, Schlechter BL, **Bekaii-Saab T**, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY. A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer. *Invest New Drugs*. 2024 Apr;42(2):221-228. doi: 10.1007/s10637-024-01430-6. Epub 2024 Mar 5. PMID: 38441850.
- 352 Chandana SR, Woods LM, Maxwell F, Gandolfo R, **Bekaii-Saab T**. Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. *Eur J Cancer*. 2024 Feb;198:113471. doi: 10.1016/j.ejca.2023.113471. Epub 2023 Dec 12. Erratum in: *Eur J Cancer*. 2024 Apr;201:113941. PMID: 38154392.
- 353 Wu C, Pai RK, Kosiorek H, Banerjee I, Pfeiffer A, Hagen CE, Hartley CP, Graham RP, Sonbol MB, **Bekaii-Saab T**, Xie H, Sinicrope FA, Patel B, Westerling-Bui T, Shivji S, Conner J, Swallow C, Savage P, Cyr DP, Kirsch R, Pai RK. Improved risk stratification scheme for mismatch repair proficient stage II colorectal cancers using the digital pathology biomarker QuantCRC. *Clin Cancer Res*. 2024 Feb 29. doi: 10.1158/1078-0432.CCR-23-3211. Epub ahead of print. PMID: 38421684.
- 354 Yaeger R, Ubaha NV, Pelster MS, **Bekaii-Saab TS**, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Jänne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. *Cancer Discov*. 2024 Apr 8:OF1-OF12. doi: 10.1158/2159-8290.CD-24-0217. Epub ahead of print. PMID: 38587856.
- 355 Mosalem O, Coston TW, Imperial R, Mauer E, Thompson C, Yilma B, **Bekaii-Saab TS**, Stoppler MC, Starr JS. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.

Oncologist. 2024 Sep 6;29(9):e1224-e1227. doi: 10.1093/oncolo/oyae098. PMID: 38776551; PMCID: PMC11379631.

- 356 Kusne Y, Lasho T, Finke C, Elsabbagh Z, McCue S, Hobday T, Starr J, **Bekaii-Saab T**, Halfdanarson TR, Patnaik MM, Ou FS, Sonbol MB. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. *JCO Precis Oncol*. 2024 Jun;8:e2400143. doi: 10.1200/PO.24.00143. PMID: 38976813; PMCID: PMC11371079.
- 357 Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhof L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquez MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, **Bekaii-Saab T**, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. *Eur J Cancer*. 2024 Sep;208:114199. doi: 10.1016/j.ejca.2024.114199. Epub 2024 Jun 30. PMID: 39002348.
- 358 Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby RM, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, **Bekaii-Saab T**, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko TK, Lopes G, Aggarwal C, Lee AI, Choueiri TK. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. *JCO Oncol Pract*. 2025 Mar;21(3):292-299. doi: 10.1200/OP-24-00565. Epub 2024 Oct 7. PMID: 39374449.
- 359 Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, **Bekaii-Saab TS**, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. *Oncologist*. 2024 Dec 14:oyae342. doi: 10.1093/oncolo/oyae342. Epub ahead of print. PMID: 39674576.
- 360 Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, **Bekaii-Saab T**, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. *Nat Med*. 2025 Mar;31(3):909-916. doi: 10.1038/s41591-024-03462-0. Epub 2025 Jan 17. PMID: 39825152; PMCID: PMC11922774.
- 361 Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfield C, **Bekaii-Saab T**, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Efficacy of Zenocutuzumab in *NRG1* Fusion-Positive Cancer. *N Engl J Med*. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. PMID: 39908431; PMCID: PMC11878197.
- 362 Eslinger C, Walden D, McGary A, Emiloju O, Ahn D, Sonbol MB, **Bekaii-Saab T**, Zhu M, Hubbard J, Wu C. Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy. *Cancer*. 2025 Feb 15;131(4):e35756. doi: 10.1002/cncr.35756. PMID: 39932790.
- 363 Hoyek C, Zheng-Lin B, Bauernfeind JJ, Al-Ahmad OH, **Bekaii-Saab T**, Chakrabarti S, Rashdan S, Sonbol MB. Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review. *JCO Glob Oncol*. 2025 Mar;11:e2400409. doi: 10.1200/GO-24-00409. Epub 2025 Mar 24. PMID: 40127379.
- 364 Sonbol MB, **Bekaii-Saab T**, Larsen CM. Fluoropyrimidine Therapy in Gastrointestinal Cancer: Balancing Survival Benefits and Cardiotoxicity Risks. *JACC CardioOncol*. 2025 Mar 20:S2666-0873(25)00088-2. doi: 10.1016/j.jacc.2025.02.006. Epub ahead of print. PMID: 40202480.
- 365 Inoue K, Nakamura Y, Caughey B, Zheng-Lin B, Ueno M, Furukawa M, Kawamoto Y, Itoh S, Umemoto K, Sudo K, Satoh T, Mizuno N, Kajiwara T, Fujisawa T, Bando H, Yoshino T, Strickler JH, Morizane C, **Bekaii-Saab T**, Ikeda M. Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for *HER2*-Amplified Advanced Biliary Tract Cancer. *JCO Precis Oncol*. 2025 Apr;9:e2400718. doi: 10.1200/PO-24-00718. Epub 2025 Apr 10. PMID: 40209139.

Book Chapters

1. * Ahmed B, **Bekaii-Saab T**. Gastrointestinal Stromal Tumors. In: Abraham J. Gastrointestinal Malignancies. 1 Edition. Volume 1. Demos Medical Publishing; 03/31/2010.1:151p.
2. **Bekaii-Saab T**. Patient Surveillance Following Pancreas Cancer Resection: A Counterpoint USA. In: Johnson F, Maehera Y, et al. Patient Surveillance after Cancer Treatment. Humana Press; 2013.125-127p.
3. * Martin LK, **Bekaii-Saab T**. Controversies in chemotherapy in advanced colorectal cancer. In: Scholefield JH, Eng C. Colorectal Cancer: Diagnosis and Clinical Management. 1st Edition. John Wiley & Sons, Ltd.; 2014.
4. * Wu C, **Bekaii-Saab T**. Gastrointestinal Malignancies. In: Baliga RR. Internal Medicine Board Review Book: Hematology-Oncology Section. New York: McGraw Specialty; 2014.
5. * Mikhail S, **Bekaii-Saab T**. Systemic treatment for metastatic or recurrent disease. In: Saba N, El-Rayes B (eds). Esophageal Cancer Prevention, Diagnosis and Therapy. 1st Edition. Switzerland: Springer International Publishing; 2015.221-224p.
6. * Noonan A, **Bekaii-Saab T**. Non-surgical Management of Hepatobiliary Malignancies. In: Cai Q, El-Rayes BF, Hao J, Kooby DA, Landry JC, Shaffer VO, Xu H (eds). Gastrointestinal Malignancies: New Innovative diagnostics and Treatment. 1st Edition. World Scientific Publishing Co.; 2016.503-526p.

Books Edited and Written

1. **Bekaii-Saab T**, El-Rayes B (editors). "Current Emerging Therapies in Pancreatic Cancer" Springer International Publishing (2017) Switzerland.
2. **Bekaii-Saab T**, El-Rayes B, Pawlik T (editors). "Handbook of Gastrointestinal Cancers Evidence-Based Treatment and Multidisciplinary Patient Care" Springer Publishing Company (2019)

Select Abstracts (From a total of over 250 since 2003; included select since 2016 only)

1. Morris V, Ciombor K, Salem M, Nimeiri H, Iqbal S, Singh P, Polite B, Deming D, Chan E, Wade J III, **Bekaii-Saab T**, Wolff R, Eng C. A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (scca) Annals Of Oncology. 2016 Jun; 27:126.
2. O'Neil B, O'Reilly S, Kasbari S, Kim R, McDermott R, Moore D, Grogan W, Cohn A, **Bekaii-Saab T**, Ivanova A, Olowokure O, Fernando N, McCaffrey J, El-Rayes B, Horgan A, Ryan T, Sherrill G, Yacoub G, Goldberg RM, Sanoff H. A multi-center, randomized, double-blind phase ii trial of folfiri plus regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy Annals Of Oncology. 2016 Oct 1; 27:
3. Ahn DH, Catenacci D, Ahn CW, Jain A, Kelley RK, Bocobo AG, Rendak R, Mikhail S, Wu C, Shroff RT, Borad M, Chen JL, Javle M, **Bekaii-Saab T**. Updated, expanded analysis with next generation sequencing (ngs) of biliary tract cancer confirms association between tumor somatic variants and chemotherapy resistance Annals Of Oncology. 2016 Oct 1; 27:
4. Mace T, Shakya R, Pitarresi JR, Swanson B, McQuinn C, Loftus S, Yu L, Young G, Zhong X, Zimmers T, Ostrowski M, Ludwig T, Dillhoff M, Schmidt C, Conwell DL, **Bekaii-Saab T**, Lesinski G. Il-6 and pd-l1 antibody blockade combination therapy limits tumor progression in murine models of pancreatic cancer Pancreas. 2016 Nov; 45: (10)1521-2.
5. Cruz-Monserrate Z, Gomez SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski G, **Bekaii-Saab T**, Farren MR, Mace T, Schmidt C, Liu Y, Deng D, Hwang R, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus R, Logsdon CD. Lipocalin-2 promotes obesity-induced pancreatic ductal adenocarcinoma by regulating inflammation in the tumor microenvironment Pancreas. 2016 Nov; 45: (10)1501.
6. **Bekaii-Saab T**, Starodub A, El-Rayes B, O'Neil B, Shahda S, Ciombor K, Noonan A, Hanna W, Sehdev A, Shaib W, Mikhail S, Neki A, Oh C, Li YZ, Li W, Borodyansky L, Li CJ. A phase 1b/ii study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts) Annals Of Oncology. 2017 Jun; 28: (Suppl 3)150.
7. Ramsey ML, Talbert E, Conwell DL, Ahn D, Farren MR, Hinton A, Dillhoff M, Krishna SG, Lesinski GB, Manilchuk A, Pawlik TM, Rajasekera P, Schmidt C, **Bekaii-Saab T**, Guttridge DC, Hart PA. Assessment of

plasma interleukin-6 as a biomarker of pancreatic cancer-induced cachexia *Pancreas*. 2017 Nov-Dec; 46(10):1428

8. **Bekaii-Saab T**, Okusaka T, Goldstein D, O'Neill B, Tabernero J, Li C, Reni M, Jin B, Oh C, Borodyansky L, Van Cutsem E. Canstem111p trial: a phase 3 study of napabucasin (napa) plus nab-paclitaxel (nptx) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mpdac) - trial in progress *Annals Of Oncology*. 2018 Jun; 29.
9. Herrmann T, Cameron D, Carothers A, **Bekaii-Saab T**. Integrating a paradigm shift in the treatment of metastatic colorectal cancer: effect of online cme on oncologists' knowledge and competence *Annals Of Oncology*. 2018 Jun; 29:81
10. Herrmann T, Carothers A, Littman G, Warters M, Cason C, **Bekaii-Saab T**. Management of patients with unresectable hcc: a simulation-based assessment of medical oncologists' practice choices *Annals Of Oncology*. 2018 Jun; 29:48
11. **Bekaii-Saab T**, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib dose optimization study (redos): randomized phase ii trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mrcr) - an ACCRU network study. *Annals Of Oncology*. 2018 Jun; 29:105. Epub 1900 Jan 01.
12. **Bekaii-Saab T**, Marcello K, Fisher G, Kopetz S, Strickler J, Venook A, Obholz K. Variability of current global practice patterns in the management of metastatic colorectal cancer *Annals Of Oncology*. 2018 Jun; 29:73
13. Mody K, Borad MJ, **Bekaii-Saab TS**, Yang JD, Ramanathan RK, Ahn DH, Mahipal A, Roberts A, Nagy RJ, Kasi PM. Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA). *J Clin Oncol*. 2018; Abstract no. 4089.
14. Yang JD, Mody K, Surapaneni P, Borad M, Roberts LR, Gores GJ, Ahn D, Mahipal A, Ramanathan R, **Bekaii-Saab T**, Roberts A, Nagy B, Kasi P. Prognostic role of real-time circulating tumor DNA profiling of biliary tract cancers *Hepatology*. 2018 Oct; 68:61A-2A
15. Ahn D, Barzi A, Miksad RA, Surinach A, Corvino FA, Valderrama A, Mamlouk K, Pulgar S, **Bekaii-Saab T**. Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mpc) treated with liposomal irinotecan (nal-iri) in US oncology clinics *Annals Of Oncology*. 2018 Oct; 29:251
16. Javle M, Kelley RK, Roychowdhury S, Weiss KH, Abou-Alfa GK, Macarulla T, Sadeghi S, Waldschmidt D, Zhu AX, Goyal L, Borad M, Yong WP, Borbath I, El-Khoueiry A, Philip P, Moran S, Ye Y, Ising M, Lewis N, **Bekaii-Saab T**. Updated results from a phase II study of infigratinib (bgj398), a selective pan-fgfr kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing fgfr2 fusions *Annals Of Oncology*. 2018 Oct; 29:720
17. Mody K, Kasi PM, Surapaneni PK, Borad MJ, Ahn DH, Mahipal A, Starr JS, Ritter A, McMillan J, Wylie N, Roberts A, Nagy RJ, **Bekaii-Saab TS**. Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC). *J Clin Oncol*. 2019; Abstract no. 289.
18. Ko A, Coveler A, Schlechter B, **Bekaii-Saab TS**, Wolpin B, Clark J, Cheng YL, Cheng TY, Langecker P, Lin SL. Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers. *J Clin Oncol* 38, 2020 (suppl 4; abstr 713)
19. Strickler J, Ng K, Cercek A, Fountzilas C, Sanchez F, Hubbard J, Wu C, Siena S, Tabernero J, Cutsem E, Kardosh A, Saeed A, Andre T, Stecher M, Palanca-Wessels M, **Bekaii-Saab TS**. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). *J Clin Oncol* 39, 2021 (suppl 3; abstr TPS153)
20. Lipsyc-Sharf M, Ou FS, Yurgelun M, Robinson D, Schrag D, Dakhil S, Stella P, Weckstein DJ, Wender DB, Faggen MG, Zemla T, Heying E, Schuetz S, Noble S, Meyerhardt J, **Bekaii-Saab TS**, Fuchs CS, Ng K. Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial. *J Clin Oncol* 38, 2020 (suppl 4; abstr 102)
21. **Bekaii-Saab TS**, Valle J, Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad B, Lihou C, Zhen H, Félix L, Asatiani E, Jiang P, Vogel A. FIGHT-302: Phase III study of first line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with *FGFR2* fusions or rearrangements. *J Clin Oncol* 38, 2020 (suppl 4; abstr TPS592)

22. McNamara M, Bridgewater J, Goyal L, Goldstein D, Shroff R, Moehler M, Lowery M, **Bekaii-Saab TS**, Kelley K, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J. Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC). *J Clin Oncol* 39, 2021 (suppl 3; abstr 348)
23. P.L.S. Uson Junior, G. Botrus, J. Yin, H. Dada, L. Drusbosky, U. Majeed, D. Ahn, M. Sonbol, M. Borad, **T. Bekaii-Saab**, K. Mody. Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer. *Annals of Oncology* (2021) 32 (suppl_5): S1084-S1095. 10.1016/annonc/annonc709
24. Majeed Umair, Uson Pedro Jr., Yin Jun, Sonbol Mohamad, Ahn Daniel, **Bekaii-Saab Tanios**, Starr Jason, Jones Jeremy, Inabinett Samantha, Wylie Natasha, Boyle Ashton, Borad Mitesh, Mody Kabir. Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy. *jco*. 2021.
25. **Bekaii-Saab T**, Valle J, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Macarulla T, Bridgewater J, Wasan H, Borad M, Vogel A, Lihou C, Zhen H, Jiang P, Langmuir P, Melisi D. Fight-302: phase 3 study of first-line pemigatinib vs gemcitabine plus cisplatin for cholangiocarcinoma with fgfr2 fusions or rearrangement *Annals of Oncology*. 2021 Jul; 32:S137
26. Kusne Y, Mesbah Z, Klanderman M, Kosiorek H, **Bekaii-Saab T**, Sonbol M. Gastric and esophageal signet ring cell adenocarcinoma: a retrospective analysis of outcomes at Mayo Clinic *Annals of Oncology*. 2021 Jul; 32:S195
27. Strickler J, Nakamura Y, Shitara K, Catenacci D, Janjigian Y, Barzi A, **Bekaii-Saab T**, Lenz H, Lee J, Van Cutsem E, Chung H, Tabernero J, Yoshino T, Siena S, Garrido-Mayor J, Palanca-Wessels M, Xie D, Marshall J. Mountaineer-02: phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated her2+gastric or gastroesophageal junction adenocarcinoma: trial in progress *Annals of Oncology*. 2021 Jul; 32:S159
28. Tabernero J, **Bekaii-Saab T**, Aguilera MS, Cubillo A, Garcia-Carbonero R, Limon L, Rodriguez-Salas N, Tournigand C, Borg C, Raghav K, Finley G, Strickler J, Beier F, Salim S, Esser R, Liu E, Adrian S, Lopez-Lopez C. Perspective: tepotinib plus cetuximab in patients with ras/braf wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-egfr antibody therapy due to met amplification *Annals of Oncology*. 2021 Jul; 32:S136-7
29. **Bekaii-Saab T**, Kang V, Walker L, Nakamura Y. Sgntuc-019: phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with her2 alterations: biliary tract cancer cohort (trial in progress) *Annals of Oncology*. 2021 Jul; 32:S108-9
30. Powderly J, Jones J, **Bekaii-Saab T**, Xing Y, Weroha SJ, Ulahannan S, Doroshov D, Valdes-Albini F, Millward C, Walter K, Wrong A, Del Castillo P, Wang LX, Nguyen N, Whidden M, Benjamin J, Isakoff S. First-in-human results with the novel tumor-targeting antibody atrc-101: phase 1b study in patients with solid tumors. *Journal for Immunotherapy of Cancer*. 2021 Nov; 9(Suppl 2):A548
31. Rahma O, Katz M, Bauer T, Wolpin B, Stucky CC, **Bekaii-Saab T**, Elias R, Dias-Costa A, Nowak J, Patrick L, Petroni G, Dougan S, Slingluff C. Randomized multicenter study of neoadjuvant chemoradiation therapy (crt) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer. *Journal for Immunotherapy of Cancer*. 2021 Nov; 9(Suppl 2):A1010
32. **Bekaii-Saab T**, Burnett H, Proskorovsky I, Yoon S, Wang Y, Ostojic H, Gaianu L, Su Y. Impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and tas-102 in the treatment of relapsed/refractory metastatic colorectal cancer. *Annals of Oncology*. 2022 Jun; 33(Suppl 4):S262
33. Strickler J, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, Wu C, Paulson A, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi P, Lenz H, Ciombor K, Elez E, Bajor D, Stecher M, Feng W, **Bekaii-Saab T**. Primary analysis of mountaineer: a phase 2 study of tucatinib and trastuzumab for her2-positive mrcr. *Annals of Oncology*. 2022 Jun; 33:S375-6
34. Botrus G, Uson PL, Kosiorek H, Akce M, Chang I, Mesbah Z, Yancey E, Blezek D, Klug J, Khalil L, Raman P, Sonbol M, Borad M, Ahn D, **Bekaii-Saab T**. Prognostic impact of sarcopenia on clinical outcomes in advanced hepatocellular carcinoma (hcc) treated with systemic therapy. *Cancer Research*. 2022 Jun 15; 82(12 Suppl):6274
35. **Bekaii-Saab T**, Spira A, Yaeger R, Buchschacher G, McRee J, Sabari J, Johnson M, Barve M, Hafez N, Velastegui K, Christensen J, Kheoh T, Der-Torossian H, Rybkin I. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic

pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS^{G12C} mutation. *Journal of Clinical Oncology* 2022 40:4_suppl, 519-519

35. Shitara K, Park H, **Bekaii-Saab T**, Kim SS, Kamath S, Pishvaian MJ, Chen C, Zhen DB, Mayor J, Tan QW, Strickler JH. Phase 1b/2 trial of tucatinib plus trastuzumab plus +/- chemotherapy or pembrolizumab in patients with metastatic her2+gi cancers. *Annals of Oncology*. 2022 Jul; 33:S502
36. Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Fernandez MEE, Bajor DL, Stecher M, Feng W, **Bekaii-Saab T**. Additional analyses of mountaineer: a phase ii study of tucatinib and trastuzumab for her2-positive mrcr. *Annals of Oncology*. 2022 Sep; 33(Suppl 7):S1394
37. Walden D, Ou FS, Larson J, Kang S, Liu A, Huff D, Griswold C, Ueberroth B, Bhamini P, Draper A, Grieb B, Ciombor KK, Raman P, Sonbol MB, Borad M, **Bekaii-Saab T**, Wu C, Ahn D. Duration of adjuvant therapy in stage iii colon cancer: a real world multi-institutional us-based experience. *Annals of Oncology*. 2022 Sep; 33(Suppl 7):S688
38. **Bekaii-Saab T**, Lach K, Hsu LI, Siadak MF, Stecher M, Ward J, Beckerman R, Strickler JH. Impact of anti-egfr therapies on her2-positive metastatic colorectal cancer (her2+mrcr): a systematic literature review and meta-analysis of clinical outcomes. *Annals of Oncology*. 2022 Sep; 33(7):S708
39. Klempner SJ, Weiss J, Pelster M, Spira A, Barve M, Ou SHI, Leal A, **Bekaii-Saab T**, Christensen JG, Kheoh T, Velastegui K, Torossian HD, Yaeger R. Krystal-1: updated efficacy and safety of adagrasib (mrtx849) with or without cetuximab in patients with advanced colorectal cancer (crc) harboring a krasg12c mutation. *Annals of Oncology*. 2022 Sep; 33(Suppl 7):S1391
40. Andre T, **Bekaii-Saab T**, Tabernero J, Siena S, Yoshino T, Norwood KG, Adelberg DE, Ward J, Yang S, Strickler JH, Van Cutsem E. Mountaineer-03: phase iii study of tucatinib, trastuzumab, and mfolfox6 as first-line treatment in her2+metastatic colorectal cancer (trial in progress). *Annals of Oncology*. 2022 Sep; 33(7):S734-5
41. Wu C, Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, Paulson AS, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Fernandez MEE, Hsu LI, Stecher M, Zhao K, **Bekaii-Saab T**. Tucatinib plus trastuzumab in patients (pts) with her2-positive metastatic colorectal cancer (mrcr): patient-reported outcomes (pros) from ph ii study mountaineer. *Annals of Oncology*. 2022 Sep; 33(Suppl 7):S700-1
42. Margossian S, Powderly J, Gabrail N, Saenger Y, Selfridge JE, Uboha N, Gong J, Van Tine B, Alese O, Kim DW, Ma W, **Bekaii-Saab T**, Jones J, Alistar A, Agensky L, Goel A, Lynam R, Moniz R, Quayle S, Rajan C, Pienta K, Levisetti M. A phase 1, open-label, dose escalation and expansion study of cue-102 monotherapy in hla-a*0201 positive patients with wt1-positive recurrent/metastatic cancers. *Journal for Immunotherapy of Cancer*. 2022 Nov; 10(Suppl 2):A667
43. Chmielowski B, Weroha J, Ulahannan S, Powderly J, Valdes-Albini F, **Bekaii-Saab T**, Doroshow D, Recio-Boiles A, Berlin J, Xing Y, Khurana S, Benjamin J, Isakoff S, Weinberg B. Interim clinical update of the phase 1b trial of atrc-101 as monotherapy or in combination with pembrolizumab for select advanced solid tumors. *Journal for Immunotherapy of Cancer*. 2022 Nov; 10(Suppl 2):A750
44. Wenric S, Davison JM, Wang YE, Mayhew GM, Beebe K, Kang HP, Milburn MV, Chung V, **Bekaii-Saab T**, Perou CM. Purity independent subtyping of tumor (purist): real-world data validation of a pancreatic ductal adenocarcinoma (pdac) gene expression classifier and its prognostic implications. *Cancer Research*. 2022 Nov 15; 82(22):2-3
45. Gile Jennifer, Palmer Mathias, Storandt Michael, **Bekaii-Saab Tanios**, Tran Nguyen, Mahipal Amit. Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma. *Journal of Clinical Oncology*. 2023; 41(4_suppl):507.
46. Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A, Ahn D, Eiring R, Hobday T, Starr J, **Bekaii-Saab T**, Patnaik M, Halfdanarson T. Prevalence of clonal hematopoiesis (ch) in neuroendocrine tumor (net) patients prior to lutetium 177 dotatate therapy (lu177) and the risk of cytopenia - a prospective study of 37 patients. *Journal of Neuroendocrinology*. 2023 Mar; 35:150
47. Elez E, Shepard D, Smolenschi C, **Bekaii-Saab T**, Jac J. An ongoing open-label, phase 2 trial of rp2 or rp3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma. *Annals of Oncology*. 2023 Jun; 34(Suppl 1):S34-5
48. Wainberg Z, Melisi D, Macarulla T, Cid RP, Chandana S, de la Fouchardiere C, Dean A, Kiss I, Lee W, Goetze T, Van Cutsem E, Paulson S, **Bekaii-Saab T**, Pant S, Hubner R, Xiao Z, Chen H, Benzaghoul F,

O'Reilly E. Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (nalirifox) versus nab-paclitaxel plus gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma: sensitivity analysis of survival from the napoli 3 trial. *Annals of Oncology*. 2023 Jun; 34(Suppl 1):S180

49. Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams R, Mahipal A, **Bekaii-Saab TS**, Cleary SP, Kendrick ML, Truty MJ. ASO Visual Abstract: Cyto reduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis-Results from a Prospective Pilot Study. *Ann Surg Oncol*. 2023 Sep; 30(9):5765. Epub 1900 Jan 01.
50. Schram A, Macarulla T, Cleary J, Neuzillet C, Arnold D, Reiss KA, **Bekaii-Saab T**, Rodon J, Goto K, Rha SY, Duruisseaux M, Leigh N, Weinberg BA, Al-Hallak MN, Joe AK, Adeyemi S, Wasserman E, Koeman KJ, Drilon A, O'Reilly EM. Durable efficacy of zenocutuzumab, a her2 x her3 bispecific antibody, in advanced nrg1 fusion positive (nrg1+) pancreatic ductal adenocarcinoma (pdac). *Annals of Oncology*. 2023 Oct; 34:S895-6
51. Zheng-Lin B, Walden D, Larson J, McDonnell S, Frank J, Raman P, Eslinger C, Ueberroth B, Ou FS, Larson N, Sonbol MB, Wu C, Tran N, Babiker H, Borad M, Roberts L, Ahn D, **Bekaii-Saab T**. Fgfr2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer. *Annals of Oncology*. 2023 Oct; 34:S222-3
52. Melisi D, Macarulla T, de la Fouchardiere C, Cid RAP, Chandana S, Dean A, Kiss I, Lee W, Goetze TO, Van Cutsem E, Paulson AS, **Bekaii-Saab T**, Pant S, Hubner R, Xiao Z, Zhang L, Benzaghoul FM, O'Reilly EM, Wainberg ZA. Health-related quality of life with nalirifox versus nabpaclitaxel plus gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mpdac): eortc qlq-c30 results from the napoli 3 trial. *Annals of Oncology*. 2023 Oct; 34:S896-7
53. Strickler JH, Cercek A, Ng K, Siena S, Andre T, Van Cutsem E, Wu C, Paulson AS, Hubbard J, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Fernandez MEE, Stecher M, Cronin P, Bieda M, **Bekaii-Saab T**. Impact of baseline molecular alterations on the efficacy of tucatinib (tuc) plus trastuzumab (tras) for her2+, ras wt metastatic crc (mrcr) in mountaineer. *Annals of Oncology*. 2023 Oct; 34:S411-2
54. **Bekaii-Saab T**, Ahn D, Yuan C, Jiao X, Kurtinecz M, Pan X, Vassilev Z, Ostojic H. Sequential treatment with regorafenib (reg) and trifluridine/tipiracil (tas) plus +/- bevacizumab (bev) in refractory metastatic colorectal cancer (mrcr) in community clinical practice in the USA. *Annals of Oncology*. 2023 Oct; 34:S442
55. Mahadevia HJ, Majeed U, Starr J, Jones JC, Ahn D, Wu S, Andring J, El Shawa H, Xiu J, Sledge G, Astsaturov I, Goel S, Philip PA, Borad M, **Bekaii-Saab T**, Babiker H. Stat3, acta2, and sparc stromal markers predict response to gemcitabine/cisplatin/nab-paclitaxel (gcn) in patients with advanced pancreatic adenocarcinoma (apdac). *Annals of Oncology*. 2023 Oct; 34:S908-9
56. Goetze T, Melisi D, Macarulla T, Cid RAP, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Van Cutsem E, Paulson S, **Bekaii-Saab T**, Pant S, Hubner R, Xiao Z, Chen H, Benzaghoul F, O'Reilly E, Wainberg A. Napoli-3: a randomized, open-label phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (nalirifox) versus nab-paclitaxel plus gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mpdac). *Oncology Research and Treatment*. 2023 Oct 3; 46(Suppl 5):12-4
57. Heinemann V, **Bekaii-Saab T**, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, Raghav K, Cercek A, Adelberg D, Ramos J, Yang S, Andre T, Strickler J. Phase 3 study of tucatinib, trastuzumab, and modified folfox6 as first-line treatment in her2+metastatic colorectal cancer (mountaineer-03, trial in progress). *Oncology Research and Treatment*. 2023 Oct 3; 46(Suppl 5):159-60
58. Fritsch R, Andre T, **Bekaii-Saab T**, Cercek A, Nakamura Y, Raghav K, Siena S, Strickler J, Van Cutsem E, Adelberg D, Ramos J, Yang S, Yoshino T, Tabernero J. Phase 3 study of tucatinib, trastuzumab, and modified folfox6 as first-line treatment in her2+metastatic colorectal cancer (mountaineer-03, trial in progress). *Swiss Medical Weekly*. 2023 Nov 20; 153(Suppl 274):70S
59. Paly V, Hernandez LG, Howe A, Khanduri P, Labisa P, Taglioni A, Siviero L, Dasari A, Eng C, Hubbard J, **Bekaii-Saab T**, Sobrero A, Elez E. Management costs of grade 3/4 adverse events associated with emerging and existing systemic therapies for metastatic colorectal cancer with at least two prior lines of therapy in Italy, Portugal, Spain, and the United States. *Value in Health*. 2023 Dec; 26(12 Suppl):S182-3
60. Merrell KW, Hallemeier CL, Harmsen WS, Ashman JB, Truty M, Leenstra JL, Timm MA, Owen D, Thiels C, Stucky, Neben M, **Bekaii-Saab T**, Rule WG, Garces Y, McWilliams RR, Lester SC, Haddock MG, Sio, Jethwa KR. Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma *Int J Radiat Oncol Biol Phys*.. 2024; 120(2S):S143.

61. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma Cancers. 2024; 16(10).
62. Hernandez LG, Paly, Padukkavidana T, Dasari A, Hubbard J, **Bekaii-Saab T**, Sobrero A, Elez E. Adverse event costs associated with systemic therapies for metastatic colorectal cancer previously treated with standard therapies and biologics in the United States, Italy, Portugal, and Spain. *Value in Health*. 2024 Jun; 27(6):S145
63. Barzi A, Appukkuttan S, Hocum B, Katta A, Babajanyan S, Cosgrove D, Sruti, Shi J, Dai W, Patton G, **Bekaii-Saab T**. Metastatic colorectal cancer (mcr) patients treated with later lines of treatment (lot): a retrospective analysis by race and ethnicity in the United States (US) community oncology setting. *Value in Health*. 2024 Jun; 27(6):S239
64. Macarulla Mercade T, Cid RAP, Womack M, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner R, Van Cutsem E, **Bekaii-Saab T**, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D. Nalirifox versus nab-paclitaxel and gemcitabine (gem plus nabp) in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mpdac): subgroup analysis of patients aged 65 years or older in napoli 3. *Annals of Oncology*. 2024 Jun; 35:S135-6
65. Hoyek C, Zheng-Lin B, Abidoye O, Walden D, Eslinger C, Sonbol MB, Wu C, Ahn D, Borad M, **Bekaii-Saab T**. Post-treatment ctDNA analysis reveals patterns of her2 therapy resistance in advanced her2-amplified colorectal cancer. *Annals of Oncology*. 2024 Jun; 35:S33
66. Ahn D, **Bekaii-Saab T**, Yuan C, Pan X, Ostojic H, Pisa F. Sequential regorafenib (r) and trifluridine/tipiracil ± bevacizumab (t) in refractory metastatic colorectal cancer (mcr) in US clinical practice: subgroup analysis by tumor sidedness and metastatic site. *Annals of Oncology*. 2024 Jun; 35:S39
67. Nakamura Y, **Bekaii-Saab T**, Hamilton E, Hayashi H, Mizuno N, Monk BJ, Nguyen D, Okines A, O'Malley DM, Pohlmann PR, Pothuri B, Reck M, Sudo K, Sunakawa Y, Takahashi S, Yu EY, Drees A, Tan S, Stinchcombe TE. Tucatinib and trastuzumab for patients with previously treated, her2-altered solid tumors (sgntuc-019): a phase 2 basket study. *European Journal of Cancer*. 2024 Oct; 211(Suppl 1):S2-3
68. Abidoye O, Hoyek C, Zheng-Lin B, Kosiorek HE, Eslinger C, Sonbol MB, Wu C, Tran NH, Babiker HM, Yoshino T, Ikeda M, Morizane C, Bando H, Nakamura Y, Fujisawa T, Shibuki T, Ahn DH, Roberts LR, Borad MJ, **Bekaii-Saab TS**. A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer. *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):628
69. Hoyek C, Zheng-Lin BB, Pirozzi A, Abidoye O, Eslinger C, Iida N, Nakamura Y, Ramaker R, Sonbol MB, Wu C, Borad MJ, Ahn DH, Ikeda M, Shibuki T, Yoshino T, Strickler JH, **Bekaii-Saab TS**. Acquired gene alterations potentially related to resistance to anti-her2 therapy in her2-positive metastatic colorectal cancer (mcr). *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):277
70. Yaeger R, Uboha NV, Klempner SJ, **Bekaii-Saab TS**, Sabari JK, Barve MA, Saltzman JN, Peguero JA, Paulson AS, Janne PA, Pelster M, Cruz-Correa M, Kim AMK, Hu N, Ahmad HA, Kopetz S. Adagrasib (ada) plus cetuximab (cetux) for kras g12c-mutated metastatic colorectal cancer (mcr): longer follow-up analysis from krystal-1. *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):131
71. Abidoye O, Chang I, Hoyek C, Pirozzi A, Okano N, Zheng-Lin B, Kosiorek HE, Eslinger C, Sonbol MB, Ahn DH, Wu CSA, Yoshino T, Ikeda M, Morizane C, Bando H, Nakamura Y, Fujisawa T, Shibuki T, Borad MJ, **Bekaii-Saab TS**. Clinical and genomic characteristics of hepatocellular carcinoma-cholangiocarcinoma: insights from real-world data. *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):556
72. Eslinger C, Chang I, Fonseca R, Sahvan O, Yee CI, Truman M, McWilliams RR, Babiker HM, Pai R, Wu C, Ahn DH, Borad M, **Bekaii-Saab TS**, Sonbol MB. Clinical outcomes and molecular characteristics of patients with locoregional ampullary carcinoma. *Journal of Clinical Oncology*. 2025 Feb; 43(4_SUPPL):732
73. Jamal F, Sahvan O, **Bekaii-Saab TS**, Sonbol MB. Evaluating the clinical benefits of anti-cancer drugs approved by Food and Drug Administration for gastrointestinal neoplasms for the past two decades. *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):820
74. Pirozzi A, Hoyek C, Zheng-Lin B, Okano N, Abidoye O, Eslinger C, Babiker HM, Majeed U, Tran NH, Rimassa L, **Bekaii-Saab TS**, Shah S, Borad MJ. Genomic alterations as predictive biomarkers for cancer-associated thrombosis (cat) in biliary tract cancer (btc). *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):634
75. Sahvan O, Jamal F, Borad MJ, **Bekaii-Saab TS**, Wu C, Ahn DH, Sonbol MB. Neoadjuvant immunotherapy and nonoperative management of dmmr gastroesophageal adenocarcinoma (gea): a retrospective case series. *Journal of Clinical Oncology*. 2025 Feb; 43(4_Suppl):451

76. Zheng-Lin BB, Hoyek C, Kosiorek HE, Abidoye O, Eslinger C, Sonbol MB, Wu CSA, Tran NH, Babiker HM, Roberts LR, Yoshino T, Ikeda M, Morizane C, Bando H, Nakamura Y, Fujisawa T, Ahn DH, Borad MJ, Shibuki T, **Bekaii-Saab TS**. Real-world impact of matched targeted therapy on survival in advanced biliary tract cancer: an international collaborative study. *Journal of Clinical Oncology*. 2025 Feb; 43(4 Suppl):536

Ask Mayo Expert Topic

1. Sanchez W, Arora AS, **Bekaii-Saab TS**, Boardman LA, Bryan MJ, Bundrick JB, Bunkers KS, Chaudhry R, Dupras DM, Grothey A, Hansel SL, Heigh RI, Hensrud DD, Kisiel JB, Larson DW, Meeusen JW, Merchea A, Riegert-Johnson DL, Shah V, Sinicrope FA, Sweetser SR, Tulledge-Scheitel SM, Umar SB, Vege SS. Colorectal Cancer: screening and management (adult) in Ask Mayo Expert. May 2018;